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Abstract 
This thesis provides characterization of rare tumor-associated antigen (TAA)-specific T cells 
concerning their in vivo prevalence, functionality, and phenotype in healthy and diseased 
individuals. Such knowledge on the existing in vivo repertoire is crucial for the understanding 
of T cell immunity towards tumors and furthermore for the utilization of TAA-specific T cells in 
immunotherapeutic approaches. Thus far, low frequencies of such TAA-specific T cells in 
blood and tissues hindered an in-depth characterization, even in tumor patients. Here, we 
establish and implemented highly sensitive methods, based on magnetic enrichment of TAA-
specific T cells in combination with a multiparameter flow cytometry analysis to overcome 
existing sensitivity hurdles and allow ex vivo description of the T cells. Two different 
activation markers were implemented, CD154 (CD40L) for ex vivo enumeration and 
characterization of blood CD4+ T cells, and CD137 (4-1BB) for subsequent characterization 
of rare antigen-specific CD4+ and CD8+ T cell subsets from blood and tumor tissue after a 
short-term in vitro expansion. 
On the one hand, T cells specific for the self-antigen WT1 and, on the other hand, T cells 
specific for the viral antigens HPV16 E6 and E7 were investigated. 
The Wilms’ tumor 1 (WT1) protein is a transcription factor expressed at high levels in several 
hematological malignancies and some solid tumors and is considered a prime target for 
cancer immunotherapy. Remarkably, in this study, WT1-specific CD4+ and CD8+ T cell 
populations were detected in the vast majority of healthy individuals. Memory responses 
specific for WT1 were commonly present in the CD4+ T cell compartment, whereas WT1-
specific CD8+ T cells almost universally displayed a naïve phenotype. Moreover, WT1-
specific memory CD4+ and naïve CD8+ T cells were found to co-exist in healthy individuals. 
Collectively, these findings suggest a natural discrepancy between the CD4+ and CD8+ T cell 
lineages responsive to self-antigens with respect to memory formation. Nonetheless, WT1-
specific T cells from both lineages were readily activated ex vivo and expanded in vitro, 
supporting the general use of strategies to exploit this expansive reservoir of self-reactive T 
cells for immunotherapeutic purposes. 
Furthermore, characteristics of HPV16-specific T cells were investigated in head and neck 
squamous cell carcinoma (HNSCC) patients, as HNSCC is frequently induced by HPV16 
infection. This study revealed that HPV16-specific T cells in the blood of HPV16pos HNSCC 
patients exhibit profound differences in prevalence, functionality, and phenotype between 
individuals. While all patients harbored HPV-specific T cells in peripheral blood, we identified 
a subgroup of patients with significantly elevated frequencies of functional effector memory 
HPV16-specific CD4+ T cells compared to other patients. Moreover, these high responder 
patients had a more active anti-tumor immunity in comparison to low responders. Despite 
  
 
 
these variations, HPV16-specific T cells with functional capacities could be isolated and 
propagated both from blood and tumor tissue of all HPV16pos HNSCC patients. Furthermore, 
this data supports the notion that HPV16-reactive tumor infiltrating lymphocytes were 
suppressed by intratumoral Treg cells, the depletion of which restored T cell effector functions 
and facilitated expansion of reactive T cells for therapeutic use.  
In summary, the techniques established in this study permit detection of rare antigen-specific 
T cells and therefore are superior to common immune monitoring methods in terms of 
sensitivity and determination of T cell properties. In particular, these techniques were 
implemented to provide novel insights into the naturally occurring repertoire of WT1- and 
HPV16-directed T cells. These findings support the use of WT1- and HPV16-specific T cells 
in immunotherapy and provide knowledge crucial for the optimal design of WT1- and HPV16-
directed immunotherapeutic interventions. 
  
 
 
Zusammenfassung 
Diese Arbeit umfasst eine Charakterisierung in Bezug auf Prävalenz, Funktionalität und 
Phänotyp von den sehr seltenen T-Zellen, die spezifisch für Tumor-assoziierte Antigene 
(TAA) sind. Wissen über das in vivo existierende T-Zellrepertoire ist für das Verständnis der 
Immunität gegenüber dem Tumor und darüber hinaus für die Entwicklung von 
immuntherapeutischen Ansätzen notwendig. Eine solche detaillierte Charakterisierung war 
bislang nicht möglich, da TAA-spezifische T-Zellen im Blut und im Tumor nur in sehr geringer 
Frequenz vorliegen. In dieser Arbeit werden hoch sensitive Methoden etabliert, basierend auf 
magnetischer Anreicherung von TAA-spezifischen T-Zellen in Kombination mit einer Analyse 
mittels Multiparameter-Durchflußzytometrie, die die bisher bestehenden Sensitivitätsgrenzen 
überwinden und damit die ex vivo Charakterisierung der T-Zellen zulassen. Zwei 
Aktivierungsmarker kamen für die Zellanreicherung zum Einsatz; zum einen wurde CD154 
(CD40L) zur ex vivo Enumeration und Charakterisierung von CD4+ T-Zellen aus dem Blut 
benutzt und zum anderen wurde CD137 (4-1BB) für die Charakterisierung von antigen-
spezifischen CD4+ und CD8+ T-Zellpopulationen aus Blut und Tumorgewebe nach einer 
kurzen in vitro Expansion eingesetzt. 
Im Speziellen wurden T Zellen untersucht, die spezifisch für das Selbstantigen WT1 sind, 
und T Zellen, die spezifisch für das E6 und E7 Antigen des humanen Papillomavirus Typ 16 
(HPV16) sind. 
Das Wilms’ Tumor 1 (WT1) Protein ist ein Transkriptionfaktor, der im hohen Maße in 
hämatologischen Tumoren und einigen soliden Tumoren exprimiert wird. WT1 gilt als  
geeignetes Zielantigen für die Immuntherapie. Erstaunlicherweise konnten in dieser Studie 
WT1-spezifische CD4+ und CD8+ T-Zellen im Blut von der Mehrheit der gesunden Spender 
detektiert werden. Eine Gedächtnisantwort, die spezifisch gegen WT1 gerichtet ist, war 
häufig im CD4+ T-Zellkompartiment zu finden, während WT1-spezifische CD8+ T-Zellen fast 
ausschließlich einen naiven Phänotyp zeigten. Darüber hinaus wurde die Koexistenz von 
WT1-spezifischen Gedächtnis CD4+ und naïve CD8+ T-Zellen in einem Individuum 
nachgewiesen. Zusammenfassend implizieren die Resultate, dass eine Diskrepanz in der 
Entwicklung von Gedächtnisantworten zwischen den CD4+ and CD8+ T-Zellkompartimenten, 
die auf Selbstantigen reagieren, vorliegt. Dennoch ließen sich WT1-spezifische T-Zellen aus 
beiden Kompartimenten in vitro aktivieren und expandieren. Dieses spricht für die 
Umsetzung von Strategien, die das Repertoire von Selbstantigen-spezifischen T-Zellen für 
immuntherapeutische Ansätze nutzen.  
Des Weiteren wurden HPV16-spezifische T-Zellen in Patienten mit Kopf-Hals-Tumor (head 
and neck squamous cell carcinoma, HNSCC) untersucht, da HNSCC häufig durch HPV16 
Infektion induziert wird. Die vorliegende Arbeit zeigt auf, dass die Häufigkeit, die 
  
 
 
Funktionalität und der Phänotyp von HPV16-spezifischen T-Zellen im Blut sich deutlich 
zwischen den HPV16pos HNSCC Patienten unterscheiden. Während in allen Patienten 
spezifische T-Zellen nachweisbar sind, konnte ein Gruppe von HPV16pos HNSCC Patienten 
identifiziert werden, die eine auffällig hohe Frequenz an HPV16-spezifischen Effektor-
Gedächtnis-CD4+ T-Zellen mit hoher Funktionalität aufweist. In diesen ‚high responder’ 
Patienten war darüber hinaus eine aktivere Anti-Tumorimmunität im Tumorgewebe zu finden 
als in den ‚low responder’ Patienten. Trotz dieser Unterschiede konnten HPV16-spezifische 
T-Zellen sowohl aus Blut als auch aus Tumorgewebe von HPV16pos HNSCC Patienten 
gewonnen werden. Dennoch verdeutlichen die Daten, dass Treg im Tumorgewebe die 
Aktivität der HPV16-spezifischen Tumor-infiltrierender  Lymphozyten abschwächen, denn 
das Eliminieren von Treg aus den in vitro gewonnenen tumor-infiltrierenden Lymphozyten 
führte zur einer deutlich verstärkten Effektorfunktion und Expansion von HPV16-spezifischen 
T-Zellen.  
Die in dieser Arbeit etablierten Methoden ermöglichen eine detaillierte Charakterisierung von 
sehr seltenen tumor-spezifischen T-Zellen und sind damit bislang üblichen Methoden des 
Immunmonitoring an Sensitivität und Informationsgehalt überlegen. Insbesondere wurden 
mittels der etablierten Methoden neue, tiefreichende Erkenntnisse über die T-Zell-Immunität 
gegenüber WT1 und HPV16 gewonnen. Die erzielten Daten sprechen für die 
immuntherapeutische Nutzung von WT1- und HPV16-spezifischen T Zellen und stellen 
wichtige Erkenntnisse für die optimale Gestaltung von WT1- und HPV16-basierten 
Immuntherapien bereit. 
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Ab antibody / antibodies 
APC antigen presenting cells 
CD cluster of differentiation 
CMV cytomegalovirus 
cTEC cortical thymic epithelial cells 
CTL cytotoxic T cell 
DC dendritic cell 
DLI Donor lymphocyte infusion 
E6 early protein 6 
E7 early protein 7 
EBV Epstein-Barr virus 
EC50 half maximal effective concentration 
FSC forward scatter 
GvHD Graft-versus-host disease 
GvL Graft-versus-leukemia 
Gy gray 
HLA human leukocyte antigen 
HNSCC Head and neck squamous cell carcinoma 
HPV human papilloma virus 
HSCT hematopoietic stem cell transplantation 
IE-1 immediate early protein 1 
IFN-γ interferon-gamma 
IL interleukin 
L1 late protein 1 
MART-1 melanoma antigen recognized by T cells 1 
MB MicroBeads 
MHC major histocompability complex 
MNC mononuclear cells 
mTEC medullar thymic epithelial cells 
NK natural killer 
PBMC peripheral blood mononuclear cells 
PI propidium iodid 
pp65 phosphoprotein 65 
TAA tumor-associated antigen 
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Teff Effector T cells 
TEM effector memory T cells 
TEM-RA end-differentiated effector memory T cells 
TH helper T cells 
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Treg regulatory T cells 
WT1 Wilms tumor 1 
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1 Introduction 
 
The human immune system fights invading pathogens. Furthermore, the immune system is 
able to eliminate aberrant, genetically altered, mutated, autologous cells which are potential 
precursors of tumor cells. Human immunity is built on two major pillars, innate immunity and 
adaptive immunity. The innate immunity, including neutrophilic, eosinophilic and basophilc 
granulocytes, monocytes, macrophages, dendritic cells, and natural killer cells provides a 
general first defense against invading pathogens. A more delicate defense is generated by 
the adaptive immunity, built by B- and T-lymphocytes. B- and T-lymphocytes are capable of 
specific recognition of foreign antigens, brought in by pathogens, with the help of highly 
specific antigen receptors. The vast repertoire of antigen receptors allows for elimination of 
pathogens that evade or overwhelm the innate immunity. Furthermore, adaptive immunity 
provides an immunological memory to protect the body from reinfection.  
The human immune system plays a major role in preventing the development of cancer. 
Especially T lymphocytes, which are essential for elimination of aberrant cells of the body. In 
case of cancer formation, however, the anti-tumor immune response is insufficient.  
 
1.1 T lymphocytes 
T lymphocytes, or T cells, originate from lymphoid progenitor cells in the bone marrow and 
mature in the thymus; the “T” in T cell stands for thymus. After maturation T cells circulate in 
the blood, lymph, and secondary lymphoid tissues, such as the lymph nodes, the spleen, and 
the mucosal lymphoid tissues, where they scan for the emergence of foreign peptides. 
Main functions of T cells are direct killing of target cells, i.e. infected or tumor cells, and 
activation of other immune cells via cell surface molecules or by the secretion of soluble 
mediators like cytokines upon antigen encounter. 
 
1.1.1 Target antigen recognition by T cells 
T cells recognize their targets via their T cell receptor (TCR). A minor population of T cells 
carries a TCR consisting of γ:δ chains, however, the majority of T cells express an α:β chain 
TCR. Each TCR chain is composed of a constant region and a variable region, the latter 
forming the antigen binding-site (Fig. 1.1). The α:β TCR binds to peptide loaded major 
histocompatibility (MHC) complexes on professional antigen-presenting cells (APC) or other 
cells of the body. Classically T cells fall into two major categories, which are CD4+ T helper 
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cells and CD8+ cytotoxic T cells, defined by the expression of the co-receptors CD4 and CD8, 
which are engaged in TCR-MHC binding. CD4+ T cells recognize peptides presented on 
MHC class II molecules and CD8+ T cells recognize peptides presented on MHC class I 
molecules. Distinct pathways of antigen processing are responsible for loading of MHC class 
I and MHC class II molecules. Specifically, antigens taken up from the extracellular fluid by 
endocytosis are digested in the endosome and loaded onto MHC class II molecules. In 
contrast, peptides loaded onto MHC class I molecules are typically derived from intracellular 
proteins introduced by viral or bacterial infection of the cell. Cytosolic proteins are degraded 
via the proteasome and transported to the ER where they are loaded onto MHC class I 
molecules (Neefjes, Jongsma et al. 2011). An exception to this rule is exerted by DC, as they 
are able to process antigens from the extracellular space via the ER onto MHC class I 
molecules. This process is called cross-presentation (Joffre, Segura et al. 2012). Additionally, 
peptides loaded onto MHC class I and MHC class II differ in length. MHC class I molecules 
have a distinctly defined binding pocket, which binds peptides of 8 to 10 amino acids in 
length. Peptide binding is stabilized by specific anchor residues at the end of the peptide. In 
contrast, the binding groove of MHC class II molecules is more flexible as it can bind 
peptides of 13 to 17 amino acids in length. The ends of these peptides are not bound, but 
instead overlap the groove, and anchor residues for MHC class II are less defined. MHC 
class I molecules are constitutively expressed on all cells of the body, whereas MHC class II 
expression is restricted to professional APC of the immune system, such as DCs, 
macrophages, and B cells. Presence of IFN-γ can trigger the expression and upregulation of 
MHC class I and MHC class II molecules. 
 
 
 
 
Figure 1.1 Structure of the T cell receptor 
complex. The T cell receptor itself is a 
heterodimer, each chain consisting of a 
constant and variable section. The variable 
section includes the CDR3 binding region, 
which accounts for the huge diversity in 
antigen-specificity of TCRs. The TCR co-
localizes with CD3γ, CD3δ, and CD3ε 
molecules and the ζ chains, which carry 
immunoreceptor tyrosine-based activation 
motifs (ITAM) intracellularly. Through 
phosphorylation of these ITAMs the TCR 
signal is transmitted to the cell (Figure taken 
from (Murphy 2011). 
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1.1.2 Development of T cells 
During maturation of the T cell in the thymus TCR rearrangement takes place. Here, different 
variable (V), joining (J), and diversity (D) segments are combined in a stochastic manner in 
both the  chain and  chain locus. This rearrangement and the combination of  and  
chains creates the diversity of TCR binding specificities, which is estimated to comprise 
>1011 possible specificities (Robins, Srivastava et al. 2010). Positive selection in the thymus 
ensures that only T cells carrying a TCR, that is able to bind self-peptide:self-MHC 
complexes, survive. This applies only to about 10% of T cells Positively selected T cells 
recognizing self-MHC complexes on cortical thymic epithelial cells (cTEC) do become single 
positive for either CD8 or CD4 depending on whether they recognize MHC class I or MHC 
class II complexes, respectively. ‘Single positive’ cells migrate from the thymic cortex to the 
medulla. In the thymic medulla negative selection takes place, which deletes the T cells 
bearing a strong affinity against self-peptide:self-MHC complexes to protect the body from 
strong autoimmunity (Fig. 1.2).  
 
 
Figure 1.2 Affinity model of T cell selection. The strength of interaction of the TCR with 
peptide:self-MHC during development within the thymus determines the fate of the T cell. No binding 
leads to elimination during positive selection, likewise very strong binding also leads to elimination in 
the course of negative selection. Strong recognition can also lead to the development of regulatory T 
cells (Treg). Recent studies provide evidence that there is a stochastic overlap in affinity, which can 
either lead to the development of a Treg or deletion of the T cell. Likewise, similar affinities can exist in 
the Treg and naïve T cell compartment (Bains, van Santen et al. 2013) (Figure adapted from (Klein, 
Kyewski et al. 2014)). 
 
To enable negative selection against the full repertoire of self-antigens of the body, medullar 
thymic epithelial cells (mTEC) are able to express antigens normally only expressed on 
specific tissues or during embryonic development. This feature of mTEC is called 
promiscuous gene expression. However, there have been reports that the negative selection 
is incomplete for certain antigens. Reasons for this insufficient negative selection can be very 
low expression of the antigen in mTEC (Gotter, Brors et al. 2004, Lv, Havari et al. 2011), 
Introduction 
4 
 
differential splicing of mRNA (Klein, Klugmann et al. 2000, Pinto, Sommermeyer et al. 2014), 
or missing  post-translational modifications of proteins in mTEC (Scally, Petersen et al. 2013, 
Van Lummel, Duinkerken et al. 2014). Strong recognition of self-antigens cannot just lead to 
deletion of T cells, but also to development of these CD4+ T cells into T cells with regulatory 
functions (Treg) (Hsieh, Lee et al. 2012). Only 2 - 4% of all thymocytes will leave the thymus 
as functional naïve T cells. 
 
1.1.3 Primary activation of T cells  
After leaving the thymus the naïve lymphocyte will circulate via lymph and blood between 
lymphoid organs until encountering its respective antigen. Naïve T cells express the lymph 
node homing receptor CD62L and the chemokine receptor CD197 (CCR7), which enable 
them to migrate to the secondary lymphoid tissues such as lymph nodes, spleen, and 
mucosal lymphoid tissues. Professional APC take up antigen at sites of infection or aberrant 
tissue formation and get activated following inflammation as part of innate immunity. This 
activation triggers the migration of APC to the secondary lymphoid organs. The T cell 
becomes activated when it meets such an activated professional APC, including DC, but also 
activated macrophages and B cells, presenting the respective antigen within the T cell zone 
of a lymphoid organ. This process is called T cell priming. The primed T cell starts to 
proliferate and differentiate into an effector T cell. For a successful priming of a naïve T cell, 
co-stimulatory signals mediated by molecules on the professional APC and the T cell are 
needed, in addition to TCR signaling through peptide:MHC binding. One crucial co-
stimulatory signal is the interaction of B7 molecules (CD80, CD86) with CD28 on the T cell. 
Primed T cells leave the secondary lymphoid organs to migrate to the site of infection. 
T cells specific for self-antigens, which were not negatively selected during their development 
in the thymus, are usually not activated in the periphery, as peripheral tissues do not express 
co-stimulatory molecules. Similarly, professional APC express very few co-stimulatory 
molecules in the absence of inflammatory signals. This peripheral self-tolerance provides a 
further safety mechanism to prevent autoimmunity. When pro-inflammatory signals such as 
pro-inflammatory cytokines produced by innate immune cells and/or co-stimulatory 
molecules on APC are missing, T cells can be anergized or converted into Treg. 
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Figure 1.3 Priming of naïve T cells. 
Professional APC need to deliver three different 
signals to a naïve T cell to activate and therefore 
prime it. First, the TCR of the T cell needs to  
specifically bind the peptide:MHC complex. In 
addition, the co-receptor CD4 or CD8 bind to 
MHC. Second, the co-stimulatory B7 molecules 
need to be expressed on the APC and bind to 
CD28 expressed on the T cell. Also other co-
stimulatory molecules, like members of the TNF 
receptor family, can provide such a signal. Third, 
the APC provides cytokines to trigger the 
differentiation of the primed T cells. In a non-
inflammatory setting APC lack co-stimulatory 
molecules and T cell contact leads to anergizing 
of the T cell (Figure taken from (Murphy 2011)). 
 
 
1.1.4 Differentiation of T cells 
Cytokine signals released by the professional APC determine the fate of the primed T cell. 
Especially for CD4+ T cells several subclasses are known, differing in the cytokines needed 
for differentiation and also in cytokines secreted by those CD4 T cells (Fig. 1.4). Different 
CD4+ T cell subsets exert different effector functions. 
 
 
 
Figure 1.4 Major T cell subsets and their effector functions. 
The main function of CD8+ T cells is the killing of target cells presenting the respective peptide on 
MHC class I molecules by the release of cytolytic granules into the immunological synapse. CD4+ T 
cells bear diverse functions. Main subclasses of CD4+ T cells include TH1, TH1, TH17, and T cells 
bearing regulatory functions (Treg) (Figure taken from (Murphy 2011)). 
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TH1 cells are specialized to stimulate innate immune responses, they activate macrophages 
and are also able to kill infected macrophages. Main effector cytokines of the TH1 subset are 
IFN-γ and TNF-α. TH1 cells are especially important for anti-tumor immunity as they can exert 
anti-tumor functions, both by direct tumor cell killing or by activation of other immune cells by 
secretion of pro-inflammatory cytokines (Haabeth, Tveita et al. 2014). TH2 cells promote the 
immune response to extracellular pathogens mainly by activating B cells. Effector cytokines 
of TH2 cells include IL-4, IL-5, and IL-13 (Wan and Flavell 2009). In addition to TH1, TH2, and 
Treg cells also TH9, TH17, TH22, and T follicular helper cells (TFH) exist. Recent studies have 
discovered even more distinct subsets and have also shown the plasticity of TH cells, adding 
to the complexity of human adaptive immunity (Lee, Turner et al. 2009, Wei, Wei et al. 2009). 
In an activated state, TH cells express CD40 ligand (CD154) on their surface, which is 
important for activation of professional APC and CD8 T cell priming. 
CD4+ T cells with regulatory functions can evolve from the thymus (natural Treg = nTreg) and 
be induced in the periphery (induced Treg = iTreg). Both Treg subsets are characterized by the 
constitutive expression of the transcription factor FoxP3 and the cell surface molecule IL-2R 
α-chain (CD25). Treg cells are able to suppress effector T cell function through contact-
dependent inhibition of T cell activation as well as inhibition of proliferation owing to release 
of soluble factors such as IL-10 and TGFβ (Corthay 2009) or competition for IL-2 (de la Rosa, 
Rutz et al. 2004).  
Priming of CD8 T cells requires CD4 T cell help to APC, especially when inflammatory 
signals are lacking to activate the APC sufficiently. CD40 ligand (CD154) on activated CD4+ 
TH cells binding to CD40 on DC results in enhanced co-stimulatory signals to the naïve CD8+ 
T cell. An activated CD8+ effector T cell can kill antigen-presenting target cells specifically via 
release of cytolytic granules. Perforin-containing granules form holes in the targeted cells 
and allow for granzyme-containing granules to enter the target cells and trigger apoptosis (de 
Saint Basile, Menasche et al. 2010). As MHC class I molecules are present on virtually all 
cells of the body, CD8+ T cells can kill autologous cells, which present non-self-peptides, as 
in the case of virus infected cells. However, the clear functional distinction between CD4+ 
helper T cells and CD8+ cytotoxic T cells is not as strict as previously thought, as cytolytic 
CD4+ T cells and CD8-expressing T cells with helper cell functions have also been identified 
in recent years (Paludan, Bickham et al. 2002, Frentsch, Stark et al. 2013). 
Once a T cell has differentiated into an effector cell, the T cell exerts its effector functions 
upon antigen encounter without the need for a professional APC providing co-stimulatory 
signals. Additionally, the T cell’s homing behavior drastically changes, as it now needs to 
leave the lymphoid tissue and enter the sites of infection. Effector cells loose the expression 
of CCR7 and CD62L, which mediate homing to the secondary lymphoid organs. CCR7 and 
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CD62L are therefore markers, which can be used to distinguish naïve from effector T cells. 
Furthermore, the protein tyrosine phosphatase CD45, involved in TCR signaling, is 
expressed in different isoforms during differentiation. Naïve T cells expressing the long 
CD45RA isoform and memory T cells expressing the shorter CD45RO isoform. According to 
the expression patterns of these molecules, the differentiation status of the T cell can be 
phenotypically determined. Naïve T cells being CD45RO- CCR7+, central memory T cells 
CD45RO+ CCR7+, effector memory T cells CD45RO+ CCR7-, and exhausted T cells being 
CD45RO- CCR7-. After clearance of the infection or prolonged antigen-stimulation, an 
effector T cell eventually progresses to an exhausted state, its effector functions decrease 
and the T cell eventually dies. But central memory T cells exist also which retain the 
expression of CD62L and CCR7 (Sallusto, Geginat et al. 2004). Initial models of T cell 
differentiation suggested a unidirectional progression from naïve to effector T cells to 
exhausted effector T cell to apoptosis in which central memory T cells are cells arrested at 
intermediate stages of differentiation preceding effector T cells. Newer models suggest the 
existence of a memory T cell population bearing stem cell-like properties. This stem T cell 
population is marked, amongst other, by the expression of the IL-7 receptor α-chain (CD127) 
in humans. CD127 is also expressed on naïve T cells but normally rapidly lost upon 
activation (Gattinoni, Lugli et al. 2011). These putative stem T cells are able to self-renew 
and give rise to central memory and effector memory T cells (Bondanza, Hambach et al. 
2011, Mackall, Fry et al. 2011). 
 
1.2 Anti-tumor immunity 
The adaptive immunity is able to conduct a directed immune response against cancerous 
cells. It is believed that many aberrant cells, which are potential precursors of tumor cells, are 
cleared by these immunological defense mechanisms, a process called immunosurveillance 
(Corthay 2014). In case of tumor formation these immunological defense mechanisms are 
impaired or not sufficient. Then the tumor is able to overcome immunosurveillance. The 
hypothesis of immunoediting states that the immunosurveillance alters the composition of 
tumors towards more aggressive forms, which are able to circumvent recognition by the 
immune defense mechanism or actively suppress it (Kim, Emi et al. 2007). It is clear that 
many tumor entities exhibit such tumor escape features. Tumor escape mechanisms include, 
on the one hand, defects in antigen processing or presentation components and therefore 
loss of antigen presentation; on the other hand, formation of a immunosuppressive 
microenvironment by attraction of suppressive cell types, such as Treg, myeloid suppressor 
cells, or release of suppressive cytokines (Kim, Emi et al. 2007). However, in the last decade 
it has been clearly shown that tumor escape can be overcome by immunotherapeutic 
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interventions even in quite aggressive forms of cancer by different strategies, e.g. increasing 
the number of anti-tumor T cells or modulating immunosuppressive features of the tumor. 
 
1.2.1 Tumor-associated antigens 
Tumor cells have an aberrant protein expression profile compared to normal cells of the body, 
which can result in presentation of distinct antigens. This feature renders them sensitive to 
recognition by cells of the adaptive immune system. Antigens especially expressed on tumor 
cells are referred to as tumor-associated antigens (TAA). T cells specific for TAA can 
mediate such an anti-tumor response. TAA fall into different classes and can be of self, 
“altered-self”, or foreign origin: (1) Foreign antigens derived from viral oncogenes such as the 
human papilloma virus (HPV) E6 and E7 protein and (2) “altered-self” antigens, e.g. mutated 
antigens such as Bcl-Abl expressed in some forms of myeloid leukemia. On the other hand, 
TAA can also be classical self-antigens as in the case of: (3) Oncofetal antigens normally 
only expressed during embryonic and fetal development or in germ-line tissues (NY-ESO-1, 
MAGE-A3), (4) tissue differentiation antigens (MART-1, gp100) or (5) antigens 
overexpressed in tumor cells, such as WT1, overexpressed in myeloid leukemia and many 
solid tumors.  
 
1.2.2 Implementation of anti-tumor T cell immunity  
Several treatment approaches have proven the potential of naturally existing immunity, 
especially T cells, for the treatment of cancer. 
Firstly, prophylactic vaccination has been successfully implemented for the protection against 
tumor formation in the case of HPV16 (and HPV18)-induced cervix carcinoma. Therapeutic 
vaccination has not been clinically established thus far; however, numerous studies have 
shown that an anti-tumor immunity can be triggered against multiple cancer entities, 
including HPV16-induced vulvar neoplasias (Kenter, Welters et al. 2009, Daayana, Elkord et 
al. 2010) and WT1-expressing tumors (Van Driessche, Berneman et al. 2012). 
Secondly, so called checkpoint inhibitors have been used to re-activate existent immunity 
against tumors. Successfully used in the clinic is a CTLA-4 inhibitor (ipilimumab) used for 
treatment of melanoma, which blocks the inhibitory CTLA-4:B7 interaction and leads to 
enhanced general activation of T cells (Hodi, O'Day et al. 2010, Ott, Hodi et al. 2013). The 
clinical effect of re-activation of intratumoral T cells underlines that naturally occurring T cells 
have a good anti-cancer potential. 
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Thirdly, adoptive transfer of naturally derived TAA-specific T cells has directly demonstrated 
their therapeutic potential. The feasibility and efficacy of adoptive T cell transfer was 
successfully proven in melanoma where tumor-infiltrating lymphocytes are expanded in vitro 
with the use of IL-2 and administered to lympho-depleted patients. This therapy has led to 
shrinkage and also clearance of major tumor lesions in metastatic melanoma patients 
(Rosenberg, Yannelli et al. 1994). Additionally to naturally derived TAA-specific T cells, 
genetically engineered T cells specific for a TAA or T cells transduced with a chimeric 
antigen receptor specific for a surface protein of the tumor cell are successfully used in the 
clinic (Porter, Levine et al. 2011, Kershaw, Westwood et al. 2013). 
For adoptive T cell therapy, several studies have highlighted that the quality of the 
administered T cells is crucial for clinical success (reviewed in (Riddell 2007) and (Klebanoff, 
Gattinoni et al. 2012). Therefore, attempts were made to design the best in vitro expansion 
protocol to achieve a good in vivo performance and persistence of T cells. Firstly, extensive 
in vitro cultivation leads to an exhausted state of T cells, characterized by loss of expression 
of co-stimulatory markers and expression of exhaustion markers such as CD57. Exhausted T 
cells were shown to have decreased effector functions compared to non-exhausted T cells in 
vivo and to have a short in vivo persistence and hence are not preferred for adoptive transfer 
(Powell, Dudley et al. 2005, Hinrichs, Borman et al. 2009). The recently identified stem T cell 
population (see section 1.1.4) is favored for the use in adoptive T cell therapy, as this 
population is characterized by good in vivo persistence (Zhang, Joe et al. 2005). Cytokines 
used for expansion are a critical factor. Use of IL-7 and IL-15 has been reported to preserve 
a non-exhausted phenotype of in vitro expanded T cell cultures, which harbor superior in vivo 
antitumor functions compared to cells expanded with IL-2 (Cieri, Camisa et al. 2013, Xu, 
Zhang et al. 2014). Secondly, polyfunctionality of the applied T cells has been shown to 
provide enhanced protection, as they combine a broader repertoire of effector functions, i.e. 
the ability of one individual T cell to secrete more than one different cytokine (Seder, Darrah 
et al. 2008). Thirdly, early adoptive transfer studies used mostly CTL clones, but within the 
last decade it became clear that CD4+ T cells are also important for anti-tumor efficacy of a 
cell product, both due to cytolytic functions of the CD4+ T cells themselves (Quezada, 
Simpson et al. 2010), help for anti-tumor CD8+ T cells (Wong, Bos et al. 2008), and 
recruitment of other cells with anti-tumor functions (Perez-Diez, Joncker et al. 2007). 
Therefore, a CD4+ and CD8+ mixed TAA-specific T cell product might have the best efficacy.  
A combined phenotypic and functional analysis of the T cell product can give important 
insights into whether a T cell population is effective in therapy. To date, the knowledge 
regarding the effective tumor-specific T cell response is incomplete. However, such 
knowledge is crucial in order to, on the one side, develop immunotherapies such as adoptive 
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T cell transfer or vaccination and, on the other side, monitor and predict clinical outcome of 
such an intervention.  
 
1.3 Detection of antigen-specific T cells 
Antigen-specific T cells can be detected with various techniques. The most common tool for 
direct detection of antigen-specific T cells are pHLAI multimers, where multimerized, peptide 
loaded MHC class I molecules are conjugated to a fluorophore, which enables detection of 
peptide-specific CD8+ T cells via flow cytometry. Recently, pHLAII multimers have also been 
successfully introduced for detection of peptide-specific CD4+ T cells (Moon, Chu et al. 2007, 
Obar, Khanna et al. 2008). Owing to the facts that only a limited amount of cells can be 
measured by flow cytometry and that multimers can produce unspecific background staining, 
which increases with increased numbers of measured cells, pHLA multimers have an 
approximate detection limit of 10-5 within PBMC. 
Another commonly used method is the enzyme-linked immuno spot assay (ELISPOT), which 
allows for detection of a released cytokine upon antigen stimulus with an estimated detection 
limit of 10-5 within PBMC (reviewed in (Schmittel, Keilholz et al. 1997)). The ELISPOT is an 
indirect method, it is therefore only semi-quantitative and does not allow for a further 
characterization of single T cells. Cytokine-producing T cells after stimulation can also be 
detected in a direct method via intracellular staining and flow cytometric analysis. However, 
only a subset of activated T cells produce a certain cytokine upon stimulation, therefore 
enumeration of the entire pool of antigen-specific T cells is not feasible. 
More recently, surface molecules upregulated after antigenic stimulation (activation markers) 
have been successfully used for visualization of antigen-specific T cells. For example, 
CD154 (CD40L) is expressed within a few hours after antigen-specific stimulation of CD4+ T 
cells. CD137 (4-1BB) is upregulated on both CD4+ and CD8+ T cells after longer stimulation 
times (>24 h). Both marker have been shown to be expressed both on activated naïve and 
memory T cells and thus enable detection of antigen-specific T cells independent of their 
differentiation status. Furthermore, when peptide pools are used for T cell stimulation a 
previous knowledge of epitope specificities and HLA status is not needed. Thus, activation 
markers, in principle, provide a compelling opportunity to detected the full repertoire of 
antigen-specific T cells. 
T cells specific for one particular antigen are commonly present in very low frequencies, as 
the human T cell repertoire comprises approximately 106 - 107 different antigen specificities 
(Arstila, Casrouge et al. 1999). Therefore, self-antigen-specific and tumor-associated-antigen 
(TAA)-specific T cells in healthy individuals cannot be detected with commonly used 
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technologies such as ELISPOT and pHLAI multimer staining, as they are not sensitive 
enough. An exception are T cells specific for the melanoma-associated self-antigen 
MelanA/MART-1, where rather high frequencies of specific T cells (up to 10-3 within CD8+ T 
cells), exhibiting a naïve phenotype, in healthy individuals were reported (Pittet, Valmori et al. 
1999, Zippelius, Pittet et al. 2002). Apart from this exception normally only T cells specific for 
immune-dominant recall antigens can be readily detected, as for example CMV pp65-specific 
T cells in CMV-infected donors, where frequencies of up to 5% pp65-specific T cells within 
the CD8+ T cell compartment can occur. 
To circumvent detection limitations for rare antigen-specific T cells, enrichment strategies 
can be employed. Here, cells of interest are magnetically labeled and applied to a column 
placed in a magnetic field where they are retained. Non-labeled cells are washed away, and 
the enriched, magnetically labeled cells are eluted (Miltenyi, Muller et al. 1990). Magnetic 
enrichment of pHLA multimer+ T cells was successfully used to detect CD4+ and CD8+ 
antigen-specific at very low frequencies from the memory and naïve repertoire (Barnes, 
Ward et al. 2004, Obar, Khanna et al. 2008, Chu, Moon et al. 2009, Alanio, Lemaitre et al. 
2010, Kwok, Tan et al. 2012). Recently, an elegant magnetic enrichment technique based on 
CD154-expression after antigen stimulation was established, which allows a simultaneous 
enumeration and functional characterization of antigen-specific T cells directly ex vivo, this 
method was named antigen-reactive T cell enrichment (ARTE) (Bacher, Schink et al. 2013). 
CD137 was also used to enrich antigen-specific T cells (Wolfl, Kuball et al. 2007). However, 
stimulation periods >24 h, which are needed for the expression of CD137 on naïve T cells, 
render CD137 only limited suitable for ex vivo characterization, as prolonged stimulation can 
alter the expression of phenotypic markers on activated T cells. 
With the help of these magnetic enrichment techniques rare TAA-specific T cells were 
detected and characterized. Two model antigens of current clinical interest were chosen, the 
self-antigen WT1 and the viral antigens HPV16 E6 and E7. Apart from providing crucial 
information on the TAA-specific T cell repertoire for each TAA separately, investigation on T 
cells specific for these two distinct TAA antigens could unravel potential principle differences 
in the T cell repertoire for self- and virus-specific T cells, due to divergent negative selection 
mechanisms during T cell development (introduced in 1.1.2).  
 
1.4 WT1 
The Wilms’ tumor 1 (WT1) protein is a transcription factor, which is expressed at high levels 
in several types of hematological malignancies as well as in some solid-tumors. WT1 
expression in adult humans is restricted to early hematopoietic precursor cells (Baird and 
Simmons 1997) and is rapidly lost upon differentiation of these precursors (Maurer, Brieger 
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et al. 1997). WT1 was ranked top in a list of potential tumor antigens to be used in anti-
cancer immunotherapy because of its oncogenic potential and presumptive immunogenicity 
(Cheever, Allison et al. 2009). Indeed, spontaneous T cell responses towards WT1 are 
induced in leukemia patients after allogeneic stem cell transplantation (SCT) or donor 
lymphocyte infusions (Rezvani, Yong et al. 2007, Kapp, Stevanovic et al. 2009, Tyler, 
Jungbluth et al. 2013) and are associated with disease regression ((Tyler, Jungbluth et al. 
2013). In order to design WT1-directed immunotherapies, knowledge about the in vivo 
existence of WT1-specific T cells is a prerequisite. However, until now, such detailed insight 
into the naturally occurring WT1-specific T cell repertoire is vastly limited. This is due to the 
fact that ex vivo detection and hence also the characterization of WT1-specific T cells so far 
is hindered owing to their exceedingly low frequencies, especially in blood of healthy donors. 
WT1-specific CD8+ T cells have been detected ex vivo in myeloid leukemia patients via 
WT1126-HLAI multimers (Sloand, Melenhorst et al. 2011) and via qPCR of IFN-γ mRNA after 
stimulation, with raised prevalence after SCT (Rezvani, Grube et al. 2003, Rezvani, 
Brenchley et al. 2005). Using highly sensitive IFN-γ mRNA detection Rezvani et al. also gave 
a first hint, that CD8+ WT1-specific T cells indeed do exist in low frequencies even in healthy 
individuals, but an in depth characterization was not feasible with the used approach 
(Rezvani, Grube et al. 2003, Rezvani, Brenchley et al. 2005). 
WT1 is under current investigation for the use in immunotherapeutic approaches. On the one 
side, several clinical WT1 vaccination trials have been done and showed promising results. 
Here, a clinical response was detectable in 45% of patients bearing solid tumors and even 
63% in patients with hematopoietic tumors and also immunological responses could be 
detected in some cases (Van Driessche, Berneman et al. 2012). However, the design of 
vaccines was not ideal as HLA-restricted peptides have been used in some trials. 
Furthermore, the immunomonitoring was also limited as it was restricted to the detection of 
WT1-HLAI tetramer+ CD8+ T cells. Further knowledge about the characteristics of WT1-
specific T cells, as provided in this study, will hopefully improve vaccine design to achieve 
optimal clinical efficiency. On the other side, usage of WT1-specific T cells for adoptive 
transfer after hematopoietic stem cell transplantation (HSCT) is currently under investigation. 
A first clinical trial has recently proven the safety of WT1126-specific CD8+ T cells in this 
setting (Chapuis, Ragnarsson et al. 2013). 
 
1.5 HPV16 E6/E7 
The human papilloma virus (HPV) is a DNA virus infecting the basal layer of epithelia by 
entering wounds or lesions of skin and mucosal tissues. Only after differentiation of the 
epithelial cells to cells of the squamous cell layer virus particles are assembled and released. 
Introduction 
13 
 
It is believed that more than 50% of people are infected by any type of HPV once during their 
life time. Certain high risk types of HPV, including HPV16 and HPV18, however, can induce 
lesions which can eventually progress to cancer if not cleared. 
The E6 and E7 proteins of HPV16 are oncogenes, which induce cell-cycle progression. The 
E6 protein of high risk HPV acts as an E3 ligase for the p53 tumor suppressor protein and 
therefore triggers its degradation (Scheffner, Werness et al. 1990). The E7 protein binds and 
destabilizes the retinoblastoma (Rb) tumor suppressor protein and related proteins (Boyer, 
Wazer et al. 1996). The expression of E6 and E7 oncoproteins is mandatory for the 
uncontrolled growth of infected cells resulting in tumor formation. Therefore, these proteins 
are suggested to be ideal targets for immunotherapeutic approaches (Cheever, Allison et al. 
2009).  
The most prominent example for HPV-induced cancer is cervix carcinoma, which is induced 
by the high risk types HPV16 or HPV18 in about 70% of cases (Munoz, Bosch et al. 2004, 
Schiffman, Castle et al. 2007). Also head and neck squamous cell carcinoma (HNSCC) can 
be induced by HPV high risk types. A subgroup of HNSCC, the oropharynx carcinoma, is 
induced by high risk type HPV16 in more than 50% of cases (Ramqvist and Dalianis 2010, 
Jayaprakash, Reid et al. 2011). The incidence of HPV induced HNSCC is rising (Chaturvedi, 
Engels et al. 2011). 
HNSCC patients bearing an HPV16pos tumor have a better prognosis than HPV16neg HNSCC 
patients. The reasons for better prognosis of HPV16pos HNSCC patients are unknown so far. 
However, there is evidence that the better outcome results from the formation of an anti-
tumor immunity. In general, the presence of CD3+ and CD8+  tumor-infiltrating lymphocytes 
(TIL) was found to be stronger in HPV16pos HNSCC tumors (Jung, Guihard et al. 2013) and 
HPV16pos tumors have a higher CD8+ to regulatory T cell (Treg) ratio (Russell, Angell et al. 
2013). Both findings were correlated with prolonged disease-specific survival. In specific, 
HPV16-specific T cells have also been detected in tumor tissue of HPV16-related HNSCC 
(Heusinkveld, Goedemans et al. 2012).  
Furthermore, the peripheral HPV16-directed immunity was investigated. For HPV-related 
cervical carcinoma the systemic HPV-immunity was linked to the intratumoral HPV16-
directed immunity and improved prognosis (Piersma, Jordanova et al. 2007). However, the 
overall functionality of peripheral HPV-specific T cells in cervical cancer seems to be 
impaired, either due to skewing to a TH2 phenotype (Clerici, Merola et al. 1997, Bais, 
Beckmann et al. 2005, Sharma, Rajappa et al. 2007) or due to impaired functionality of the 
TH cells (de Jong, van Poelgeest et al. 2004). For HNSCC, a systemic HPV16-specific T cell 
immunity was also found in the periphery of HPV16pos HNSCC patients. MHC class I 
tetramer analysis revealed higher frequencies of CD8+ HPV16-specific T cells in the blood of 
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HPV16pos HNSCC patients compared to HPV16neg patients and healthy individuals (Albers, 
Abe et al. 2005, Hoffmann, Arsov et al. 2006). Similar to cervix carcinoma, the peripheral 
HPV16-specific immunity in HNSCC patients revealed a partial functional impairment of T 
cells and the absence of a systemic HPV16-directed T cell immunity in some HPV16pos 
HNSCC patients (Heusinkveld, Goedemans et al. 2012). A detailed characterization in terms 
of frequency, phenotype, and functionality of such systemic HPV16-specific T cell immunity 
in HNSCC patients, however, has been missing until now. 
Two phase II clinical trials for therapeutic vaccination for patients with vulvar intraepithelial 
neoplasia, a pre-stage of cervix carcinoma, are ongoing. Both studies use a HPV16 vaccine, 
consisting of either HPV16 E6 and E7 peptides or an HPV16 E6E7L2 fusion protein, and 
showed promising results, as both achieved clinical response rates >60% (Kenter, Welters et 
al. 2009, Daayana, Elkord et al. 2010). For therapeutic HPV16 vaccination of HNSCC the 
first clinical phase I trials have been started (Center SKCC 2013 and Inovio Pharmaceuticals 
2014, ClinicalTrials.gov). Adoptive transfer of HPV16-specific T cells is also under current 
investigation (Ramos, Narala et al. 2013), but has not been implemented in the clinic as of 
yet. 
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1.6 Objectives 
In this study, unbiased and in-depth knowledge about rare tumor antigen-specific T cells is 
provided. This knowledge allows for conclusions on the feasibility and efficacy of immune-
based anti-cancer therapies, such as vaccination and adoptive T cell transfer. 
In the first part of this thesis the establishment of the highly-sensitive strategies, which were 
used to characterize the rare antigen-specific T cells, is outlined. Main objectives were: (i) 
Establishment of method(s) for ex vivo detection and characterization of rare antigen-specific 
T cells and (ii) establishment of an efficient method to generate antigen-specific T cell 
cultures starting from low frequent, presumably naïve T cells. The established techniques 
were then used to provide in-depth characterizations of TAA-specific T cells. Here, T cells 
specific for two distinct TAAs were investigated, the self-antigen WT1 and the viral antigens 
E6 and E7 derived from HPV16.  
In the second part of this thesis the in-depth characterization of WT1-specific T cells is 
described. This second part aims at the investigation of quantity and quality of WT1-specific 
T cells in healthy donors to provide crucial knowledge for immunotherapeutic interventions in 
leukemia and other solid tumor entities.  
In the third and final part of this thesis HPV16-specific T cells are characterized in HPV16pos 
and, for comparison, in HPV16neg patients and healthy individuals. Both blood and tumor 
derived HPV16-specific T cells of HNSCC patients were investigated to obtain so far missing 
knowledge on HPV16-directed peripheral and intratumoral immunity in those patients, which 
is valuable for the design of immunotherapeutic interventions in HPV16pos HNSCC. 
The approach used and the results obtained in this study are unique, as a characterization of 
these tumor-antigen specific T cells was so far not feasible due to their low frequencies. The 
established highly sensitive enrichment methods, for the first time, enable the detection and 
comprehensive functional and phenotypical characterization of these rare tumor-antigen 
specific T cells. Additionally, in contrast to other studies focusing on WT1- or HPV16-specific 
T cells this study provides a characterization of the full repertoire of antigen-specific T cells 
including both CD4+ and CD8+ T cells, naïve as well as memory T cells. 
The consequences of the findings relating to the design of immunotherapeutic interventions 
will be discussed. 
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2 Materials and Methods 
 
2.1 Reagents, media, supplements, and antigens 
2.1.1 Staining antibodies 
The following antibody reagents were used for staining and flow cytometric measurements: 
anti-CD3-VioGreen (BW264/56), anti-CD4-allophycocyanin-Vio770 (VIT4), anti-CD8-PE-
Vio770 (BW135/80), anti-CD14-PerCP (TÜK4), anti-CD20-allophycocyanin, anti-CD20-
PerCP (LT20), anti-CD27-FITC (M-T271), anti-CD28-FITC (15E8), anti-CD31-FITC (AC128), 
anti-CD44-allophycocyanin-Vio770 (DB105), anti-CD45-VioGreen (5B1); anti-CD45RA-
VioBlue (T6D11), anti-CD45RO-FITC (UCHL1), anti-CD57-VioBlue (TB03), anti-CD62L-FITC 
(145/15), anti-CD107a-PE (1D4B), anti-CD127-FITC (MB15-18C9), anti-CD137-
allophycocyanin, anti-CD137-biotin, anti-CD137-PE (4B4-1), anti-CD154-allophycocyanin, 
anti-CD154-VioBlue (5C8), anti-CD178-PE (NOK-1), anti-CD279-allophycocyanin 
(PD1.3.1.3), anti-CD197 (CCR7)-allophycocyanin, anti-CD197 (CCR7)-PE (150503), anti-
CD324-allophycocyanin (67A4), anti-CD326-VioBlue (HEA-125), anti-FoxP3-PE (3G3), anti-
HLA-ABC-PE (REA230), anti-IL-2-PE-Vio770 (N7.48A), anti-IL-4-PE (7A3-3), anti-IL-17-FITC 
(CZ8-23G1), anti-IFN-γ-FITC, anti-IFN-γ-PE-Vio770 (45-15), anti-TIM-3-allophycocyanin 
(F38-2E2), anti-TNF-α-PE, and anti-TNF-α-VioBlue (cA2) (all Miltenyi Biotec, Bergisch 
Gladbach, Germany).  
 
2.1.2 MHC/peptide multimers 
Soluble biotinylated pHLA-A*0201 molecules loaded with WT137-45 (VLDFAPPGA), WT1126-134 
(RMFPNAPYL), WT1187-195 (SLGEQQYSV), WT1235-243 (CMTWNQMNL), or cytomegalovirus 
(CMV) pp65495-503 (NLVPMVATV) were produced as described previously (Price 2005 
JExpMed). Tetramerization was done by incubating 2 nmol pHLA molecules with 0.5 nmol 
streptavidin-PE or streptavidin-allophycocyanin (both BioLegend, San Diego, USA) at 4°C, 
PBS supplemented with Protease Inhibitor (Roche, Basel, Switzerland) was used for dilution. 
 
2.1.3 Antibodies for cell culture 
Pure anti-CD28 (clone 15E8), anti-CD40 (clone HB14), and anti-MHC class I (clone W6/32) 
were obtained from Miltenyi Biotec. 
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2.1.4 Reagents for cell isolation 
All antibody bead reagents, separation, and isolation kits used in this study were obtained 
from Miltenyi Biotec. 
 
2.1.5 Media and supplements 
RPMI1640 (Miltenyi Biotec) was supplemented with 2mM L-Glutamine (PAA Laboratories 
GmbH, Pasching, Austria) and 5% human AB-Serum (Lonza, Basel, Switzerland). X-Vivo15 
(Lonza) was supplemented with 5% human AB-serum (Lonza). 
 
2.1.6 Recombinant cytokines 
Recombinant human IL-7, IL-15, IL-21 and IFN-γ were obtained from Miltenyi Biotec and 
recombinant human Proleukin S was obtained from Novartis Pharma, Basel, Switzerland. 
 
2.1.7 Buffer 
0.1 M phosphate-buffered saline containing 137 mM NaCl, 2.6 mM KCl, 8.1 mM Na2HPO4, 
and 1.4 mM KH2PO4 (all chemicals purchased from Sigma Aldrich, St. Louis, USA) was 
stored as 10x stock solution and freshly diluted. Sterile 0.1 M phosphate-buffered saline 
containing 2 mM EDTA was obtained from Miltenyi Biotec and optionally supplemented by 
sterile 0.5% human AB-Serum (PEB-buffer). Buffers for MACSPlex Cytokine 12 Kit and 
Tumor Dissociation Kit (both Miltenyi Biotec) was used as provided and indicated within kits. 
InsideFix solution and 10x InsidePerm solution are provided with the Rapid Cytokine 
Inspector Kit (Miltenyi Biotec). 
 
2.1.8 Antigens 
PepTivator CMV pp65, EBV EBNA-1, EBV LMP2a, HPV16 E6, HPV16 E7, and WT1 were 
obtained from Miltenyi Biotec. PepTivator peptide pools consist of 15-mer peptides 
overlapping by 11 amino acids and spanning the complete protein sequence. Peptides 
WT137-45, WT1126-134, WT1187-195, WT1235-243 were synthesized by O. Braun and S. Kramer, 
Miltenyi Biotec. 
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2.1.9 Other 
Propidium Iodide solution (PI) was obtained from Mitlenyi Biotec. CellTrace Violet was 
obtained from Invitrogen, Carlsbad, USA. Monensin was obtained from eBioscience, San 
Diego, USA. Mitomycin C and Brefeldin A and antibiotic antimycotic solution were obtained 
from Sigma-Aldrich. 
 
2.2 Consumables, devices, and software 
MACSQuant Analyzer 10 Miltenyi Biotec 
Cell culture hood, Hera Safe KS Thermo Fischer Scientific, Waltham, USA 
CO2 Incubator, Hera Cell® Thermo Fischer Scientific 
Hematologic analyzer, Sysmex KX-21 Sysmex Corporation, Japan 
Centrifuge, Eppendorf 5415D Eppendorf, Hamburg, Germany 
Centrifuge, Multifuge X3R Heraeus Instruments, Hanau 
Centrifuge, Multifuge 4KR Heraeus Instruments 
Centrifuge 4515R Eppendorf 
MACSmix Tube Rotator Miltenyi Biotec 
pH-Meter, pH-Meter 765 Calimatic Elektronische Messgeräte GmbH, 
Berlin, Germany 
Irradiator RS 2000 Rad Source Technologies, Inc., Suwanee, USA 
MACS Separator (Mini, Midi, Octo, Quadro) Miltenyi Biotec 
MACS separation columns (MS, LS, LD) Miltenyi Biotec 
gentleMACS Dissociator Miltenyi Biotec 
gentleMACS C Tubes Miltenyi Biotec 
Microscope, Leica DM IL LED Leica Microsystems, Wetzlar, Germany 
Orbital shaker Titramax 100 Heidolph, Schwabach, Gemany 
Conical bottom tubes, 50 ml, 15 ml Falcon (BD Biosciences), New Jersey, USA 
96/48/24/12-well flat bottom cell culture plates Falcon (BD Biosciences) 
75/175 cm2 cell culture flasks Falcon (BD Biosciences) 
Cell Strainer 70 µm Falcon (BD Biosciences) 
96-well filter plate, 0.2 µm PVDF membrane Corning, Corning, USA 
Cell Scraper MIDSCI, St. Louis, USA 
Surgical Scalpell Aesculap AG, Tuttlingen, Germany 
NALGENE® Cryogenic vials  Nalge Nunc International, Rochester, USA 
Dispenser Tips Th. Geyer, Renningen, Germany 
Microcentrifuge tubes STARLAB, Hamburg, Germany 
MACSQuantify, version 2.5 Miltenyi Biotec 
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Microsoft Office Professional 2010 Microsoft Coorporation, Redmond, USA 
Graph Pad Prism 6.0 GraphPad Software, Inc., La Jolla, USA 
TIGR MeV Dana-Farber Cancer Institute, Boston, USA 
Adobe Illustrator CS3 13.0 Adobe Systems, San Jose, USA 
 
2.3 Cell separation and processing 
2.3.1 Patients’ characteristics 
15 HNSCC patients were included in study at time of tumor resection and did not receive 
prior treatment. All six included HPV16pos HNSCC patients had tonsillar tumors. Of the nine 
included HPV16neg HNSCC patients five had tonsillar tumors, three tumors in the oral cavity 
and one in the hypopharynx. Primary tumor tissue and 50 ml of peripheral blood was 
obtained from patients during surgical intervention. 
10 HNSCC patients were included in this study during a follow-up visit between 1 and 57 
months after diagnosis. Six included HNSCC follow-up patients were HPV16pos, five had 
oropharyngeal tumors (tonsil and base of tongue). Three included HNSCC follow-up patients 
were HPV16neg, two patients had tonsillar tumors and one a tumor in the oral cavity. One 
follow-up patient was not included in the study as the status of HPV16 infection was not 
determined. HNSCC tumors were resected shortly after diagnosis and patients received 
radio- or chemotherapy or both. 50 ml of peripheral blood was obtained from these follow-up 
patients during a follow-up visit. 
Patients characteristics are given in Table 2.1 and 2.2. This study was performed according 
to established ethical guidelines and all blood and tumor donors gave informed consent. 
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Table 2.1: Characteristics of HNSCC patients included at time of surgery. m: male, f: female, t.d.: 
technical difficulties, tumor were classified according to the TNM system accepted by the American 
Joint Committee on Cancer (AJCC): T: size and/or extent of the primary tumor, N: the amount of 
spread to nearby lymph nodes, M: presence of metastasis. 
 
 
 
Table 2.2: Characteristics of HNSCC patients included at follow-up. n.d.: not determined, m: male, 
f: female, n: no, y: yes, t.d.: technical difficulties, tumor were classified according to the TNM system 
accepted by the American Joint Committee on Cancer (AJCC): T: size and/or extent of the primary 
tumor, N: the amount of spread to nearby lymph nodes, M: presence of metastasis. 
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2.3.2 PBMC preparation 
Buffy coats or leukapheresis products from healthy donors were obtained from the university 
hospital in Dortmund and Cologne. This study was performed according to established 
ethical guidelines and all blood donors gave informed consent. PBMC were isolated under 
sterile conditions by Ficoll-Hypaque (GE Healthcare, Chalfont St. Giles) density gradient 
centrifugation. 
 
2.3.3 Tumor dissociation 
HNSCC tumors were surgically removed and stored in MACS Tissue Storage Solution 
(Miltenyi Biotec) at 4°C for a maximum of 6 h. Subsequently, tumors were cut into pieces of 2 
mm size and dissociated according to the GentleMACS protocol for dissociation of tough 
tumors (Miltenyi Biotec), enzyme R was omitted. Erythrocytes were depleted using CD235a-
MB, according to the provided protocol (Miltenyi Biotec). 
 
2.3.4 Separation of T cell subsets 
2.3.4.1 Isolation of Pan T cells 
Freshly isolated PBMC from buffy coats were used for isolation of Pan T cells. Pan T cells 
were sorted at >99% purity using a human Pan-T Cell Isolation Kit (Miltenyi Biotec).  
 
2.3.4.2 Isolation of naïve T cells 
Freshly isolated PBMC from leukapharesis products were used for the isolation of naïve T 
cells. Naïve T cells were sorted at >99% purity using a human Naïve Pan-T Cell Isolation Kit 
(Miltenyi Biotec). 1x108 sorted naïve T cells were supplemented with 1x107 antigen-
presenting cells (2.3.2.4) and peptide pool for stimulation. 
 
2.3.4.3 Isolation of memory T cells 
Freshly isolated PBMC from leukapharesis products were used for the isolation of memory T 
cells. Memory T cells were sorted using a human Pan-T Cell Isolation Kit (Miltenyi Biotec) 
and additionally depleted of CD45RA+ cells using CD45RA-MicroBeads (Miltenyi Biotec), 
resulting in >99% purity of memory T cells. 1x108 sorted memory T cells were supplemented 
with 1x107 antigen-presenting cells (2.3.2.4) and peptide pool for stimulation. 
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2.3.4.4 Isolation of antigen-presenting cells 
Freshly isolated PBMC from leukapharesis products were used for the isolation of antigen-
presenting cells. Antigen-presenting cells were obtained by depletion of CD3+ cells using 
CD3-MB according to the provided protocol (Miltenyi Biotec). 
 
2.3.5 Stimulation of T cells 
Stimulation of isolated PBMC or dissociated tumor was done in RPMI 1640 medium, 
supplemented with 5% human AB Serum (Lonza, Basel), 2 mM L-Glutamine (GE 
Healthcare) and 1 µg/ml CD28 functional grade pure Ab (Miltenyi Biotec). PBMC were 
stimulated at 1x107 cells/ml using PepTivator (Miltenyi Biotec), at a final concentration of 0.6 
nmol/ml/peptide. Controls in the absence of exogenous peptide were included. Single cell 
suspensions obtained from tumor dissociation were stimulated under similar conditions, 
however due to low cell numbers cell density was sometimes lower than 1x107 cells/ml. 
Controls in the absence of exogenous peptide were included where possible. For generation 
of WT1-specific T cell cultures from healthy donors WT1 PepTivator and the optimal epitope 
WT1126-134 (RMFPNAPYL) were used for stimulation. For generation of HPV16-specific T cell 
cultures from healthy donors and HNSCC patients HPV16 E6 PepTivator and HPV16 E7 
PepTivator were used for stimulation. 
 
2.3.6 Enrichment of antigen-specific T cells 
2.3.6.1 Enrichment via CD154 for ex vivo characterization of antigen-specific T cells 
For ex vivo characterization of antigen-specific T cells, PBMC were stimulated for 7 h in the 
presence of 1 µg/ml CD40 mAb at functional grade purity (Miltenyi Biotec). Brefeldin A (1 
µg/ml; Sigma-Aldrich, St. Louis) was added 2 h before harvest. CD154+ cells were isolated 
by indirect magnetic labeling using CD154-allophycocyanin and anti-allophycocyanin-
MicroBeads (Miltenyi Biotec). Samples were loaded on MS Columns (Miltenyi Biotec) and 
intracellular staining was performed directly in the magnetic field using an Inside Stain Kit 
(Miltenyi Biotec). CD154+ cells were eluted using 450 µl PEB-buffer and 400 µl were directly 
analyzed at the MACSQuant Analyzer. Frequencies of antigen-specific CD4+ T cells were 
calculated by subtracting the mean number of CD4+ CD154+ cells (triplicates) obtained after 
enrichment of non-stimulated PBMC from the mean number of CD4+ CD154+ cells 
(triplicates) obtained after enrichment of peptide-stimulated PBMC and dividing by the total 
number of CD4+ T cells applied to the column. Frequencies of antigen-specific CD8+ T cells 
were determined respectively. A positive antigen-specific response was recorded if the mean 
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CD4+ CD154+ count after peptide pool stimulation exceeded the 95% confidence interval for 
the CD4+ CD154+ count in the unstimulated sample (mean plus two times the standard error 
of the mean). For patient material only single or duplicate samples were done. 
 
2.3.6.2 Enrichment via CD137 for in vitro expansion of antigen-specific T cells 
For in vitro expansion of antigen-reactive CD4+ and CD8+ T cells, PBMC of healthy donors or 
patients or single cell suspensions obtained from dissociation of fresh HNSCC tumors were 
stimulated for 24-36 h in the presence of 1 µg/ml CD28 mAb at functional grade purity 
(Miltenyi Biotec). Cells were harvested on ice using a cell scraper to remove also adherent 
and semi-adherent cells. CD137+ cells were isolated by indirect magnetic labeling using 
either CD137-PE and anti-PE-MB (Miltenyi Biotec) or CD137-allophycocyanin and anti-
allophycocyanin-MB according to the protocol of the CD137 MicroBead Kit (Miltenyi Biotec). 
Samples were loaded on MS Columns (Miltenyi Biotec), flow-through (CD137-) cells were 
collected for preparation of feeder cells. CD137+ cells were eluted using 500 µl X-Vivo15, 
spin down and plated in 24-well plates according to 2.3.7. 
 
2.3.6.3 Enrichment via pHLA tetramer 
For antigen-specific T cell enrichment, 1x108 Pan-T cells were labeled with PE-conjugated 
WT137-45 tetramer (0.5 µg/ml) for 15 min at 37°C. Allophycocyanin-conjugated WT137-45 
tetramer (1 µg/ml) and Abs were then added for 15 min at 4°C. After washing, cells were 
incubated with anti-PE-MB (Miltenyi Biotec) for 15 min at 4°C and washed again. Separation 
was performed using two subsequent MS columns according to the manufacturer’s protocol 
(Miltenyi Biotec). The positive fraction was analyzed directly using a MACSQuant flow 
cytometer (Miltenyi Biotec). Cells were gated hierarchically as follows: lymphocytes, singlets, 
viable cells, CD14- and CD20-, CD3+ and CD8+. Frequencies of WT137-45-specific CD8+ T 
cells were determined by dividing the number of WT137-45 tetramer-PE/allophycocyanin 
double-positive CD8+ T cells by the number of total CD8+ cells applied to the column. 
 
2.3.7 Expansion of antigen-specific T cells 
Antigen-reactive CD4+ and CD8+ T cells were isolated after 24-36 h using a CD137 
MicroBead Kit (Miltenyi Biotec) and expanded in X-Vivo15 (Lonza) supplemented with 5% 
human AB serum (Lonza). Autologous feeder cells were prepared by depletion of CD3+ cells 
from the negative fraction of CD137 enrichment. To inhibit proliferation of feeder cells they 
were treated with 25 μg/ml mitomycin C (Sigma-Aldrich) or irradiated with 50 Gy in an X-ray 
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irradiator. Activated and enriched CD137+ cells were co-cultivated with feeder cells at a ratio 
of 1:100 with a final density of 5x106 cells/ml in 24-well plates in medium supplemented with 
15 ng/ml IL-21. From day 2 on medium supplemented with recombinant IL-7 (5 ng/ml), IL-15 
(5 ng/ml), and IL-21 (10 ng/ml) was used added. Medium, including the recombinant 
cytokines, was replenished every second day. Cells were washed and counted at day 6 and 
then expanded for further 3 days. Before restimulation experiments were done T cells were 
cultured in X-Vivo-15 containing only 5% AB-Serum and no cytokines for at least two days. 
 
2.3.8 Cultivation of primary tumor cells 
Tumor fragments were cultivated in RPMI supplemented with 10% human AB serum (Lonza), 
antibiotic antimycotic solution (1x, Sigma Aldrich) and Thiazovivin (10 µM, Miltenyi Biotec). 
 
2.3.9 Freezing and thawing of cells 
T cells and autologous APC were frozen in cell concentration of maximum 2x107 cells/ml in 
X-Vivo15 supplemented with 20% AB-Serum (Cellgro, Mediatech Inc.) and 10% DMSO 
(Sigma Aldrich). The cells were taken up in pre-cooled X-Vivo15 and AB-Serum and 
transferred to pre-cooled cryovials, DMSO was added and mixed. Cryovials were rapidly 
wrapped with tissue paper and frozen at -70°C The cells were thawed by incubation in a 
37°C water bath and transferred into pre-warmed RPMI 1640 or X-Vivo15 supplemented with 
5% AB-Serum. After complete thawing the cells were centrifuged and resuspended in 
medium 
 
2.4 Detection methods 
2.4.1 Determination of HPV16 Status of HNSCC tumors 
Determination of HPV16 status was performed by PCR of viral DNA as published previously 
(Klussmann, Weissenborn et al. 2001, Preuss, Weinell et al. 2008). In brief, DNA integrity 
was determined by β-globin gene PCR, and HPV-DNA was detected by use of a nested PCR 
protocol with degenerated primers A5/A10-A6/A8 followed by sequencing of positive HPV 
PCR products. 
 
2.4.2 Cell Surface marker staining  
For flow cytometric analysis of cell surface markers 0.1 - 1x106 cells were resuspended in 50 
μl cold PEB. Cells were stained with fluorochrome-coupled antibodies in a titer of 1:11 for 10 
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min at 4°C. Cells were washed with 900 µl PEB and centrifuged at 300 g for 5 - 10 min, 
resuspended in PEB, and analyzed. Cell surface marker staining was accordingly performed 
in 96-well flat-bottom cell culture plates, but staining was directly done in medium and 
washing volume was reduced to 100 µl PEB. 
 
2.4.3 pHLA tetramer staining  
pHLA tetramer staining was done with 1 µg/ml WT1 tetramer-PE or CMV pp65495-503 tetramer-
PE for 45 min at 4°C. For the last 10 min other surface staining antibodies were added. 
Samples were washed once using PEB-buffer and directly analyzed. 
 
2.4.4 Staining of intranuclear FoxP3 
Staining of the transcription factor FoxP3 was done using Fixation/Permeabilization solution 
and 10x Permeabilization solution provided with the FoxP3 Staining buffer set (Miltenyi 
Biotec). Samples were handled on ice and pre-cooled solutions were used through-out the 
staining procedure. Samples resuspended in 50 µl PEB-buffer were stained with cell surface 
staining antibodies for 10 min at 4°C. Samples were washed with 1 ml of PEB-buffer, 
resuspended in 1 ml freshly prepared, cold Fixation/Permeabilization solution, mixed, and 
incubated for 30 min at 4°C. Samples were washed once using 1 ml PEB-buffer and once 
using freshly prepared, cold 1x Permeabilization solution. Cell pellet was resuspended in 90 
µl 1x Permeabilization solution, 20 µl FcR blocking reagent (Miltenyi Biotec) was added and 
incubated for 5 min at 4°C. 10 µl anti-FoxP3-allophycocyanin or anti-FoxP3-PE antibody was 
used for staining for 30 min at 4°C. Samples were washed once using 1x Permeabilization 
solution, resuspended in 200 µl PEB-buffer, and directly analyzed. 
 
2.4.5 Intracellular cytokine staining 
Antigen-specific cytokine expression of expanded T cell cultures was determined by co-
cultivation of 1 – 2.5x105 T cells with 5x104 antigen-loaded APC in 50 µl RPMI supplemented 
with 5% AB-Serum, 1 µg/ml CD28 mAb in a 96-well cell culture plate for 6 h. 1 µg/ml 
brefeldin A was added after 2 h of co-culture. Cells were stained intracellular directly in the 
96-well cell culture plate. Staining antibodies for cell surface marker staining and cytokine 
staining were added at a titer of 1:11, mixed and incubated for 10 min at room temperature. 
25 µl InsideFix solution (Miltenyi Biotec) was added, plate was mixed using an orbital shaker  
and incubated for 20 min at room temperature. 25 µl 10x InsidePerm solution (Miltenyi 
Biotec) was added, plate was mixed using an orbital shaker and incubated for 10 min at 
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room temperature. Samples were washed once using 100 ml PEB, centrifuged and 
resuspended in 200 µl PEB. Samples were directly analyzed at the MACSQuant Analyzer or 
stored at 4°C for maximum 12 h. 
 
2.4.6 Detection of released cytokines by Multiplex 
Cellculture supernatants were collected after 6 – 36 h stimulation of T cells or dissociated 
tumor material on ice, centrifuged for 10 min at 10000 g at 4°C, transferred to a new, cold 
microcentrifuge tube and stored at -70°C until further analysis. Assay was performed using 
the MACS Plex cytokine 12 Kit, human (Miltenyi Biotec) according to the provided protocol. 
Supernatants were diluted 1:2 and were measured in triplicates where possible. Analysis 
was done using the MAQSQuant Express Mode for MACSPlex. 
 
2.4.7 Determination of CD107a expression 
Antigen-specific cytotoxic potential of expanded T cell cultures was determined by co-
cultivation of 1 – 2.5x105 T cells with 5x104 antigen-loaded APC in 50µl RPMI supplemented 
with 5% AB-Serum, 1 µg/ml CD28 mAb, 1 µg/ml monensin and 5µl of CD107a-PE in a 96-
well cell culture plate for 6 h. Subsequently cells were transferred to microcentrifuge tubes, 
washed once, resuspended in 50 µl PEB. Staining antibodies for surface and intracellular 
staining were added at a titer of 1:11 and samples were mixed and incubated for 10 min at 
room temperature. Then cell were fixed by addition of 25 µl InsideFix solution (Miltenyi 
Biotec), mixing and incubation for 20 min at room temperature. Cells were then 
permeabilized by addition of 25 µl 10x InsidePerm solution (Miltenyi Biotec), mixing and 
incubation for 10 min at room temperature. Cells were washed once by addition of 500 µl 
PEB, centrifuged, resuspended in 200 µl PEB and analyzed. 
 
2.4.8 Cytotoxicity assay 
For measurement of direct cytotoxicity, T2 cells were either pulsed with peptide pools 
(specific: WT1; unrelated: HPV16 E7; Miltenyi Biotec) or left unpulsed overnight, labeled with 
different concentrations of CellTrace Violet (Invitrogen, Carlsbad) for 5 min at 37°C. 
Unloaded T2 cells were labeled with 1 µM, WT1 loaded T2 cells were labeled with 0.1 µM, 
and HPV16 E7-loaded T2 cells were labeled with 0.0125 µM CellTrace Violet. Cells were 
washed 3 times, and pooled subsequently. 0.25x104 labeled and pooled T2 cells were then 
co-cultured with 0.5x104, 2.5x104, 1.25x105, or 2.5x105 expanded T cells to achieve different 
effector to target (E:T) ratios in a 96-well flat-bottom cell culture plate for 4 h. For blocking 
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experiments, 1 µg/ml MHC class I mAb (W6/32) was added to the co-culture. Subsequently, 
cells were stained by adding 2 µl anti-CD20-allophycocyanin, mixing and incubation for 10 
min at 4°C to label T2 cells. 50 µl PEB-buffer was added and cells were analyzed directly at 
the MACSQuant Analyzer. PI (1 µg/ml) was added to each well directly prior to measurement. 
Antigen-specific killing was determined by flow cytometric measurement of T2 cell viability. 
Percentage killing was calculated by subtracting the ratio of living antigen-loaded T2 cells 
after co-culture in the presence or absence of T cells from unity. Percentage antigen-specific 
killing was calculated by subtracting killing determined for non-loaded T2 cells from killing 
determined for antigen-loaded T2 cells. 
 
2.4.9 Determination of functional avidity  
For determination of functional avidity, T2 cells were pulsed overnight with escalating doses 
of the optimal CMV pp65495-503 (NLVPMVATV) peptide or WT137 peptide (VLDFAPPGA) and 
co-cultured with expanded T cells at a ratio of 1:5 for 6 h. CD107a expression was 
determined as described before (2.4.7). Cytokine expression was determined as described 
before (2.4.5). 
 
2.5 Statistics 
Descriptive statistics were done using Microsoft Excel 14.0, Graph Pad Prism 6.0 and TIGR 
Multi Experiment Viewer 4.9. Calculation of statistical significances and correlations was 
done with Graph Pad Prism 6.0.  For all data sets showing a Gaussian distribution the 
parametric paired or unpaired two-tailed Student t test was used. Significance was defined 
as: * = p < 0.05, ** = p < 0.01, and *** = p ≤ 0.001.  
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3 Results 
 
3.1 Establishment of enrichment strategies based on activation markers for 
the detection of rare antigen-specific T cells 
T cells specific for TAA, such as WT1 and HPV16, are present in the blood of healthy and 
diseased individuals only in very low frequencies. Due to frequencies below 1x10-4 cells 
within PBMC these TAA-specific T cells cannot be detected ex vivo with commonly used 
detection methods for antigen-specific T cells, such as flow cytometric detection of pMHC 
multimer+ T cells or ELISPOT. However, implementation of an magnetic enrichment of 
antigen-specific T cells, as already demonstrated for magnetic enrichment of pMHC 
multimer+ T cells (Moon, Chu et al. 2007, Obar, Khanna et al. 2008, Kwok, Tan et al. 2012), 
cytokine secreting T cells (Goodyear, Pratt et al. 2008) and activation marker expressing 
cells (Bacher, Schink et al. 2013) can drastically enhance the sensitivity. 
Therefore, it was investigated whether a combination of magnetic enrichment of activation 
marker expressing T cells with a subsequent multi parameter flow cytometric analysis is 
suitable for the detection and characterization of rare TAA-specific T cells. The methods 
were evaluated for T cells specific for the recall antigens such as CMV or EBV, which have 
been detected and enumerated ex vivo and comprise up to 10% (10-1) of the CD4+ and CD8+ 
T cell compartment, respectively (Sylwester, Mitchell et al. 2005). In the next step the 
methods were transferred to rare TAA-specific T cells. To allow the detection of the complete 
repertoire of antigen-specific T cells, enrichment of activation marker expressing T cells after 
short-time stimulation using a pool of peptides spanning the amino acid sequence of the 
proteins, was evaluated. For ex vivo detection, enumeration, and characterization enrichment 
of CD154+ cells after antigen stimulation was implemented; for characterization following in 
vitro expansion enrichment of CD137+ cells after antigen stimulation was employed. 
 
3.1.1 Enrichment of CD154+ T cells 
CD154 (CD40L) is a member of the TNF-family of co-stimulatory molecules and has been 
introduced as a molecule specifically expressed on activated, not resting TH cells after 
stimulation times of 4 h to 24 h (Chattopadhyay, Yu et al. 2005, Frentsch, Arbach et al. 2005). 
Enrichment of antigen-specific T cells using the T cell activation marker CD154 has recently 
been well characterized (Bacher, Schink et al. 2013). Antigen-reactive T cell enrichment 
(ARTE) facilitates direct ex vivo analysis of antigen-specific CD4+ T cells after a magnetic 
enrichment of antigen-activated, CD154-expressing cells. The short antigen stimulation times 
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needed for CD154 up-regulation allows for the complete antigen-reactive TH cell 
compartment to be simultaneously enumerated and phenotyped according to the cytokine 
expression profile and expression of cell surface differentiation markers by multi-parametric 
flow cytometry. 
First, ex vivo detection and characterization of T cells specific for recall antigens via CD154 
enrichment and multi-parametric analysis by flow cytometry was established. To this end, 
2.5x107 PBMC obtained from CMVpos healthy donors were stimulated in vitro for 7 h using a 
CMV pp65 peptide pool, CD154-expressing cells were enriched. The count of CD154+ T cells 
was determined by flow cytometry before and after enrichment in the positively selected cell 
population as well as in the flow-through fraction. 
 
 Figure 3.1: Enrichment of CD154+ cells allows detection of rare antigen-specific T cells. 2.5x107 
cells or 5.0x107 PBMC of a CMVpos healthy donor were stimulated using CMV peptide pool or TAA 
peptide pools (WT1 and HPV16), respectively, for 7 h. Dot plots of a representative CMVpos healthy 
donor are shown. CD4+ CD154+ cells were assessed before (left) and after enrichment (middle). Cell 
count and percentage of CD4+ CD154+ and CD4+ CD154+ TNF-α+ cells within CD4+ T cells and of 
CD8+ CD154+ and CD8+ CD154+ TNF-α+ cells within CD8+ T cells is given. CD154 labeling of the flow-
through of the separation is shown to prove efficiency of the enrichment procedure (right). 
 
Antigen-specific CD154+ T cells were detected before enrichment in the CMV stimulated 
samples (0.4% within CD4+ T cells) (Fig. 3.1). After enrichment of CD154+ cells elevated 
numbers of CD154+ CD4+ T cells were detected in the stimulated sample compared to the 
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unstimulated control. Addition of a secretion inhibitor to the cultures 2 h before harvesting 
allowed for co-staining of effector cytokines by intracellular staining. More than 70% of 
CD154+ cells produced TNF-α. Furthermore, antigen-specific CD8+ CD154+ T cells, of which 
>55% produced TNF-α, were detected after enrichment (Fig. 3.1). Hardly any CD154+ 
expressing cells were detected in the negative fraction (flow-through) of the enrichment, 
demonstrating that the enrichment procedure was efficient. 
The CD154 enrichment approach can be used to enumerate frequencies of antigen-specific 
T cells. CMV-specific CD4+ T cells can be detected before enrichment and therefore provide 
a good opportunity to validate the enumeration procedure (Table 3.1).  
For CMV stimulation 2.5x107 cells have been used, of which 39% were CD4+ T cells. CD4+ 
cell count was determined before cells were applied to the column, as some cells get lost 
during staining and washing. The CD154+ CD4+ cell count detected after enrichment in the 
unstimulated sample was subtracted from the cell count detected in the stimulated sample. 
The absolute count needs to be extrapolated as not the whole sample can be measured, but 
only 4/5. By dividing the absolute count of antigen-specific CD4+ T cells by the number of 
CD4+ T cells applied on the column the frequency of antigen-specific CD4+ T cells was 
calculated. The calculated frequency (0.25%) lies in the same range as the frequency 
detected in the sample before enrichment (0.40%), but may in some cases underestimate 
the real frequency by factor of 1.5 up to 2 (Table 3.1). 
 
Table 3.1: CD154+ cell enrichment allows enumeration of antigen-specific T cells. Example of 
enumeration of CMV-, WT1-, and HPV-specific T cells before and after enrichment of CD154+ cells. 
Cell counts and calculated frequencies within CD4+ T cells are given. Ag = antigen, n.d. = not detected. 
 
 CMV WT1 HPV 
PBMC used for stimulation 2.5x107 5x107 5x107 
CD4+ T cells applied on to the column 0.78x107 1.8x107 1.8x107 
CD154+ CD4+ cells in stimulated sample 15845 800 1050 
Ag-specific CD154+ CD4+ T cells  15678 466 716 
Extrapolated count of Ag-specific CD154+ CD4+ cells  19597 582 895 
Calculated frequency of Ag-specific CD154+ CD4+ 
cells within CD4+ (after enrichment) 
2.5x10-3 (0.25%) 3.2x10-5 4.9x10-5 
Measured frequency of Ag-specific CD154+ CD4+ 
cells within CD4+ (before enrichment) 
4x10-3 (0.40%) n.d. n.d. 
 
Results 
31 
 
The same stimulation, enrichment, and analysis approach was done for the detection of 
WT1- and HPV16-specific T cells to prove feasibility for rare antigen-specific T cells. Before 
enrichment no elevated counts of CD154-expressing T cells were detected compared to the 
unstimulated control, in contrast to CMV-stimulated samples, clearly indicating that WT1- and 
HPV16-specific T cells are low frequent in healthy donors and cannot be detected without 
enrichment step (Fig. 3.1). After enrichment of CD154+ cells elevated counts of CD4+ 
CD154+ cells were detected in both the WT1 and HPV16 stimulated samples compared to 
the unstimulated sample, showing that also low frequent TAA-specific T cells can be 
enriched and detected using this approach. The starting cell number for detection of rare 
antigen-specific T cells should be at least 1x107 PBMC to ensure detection of at least 10 to 
100 specific events.  
The CD154 enrichment approach also allows determination of the differentiation status and 
the functionality of antigen-specific T cells. To this end, cells were co-stained for 
differentiation markers CD45RO and CCR7 and for cytokines in samples of PBMC from an 
EBVpos healthy donor stimulated with EBV antigens. These data show that both memory 
(CD45RO+) and naïve (CD45RO- CCR7+) T cells can be enriched via CD154 after antigen-
specific stimulation (Fig. 3.2). TNF-α-producing T cells revealed a memory phenotype 
predominantly, but also naïve TNF-α+ T cells were detected. IFN-γ-producing EBV-specific 
TH cells were memory T cells exclusively. Phenotyping is exemplarily shown for EBV-specific 
T cells, but similar patterns were observed for other antigen specificities. 
 
 
Figure 3.2: Enrichment of CD154+ cells allows phenotyping of antigen-specific T cells. 5.0x107 
PBMC were stimulated using EBV peptide pools EBNA-1 and LMP2a for 7 h and subsequently 
CD154+ cells were enriched. Dot plots of a representative healthy donor are shown. CD4+ CD154+ cell 
counts and frequencies were assessed after enrichment. 
 
Direct co-staining for several cytokines allows detection of poly-functionality of antigen-
specific T cells. Apart from TNF-α and IFN-γ (Fig. 3.3A) also other cytokines were 
counterstained in an independent staining panel (Fig. 3.3B). IL-2 expression was commonly 
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co-detected in samples where TNF-α and IFN-γ production was detected. Some donors 
revealed a small proportion of IL-10-producing T cells among the CD154+ antigen-specific TH 
cells. IL-17 production was not detected in EBV and CMV antigen-stimulated samples. 
 
 
Figure 3.3: CD154 enrichment allows detection of poly-functional TH cells. 5x107 PBMC were 
stimulated using EBV peptide pools EBNA-1 and LMP2a for 7 h and subsequently CD154+ cells were 
enriched. Dot plots of two representative healthy donors are shown. (A) Co-staining of TNF-α and IFN-
γ on CD4+ CD154+ T cells. (B) Detection of IL-2, IL-10, and IL-17 among CD4+ CD154+ T cells. 
 
Taken together, detection of CMV- and EBV-specific CD4+ and CD8+ T cells proves the 
suitability of characterization of antigen-specific T cells in terms of prevalence, differentiation 
status, and functionality using CD154+ cell enrichment. Enumeration of antigen-specific T 
cells is possible and reliable for the CD4+ T cell compartment. Furthermore, the feasibility for 
the detection and characterization of rare WT1- and HPV16-specific T cells was shown.  
 
3.1.2 Enrichment of CD137+ T cells 
CD137 (4-1BB) is a member of the TNF-family of co-stimulatory molecules and plays a major 
role in activation, survival, and proliferation of memory CD4+ and CD8+ T cells (Sabbagh, 
Snell et al. 2007). CD137 has been described as a marker to detect naïve and memory 
antigen-specific T cells after antigen stimulation and has also been used to sort antigen-
specific T cells (Pollok, Kim et al. 1993, Wolfl, Kuball et al. 2007). In contrast to CD154, the 
kinetic of upregulation of CD137 is slower, as it is expressed on activated T cells 12 h up to 
72 h after stimulation (Wolfl, Kuball et al. 2007, Wehler, Karg et al. 2008). A recent 
publication showed that CD137 expression is also found on activated Treg cells already after 
5 h of stimulation (Schoenbrunn, Frentsch et al. 2012). Therefore, CD137 marks both 
activated CD4+ and CD8+ effector T cells (Teff), but also Treg. 
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Similar to the CD154 protocol the CD137 protocol was tested for T cells specific for recall 
antigens and then transferred to the tumor-antigens of interest, WT1 and HPV16 E6 and E7, 
for which T cells are expected to be present in low frequencies in healthy donors. 
 
3.1.2.1 CD137 is co-expressed with other T cell activation markers 
To confirm that CD137 is upregulated specifically on antigen-specific T cells, co-expression 
with other T cell activation markers, such as CD154 and CD69, was analyzed. To this end, 
5x107 PBMC obtained from a CMVpos healthy donor were stimulated in vitro for 24 h using a 
CMV pp65 peptide pool and CD137+ cells were magnetically enriched. Expression of CD137, 
CD154, and CD69 was analyzed by flow cytometry before enrichment and after enrichment 
in the positively selected cells and in the flow-through. Before enrichment CD137+ were 
detected within CD4+ and CD8+ T cells, a subpopulation of CD4+ CD137+ cells expressing 
also the activation marker CD154 and all CD8+ CD137+ cells expressing the activation 
marker CD69 (Fig. 3.4A). After enrichment of CD137+ cells CD154 was co-expressed on the 
majority of CD4+ CD137+ T cells (Fig. 3.4B). However, a reasonable fraction of CD4+ CD137+ 
cells did not express CD154, this fraction most likely includes antigen-specific Treg, which are 
known to not upregulate CD154 upon stimulation (Schoenbrunn, Frentsch et al. 2012), but 
also contains non-antigen-specific T cells (discussed in more detail in 3.1.2.3). CD4+ CD154+ 
CD69+ and thus activated CD4+ T cells were highly enriched in the positive fraction, clearly 
indicating that CD137 enrichment indeed selects antigen-activated CD4+ T cells. Likewise, 
CD8+ T cells that co-express CD137 and CD154 were detected after enrichment of CD137+ 
cells. Additionally, CD69 was highly co-expressed on CD137+ T cells, confirming their 
activated status following antigen-stimulation. The negative fraction of the enrichment 
contained hardly any CD137+ T cells, suggesting that CD137+ cells have been depleted 
efficiently and the majority of activated antigen-specific T cells was sorted into the positive 
fraction (Fig. 3.4C). These data show that CD137 is a suitable marker for the ex vivo 
enrichment of activated antigen-reactive CD4+ and CD8+ T cells after antigen stimulation. 
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Figure 3.4: Feasibility test for enrichment of antigen-specific T cells via CD137. (A-C) Staining of 
activation markers CD137, CD154, and CD69 on CD4+ (left) and CD8+ (right) T cells after 24 h 
stimulation of 5x107 PBMC obtained from a CMVpos donor with CMV pp65 peptide pools. (A) Before 
enrichment, (B) on positive fraction after enrichment of CD137+ cells, and (C) on negative fraction after 
enrichment of CD137+ cells. 
 
 
3.1.2.2 CD137+ cells are accurately detected after enrichment with anti-CD137-PE 
In order to disclose differences in detection when different reagents are used for enrichment 
of antigen-specific CD137+ cells, labelling with anti-CD137-Biotin and anti-Biotin-MB was 
compared to labelling with anti-CD137-PE and anti-PE-MB. To this end, 1x107 PBMC from a 
CMVpos healthy donor were stimulated using CMV pp65 peptide pool for 18 h. Labelling with 
anti-CD137-PE results in comparable frequencies of detected CD137+ T cells both with and 
without additional labelling with anti-PE-MB (2.0 to 2.1% within CD4+ T cells and 4.0 to 4.3% 
within CD8+ T cells) (Fig. 3.5). Comparable frequencies of CD137+ T cells were detected 
when the staining was performed with anti-CD137-Biotin and anti-Biotin-PE (2.4% within 
CD4+ T cells and 4.5% within CD8+ T cells). However, when cells were additionally labeled 
with anti-Biotin-MB a decreased frequency of CD137+ T cells was found, independent of 
whether a subsequent staining was done with anti-CD137-PE or anti-Biotin-PE (0.6 to 0.7% 
within CD4+ T cells and 2.3 to 2.6% within CD8+ T cells). These results indicate that labeling 
with anti-Biotin-MB blocks in part the binding of anti-Biotin-PE, which results in 
underestimating the frequencies of CD137+ T cells.  
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Figure 3.5: Anti-CD137-PE allows accurate determination of CD137+ cells with and without MB-
labelling. 1x107 PBMC from a CMVpos healthy donor were stimulated using CMV pp65 peptide pool 
for 18 h and stained using either anti-CD137-PE or anti-CD137-Biotin as indicated, washed, and 
subsequently labelled with either anti-PE-MB, anti-Biotin-MB, or no MB as indicated. After washing 
cells were stained with either anti-CD137-PE or anti-Biotin-PE as indicated. (A) Dot plots of stimulated 
and stained PBMC. Percentage of CD137+ cells within CD4+ and CD8+ T cells is given, respectively. 
(B) Frequency of CD137+ cells within CD4+ (left) and CD8+ (right) T cells measured for the indicated 
labelling and staining conditions. Bars represent mean of 3 measurements, which have been done 
with PBMC of three donors, and standard deviation is given.  
 
Using the PE-System an increased level of CD137+ cells was discovered in the unstimulated 
sample (Fig. 3.6) compared to the Biotin-System. These CD137+ cells are most likely pre-
activated T cells that are not specific for the antigen used for stimulation. The higher 
background detected in the PE-System is due to the differences in detection efficiency, but 
number and quality of enriched cells in both the PE- and Biotin-System do not differ. The 
combination of CD137-PE and anti-PE-MB was chosen for the labeling in further analyses. 
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Figure 3.6: CD137-PE enrichment system detects higher frequencies of CD137+ cells after 
CD137 enrichment. PBMC from a CMVpos healthy donor were stimulated using either no peptide 
(w/o), WT1 peptide pool, HPV16 and HPV18 peptide pools, or CMV pp65 peptide pool for 18 h and 
subsequent enrichment of CD137+ cells either via CD137-PE and PE-MB (A) or CD137-Biotin and 
biotin-MB (B). Detection of CD137+ cells was done by staining with CD137-PE in all samples. Mean 
and standard deviation are given. 
 
3.1.2.3 CD137+ effector and regulatory T cells are enriched via CD137 
CD137 was shown to be also expressed on Treg upon 5 h of antigen stimulation, whereas 
effector T cells need longer (>12 h) stimulation times (Schoenbrunn, Frentsch et al. 2012) for 
surface expression of CD137. Therefore it is expected that the CD137 enrichment approach 
also enriches antigen-specific, activated Treg. To test whether activated Treg are enriched with 
our approach we stimulated 5x107 PBMC of an EBVpos healthy donor using EBV EBNA-1 and 
LMP2a peptide pools for 34 h and enriched CD137+ cells. The transcription factor FoxP3 and 
the IL-2 receptor α-chain (CD25) are the most common markers to identify nTreg. Accordingly, 
FoxP3 and CD25 were used to identify Treg. However, both CD25 and also recently FoxP3 
have been described to not exclusively be expressed on Treg, but also transiently on activated 
effector T cells (Allan, Crome et al. 2007, Wang, Ioan-Facsinay et al. 2007). Indeed, high 
amounts of CD4+ FoxP3+ CD25+ cells were detected after enrichment when recall antigens 
with a high frequency of memory T cells, such as EBV antigens, were used for stimulation 
(Fig. 3.7A). These CD4+ FoxP3+ CD25+ showed a CD137dim staining.  
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Figure 3.7: CD137dim FoxP3+ CD25+ CD4+ T cells are enriched via CD137 enrichment. PBMC of 
an EBVpos healthy donor were stimulated with EBV EBNA-1 and LMP2a peptide pools (EBV) or left 
unstimulated (w/o) for 34 h. Subsequently CD137+ cells were enriched via anti-CD137-PE and anti-
PE-MB. Dot plots of a representative healthy donors are shown. Cells were gated on CD4+ (left) and 
CD8+ (right) T cells after enrichment of CD137+ cells from (A) PBMC or (B) CD25-depleted PBMC. 
Cell count and percentage within gated cells are given. CD137dim cells are encircled by a bold red line.   
 
To further investigate whether these FoxP3+ CD137dim cells are nTreg, experiments were 
performed where CD25+ cells, which include all nTreg and also pre-activated Teff, were 
depleted prior to antigen specific stimulation and CD137 enrichment (Fig. 3.7B). When 
CD25+ cells were removed the enriched CD137+ population in the unstimulated sample was 
diminished, indicating that a background of CD137+ pre-activated T cells was depleted. 
Furthermore, the CD137dim population is not detectable after CD137 enrichment in the 
stimulated sample, which indicates that this CD137dim population indeed consists of activated 
nTreg. However, the amount of CD137dim CD25+ FoxP3+ T cells exceeded the number of 
antigen-specific CD137high cells by several times (in the depicted example the ratio of CD137 
expressing Treg to Teff was 5:1), which makes it unlikely that all CD137dim cells were antigen-
specific Treg. Recently, ratios of fungi-specific Treg to Teff were determined, for A. fumigatus 
the number of Treg did indeed exceed the number of specific Teff in some donors, but only by 
1.5-fold in the mean (Bacher, Kniemeyer et al. 2014). In our experiments, the distinct 
CD137dim population was only detected in samples in which also a high Teff memory 
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response against the chosen antigen was induced, therefore we hypothesize that the 
CD137dim population contained, additionally to antigen-specific nTreg, also Treg that have been 
activated by bystander activation, most likely induced by soluble factors. 
 
 
Figure 3.8: Depletion of CD25+ cells can increase activation of antigen-specific T cells. PBMC or 
CD25-depleted PBMC were stimulated using EBV EBNA-1 and LMP2a peptide pools for 7 h and 
subsequently CD154+ cells were enriched. Dot plots after enrichment of CD154+ cells are shown for 
CD4+ (left) and CD4- (right) T cells of one representative healthy donor. Cell counts are given. 
 
Depletion of CD25+ cells resulted in some cases in a detection of higher numbers of naïve 
and memory CD4+ and CD8+ antigen-specific effector T cells (Fig. 3.8). These data imply that 
the activation of antigen-specific effector T cells can be hampered by activated, antigen-
specific Treg. 
 
3.1.2.4 Low frequent T cells can be enriched via CD137 
The CD137 enrichment approach was transferred to the tumor-antigens of interest, WT1 and 
HPV16 E6 and E7. To this end, 1x108 PBMC were stimulated for 24 to 36 h and CD137+ 
cells were enriched. CD137-expression was analyzed before and after enrichment. 
Frequencies of CD137+ cells in the enriched fraction did only slightly increase when PBMC 
were stimulated with WT1 (30.4 to 86.0% and 13.2 to 64.1% within CD4+ and CD8+ cells, 
respectively) or HPV16 (47.3 to 86.3% and 10.6 to 74.7% within CD4+ and CD8+ cells, 
respectively), compared to the unstimulated control (16.6 to 80.0% and 7.9 to 38.0% within 
CD4+ and CD8+ cells, respectively), as the numbers of these specific T cells were very low, 
as already observed using the CD154 enrichment approach. When collecting data from 
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several samples of different healthy donors, however, a significant increase in frequencies of 
CD137+ T cells was detected in the stimulated samples compared to the unstimulated 
samples (Fig. 3.9). Thus, these results indicate that WT1- and HPV16-specific T cells have 
been enriched from healthy donors, however, suggest that a majority of enriched T cells in 
the samples were in vivo pre-activated and not induced by antigenic stimulation. 
 
 
 
Figure 3.9: Enrichment of rare CD137-expressing antigen-specific T cells. 1x108 PBMC from 
healthy donors were stimulated with either WT1 peptide pool or HPV16 E6 and E7 and HPV18 E6 and 
E7 peptide pools as indicated or left unstimulated (w/o) for 24 - 36 h. CD137+ cells were enriched via 
anti-CD137-PE and anti-PE-MB. (A and B) Samples before enrichment. (A) Dot plots of a 
representative sample, unstimulated and stimulated with WT1 peptide pool, CD137 expression on 
CD4+ (left) and CD8+ (right) T cells is depicted. (B) Frequency of CD137+ T cells within CD4+ (left) and 
CD8+ (right) T cells is shown for 12 donors, 4 independent experiments were done. Mean is given. (C 
and D) Samples after enrichment of CD137+ cells. (C) Dot plots showing staining of an aliquot of a 
representative sample (same donor as depicted in (A)), unstimulated and stimulated with WT1 peptide 
pool, CD137 expression on CD4+ (left) and CD8+ (right) T cells is depicted. (D) Frequency of CD137+ 
T cells within CD4+ (left) and CD8+ (right) T cells is shown for the same 12 donors as depicted in (B). 
Mean is given. 
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3.1.2.5 Antigen-specific T cell lines can be generated after CD137 enrichment 
To clearly demonstrate the presence of TAA-reactive T cells in the CD137+ fraction and 
obtain sufficient cell numbers for further phenotypical and functional characterization, a 
protocol was established to generate WT1- and HPV-specific T cell lines (Fig. 3.10A). 
Therefore 1x108 PBMC were stimulated with the antigens for 24 – 36 h, CD137+ cells were 
enriched, and subsequently co-cultured with CD3-depleted, irradiated autologous feeder 
cells (APC) derived from the negative fraction of the CD137 enrichment step for 11 to 12 
days. IL-21 was added on day zero, from day two on cells were replenished with IL-21, IL-7, 
and IL-15 every second day. On day 9, cells were washed to remove the cytokines to start a 
resting phase before an antigenic restimulation for further analysis.  
Flow cytometric analysis of the enriched cell fractions revealed significantly elevated 
numbers of CD4+ CD137+ and CD8+ CD137+ T cells in stimulated samples compared to 
unstimulated controls (Fig. 3.10B). Absolute cell numbers after enrichment ranged from 
1.2x104 to 4.3x104 (mean 3.3x104) viable CD137+ leukocytes in the WT1stimulated samples 
and 0.3x104 to 1.3x105 (mean 3.5x104) viable CD137+ leukocytes in the HPV stimulated 
samples; compared to 0.9x104 to 3.2x104 (mean 2.5x104) in the control samples. During the 
9-day culture period enriched T cells from either the stimulated as well as the unstimulated 
sample expanded about 100-fold (Fig. 3.10C). 
 
 
 
Figure 3.10: Generation of antigen-specific T cell lines via CD137 enrichment. (A) Scheme of 
enrichment and expansion protocol for the generation of antigen-specific T cell lines via CD137 
enrichment. (B) Cell count of viable CD137+ lymphocytes after enrichment of CD137+ cells from 1x108 
PBMC either without stimulation or stimulated with the indicated antigens, n = 17 healthy donors. 
Mean is given. (C) Expansion rate of CD3+ cells within 9 days. Mean is given. 
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Antigen-specificity was confirmed after expansion by restimulation assays using antigen-
loaded APC (Fig. 3.11). Only few T cells were activated when co-cultivated with unloaded, 
autologous APC. T cell cultures contained up to 54% and 15% WT1-specific CD4+ and CD8+ 
TNF-α-producing T cells, respectively; and 65% and 31% HPV-specific TNF-α-producing 
CD4+ and CD8+ T cells, respectively. 
 
Figure 3.11: Restimulation of antigen-specific T cell lines. (A and B) TNF-α producing CD4+ (left) 
and CD8+ (right) T cells after restimulation of expanded T cells from 17 healthy donors with the 
indicated stimuli, no antigen, unloaded autologous APC, or autologous APC loaded with the respective 
peptide pool WT1 (A) and HPV16 E6, E7 and HPV18 E6, E7 (B). Mean is given. Significance was 
determined using paired Student’s t-test. 
 
We further investigated the influence of Treg on the generation of antigen-specific T cells via 
the CD137 enrichment approach. CD4+ FoxP3+ T cells get highly enriched through the 
CD137 enrichment step, due to the enrichment of Treg and activated Teff that transiently 
upregulate FoxP3 (see section 3.1.2.3). However, the levels of CD4+ FoxP3+ T cells were 
very low after the 9 day expansion phase (Fig 3.12A), as the chosen expansion conditions 
using IL-7, IL-15, and IL-21 did not favor the expansion of Treg. Additionally, we checked 
whether pre-depletion of CD25+ cells alters the generation of antigen-specific T cell lines via 
CD137 enrichment (Fig. 3.12). The expansion rate of T cells after enrichment was 
comparable in both unsorted and CD25-depleted samples (Fig. 3.12B). Interestingly, 
significantly more CD8+ T cells were detected after the expansion of the CD25-depleted 
samples, most likely due to the fact that CD25-depletion removes most exclusively CD4+ T 
cells and thus skews the T cell composition towards CD8+ T cells (Fig. 3.12C). The quality 
and frequency of antigen-specific CD8+ and CD4+ T cells was not significantly different after 
expansion (Fig. 3.12D, E). In summary, the enrichment of CD137+ Treg cells was not an issue 
for the enrichment and expansion of low frequent effector T cells, such as WT1- and HPV16-
specific T cells, as the depletion of CD25+ cells did not alter the quality and expansion 
capacity of the enriched antigen-specific effector T cells. Therefore we did not deplete CD25+ 
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cells before enrichment in further experiments. However, in some cases, for antigens that 
show high abundance of specific Treg depletion of CD25+ cells might be favorable to ensure 
an optimal expansion. 
 
 
Figure 3.12: Influence of FoxP3+ T cells on 
generation of antigen-specific T cell lines 
via CD137 enrichment. (A) Percentage of 
FoxP3+ cells within CD4+ T cells before and 
after enrichment of CD137+ cells and after 9 
day expansion of CD137+ cells. Bars 
represents mean of 3 donors, standard 
deviation is given. (B-E) Characteristics of 
expanded T cells after 9 day expansion of 
WT1- or HPV-stimulated CD137+ cells either 
preformed with unsorted or CD25-depleted 
PBMC. (B) Cell count of CD3+ T cells (n = 8), 
(C) percentage of CD8+ T cells within CD3+ T 
cells (n = 6), and (D and E) percentage of 
antigen-specific CD107a-expressing CD8+ (D) 
and CD4+ (E) T cells upon restimulation (n = 6) 
is depicted. Bars represent mean. Significance 
was determined using paired Student’s t-test. 
 
 
 
 
  
 
 
 
 
In the next step, the established techniques based on antigen-specific stimulation with 15mer 
peptide pools and enrichment of activation marker-expressing T cells were used to 
characterize TAA-specific T cells.  
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3.2 Characterization of WT1-specific T cells in healthy individuals 
The Wilms’ tumor 1 (WT1) protein is a self-antigen, which is expressed at high levels in 
several types of hematological malignancies as well as in some solid-tumors. WT1 has been 
ranked as a top antigen for immunotherapy (Cheever 2009). This gave rise to multiple 
studies evaluating various WT1-based vaccination approaches and also adoptive transfer of 
WT1-specific T cells for cancer therapy. Until now, however, in-depth knowledge of the 
natural occurring T cell repertoire is vastly missing. Highly sensitive analysis methods, based 
on magnetic enrichment (introduced in 3.1), enabled ex vivo characterization and efficient in 
vitro propagation of WT1-specific T cells in healthy donors. 
 
3.2.1 Ex vivo characterization of WT1-specific T cells  
3.2.1.1 Majority of healthy donors have a pool of WT1-reactive CD4+ memory T cells 
For detailed enumeration and characterization of rare, preexisting CD4+ WT1-specific T cells 
in healthy donors directly ex vivo, the Ag-reactive T cell enrichment (ARTE) protocol was 
utilized (introduced in 3.1.1). ARTE facilitates direct ex vivo analysis of antigen-specific CD4+ 
T cells down to frequencies of 10-5-10-6 specific T cells within 107-108 total PBMC after a 
magnetic enrichment of antigen-activated, CD154-expressing cells.  
In order to detect and characterize WT1-specific CD4+ T cells ex vivo, 5x107 PBMC of 
healthy donors were cultured either with or without addition of the WT1 peptide pool for 7 h 
and subsequently enriched CD154+ expressing T cells. Significantly higher numbers of 
CD154+ T cells can be detected in the positive enriched fraction of WT1-stimulated samples 
(50 to 555 cells, mean 190 cells) compared to the unstimulated control samples (27 to 198 
cells, mean 87 cells) (Fig. 3.13A), only in 2 out of 24 samples no elevated CD154+ cell count 
was detectable upon stimulation. On the basis of the detected count of WT1-specific CD154+ 
cells and the overall number of CD4+ T cells used in the particular experiment, the 
frequencies of WT1-reactive T cells were calculated to range between 1x10-6 and 2x10-5 
within the CD4+ T cell compartment (Fig. 3.13B). 
As these results imply a considerable variation in the frequency of detectable WT1-reactive 
CD154+ cells, a more comprehensive characterization of the WT1-reactive CD4+ T cells 
regarding their differentiation status and cytokine profile was included. This analysis was 
done under identical conditions for 20 of the 24 donors, in which phenotypic markers 
CD45RO, CD45RA, and CCR7 and, in a separate sample, TNF-α, IFN-γ, and in some 
donors also IL-2,  IL-4, IL-10, and IL-17 were stained in the positively selected cells. 
Determination of the phenotype of the positively selected cells revealed that in samples of 
some healthy donors WT1-reactive naïve and memory Th cells can be detected, whereas in 
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others only a few WT1-reactive Th cells, exhibiting a naïve phenotype, were detected. On the 
basis of this finding we divided the 20 donors in two groups. The first group of samples 
showing a memory and naïve response for WT1 was assigned “memory response” group (n 
= 13). The second group of samples showed solely a naïve response for WT1 and was 
therefore assigned “no memory response” group (n = 7). 
In the “memory response” group all samples revealed a higher number of CD154+ cells 
showing memory (CD45RO+ CCR7+/-) and naïve (CD45RO- CCR7+) phenotype in the 
stimulated compared to the corresponding unstimulated samples (Fig. 3.13C). Furthermore, 
these 13 samples showed at least 1.5-fold higher numbers of CD154+ cells after enrichment 
in the WT1 stimulated samples compared to background. Additionally, ten or more CD154+ 
TNF-α+ events above background could be detected in these samples and the frequency of 
TNF-α+ cells within CD154+ cells was generally higher than in the “no memory response” 
group (mean 29.6%, range 14.1 – 53.6%) (Fig. 3.13F).  
 
 
Figure 3.13 (A – C): For figure legend see next side.  
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Figure 3.13: WT1-specific CD4+ memory T cells can be detected in the majority of donors. 5x107 
PBMC were stimulated using WT1 peptide pool or left unstimulated for 7 h and CD154+ cells were 
enriched subsequently. (A) Cell count (n) of CD4+ CD154+ cells after enrichment of CD154+ cells in 
unstimulated (w/o) and WT1 stimulated (WT1) samples (n = 24; means of at least 2 technical 
replicates are depicted, 12 independent experiments were performed, significance was determined 
using paired Student’s t-test). (B) Calculated frequencies of CD4+ CD154+ cells within total CD4+ T 
cells (n = 22). (C and D) Dot plots (left) and enumeration (right) of flow cytometric analysis of TNF-α 
expression and phenotyping of CD4+ CD154+ cells. Dot plots show unstimulated and stimulated 
samples for two representative donors, one exhibiting a TH memory response (C) and one exhibiting 
no memory response (D). Enumeration of enriched CD4+ CD154+ cells, subdivided into naïve 
(CD45RO- CCR7+), central memory (TCM, CD45RO+ CCR7+), effector memory (TEM, CD45RO+ CCR7-), 
and exhausted effector (TEM-RA, CD45RO- CCR7-) T cells and subdivided according to cytokine 
expression in unstimulated (w/o) and WT1 stimulated (WT1) samples. Total cell count obtained from 
5x107 PBMC for donors showing a Th memory response (C) and showing no memory response (D) is 
given. (E) Dot plots of flow cytometric phenotyping of TNF-α- and IFN-γ-producing cells of WT1 
stimulated cells of a representative donor showing a memory response against WT1 (n = 3 donors). 
(F) Frequency of TNF-α producing cells within WT1-reactive CD4+ CD154+ cells (background cell 
count detected in corresponding unstimulated samples was subtracted, n = 24; 12 independent 
experiments were performed). 
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Phenotype of cytokine producing WT1-specific T cells was confirmed by direct co-staining of 
CCR7, CD45RO, TNF-α and IFN-γ (Fig. 3.13F) in additional three healthy donors. WT1-
specific TNF-α-producing cells are mostly memory T cells, but also naïve T cells were 
detected, whereas IFN-γ producers were exclusively found in the memory compartment. 
Notably, in the “memory response” samples IL-2 production was detected in five out of seven 
donors tested, IFN-γ production in 5 out of 14 samples and IL-17 production in one out of 
seven samples tested.  
In contrast, in the “no memory response” group (n = 7) only in four of these seven donors few 
WT1-specific CD154+ TNF-α+ events were identified (two to eight CD154+ TNF-α+ events 
above background). All CD154+ events recognized above background were of naïve 
(CD45RO- CCR7+) phenotype (Fig. 3.13D). 
Notably, no WT1-specific IL-4 and IL-10 expression could be observed in the 20 tested 
donors. Furthermore, CD8+ CD154 expressing WT1-specific T cells could not be detected 
within this set of experiments (data not shown).  
These data confirm that functional CD4+ WT1-specific T cells exist in all healthy donors and 
furthermore suggest that the majority (>60%) of healthy donors have a CD4+ memory T cell 
pool reactive for WT. 
 
3.2.1.2 CD8+ WT1-specific T cells derive predominantly from the naïve T cell repertoire in 
healthy donors 
The ARTE protocol described above is a useful tool for ex vivo detection of antigen-specific T 
cells, which fully covers the CD4+ compartment but only a minor subset of antigen-reactive 
CD8+ T cells. To investigate the ex vivo phenotype of the pool of CD8+ WT1-specific T cells, 
pMHC class I (MHCI) tetramer technology was used for cell identification. The WT137-45-
MHCI tetramer was chosen for this purpose, because of high abundance of WT137-45-specific 
T cells seen in expanded T cells after CD137 enrichment (Fig. 3.17). Due to the expected 
low frequencies a high number of starting cells and a magnetic enrichment step is required to 
detect these WT137-45-specific CD8+ T cells at all and to make the assay as sensitive as 
possible. Therefore, pan T cells were selected from PBMC of HLA-A2+, healthy donors, 
subsequently 0.8-1.2x108 T cells were labeled with the WT137-45-MHCI tetramer and 
magnetic beads, and enriched (Fig. 3.14A). In 16 samples CD8+ WT137-45-MHCI tetramer+ 
events ranged from 1 to 55 cells (mean = 14 cells). As unspecific staining of tetramers is an 
issue when detecting low frequent T cells, two internal control mechanisms were utilized. 
First, dual labeling of tetramer+ cells was done, using a PE- and allophycocyanin-conjugated 
version of the WT137-45-MHCI tetramer. Enrichment was done using anti-PE-MB, but only 
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allophycocyanin and PE double positive events in the positive fraction were counted as true 
WT137-45-MHCI tetramer+ events. Secondly, staining of the MHCI tetramer on CD4+ T cells 
was used as internal negative control (Fig. 3.14B). Substantial background staining on CD4+ 
T cells, however, was only detected in one sample showing ten CD4+ tetramer+ cells. 
Moreover, only samples in which at least five CD8+ tetramer+ cells were detected were taken 
into account for both enumeration and phenotyping (n = 10). Frequencies of WT137-45-specific 
CD8+ T cells determined with this assay range from 3x10-7 up to 3x10-6 within CD8+ (mean 
1x10-6) (Fig. 3.14C). The majority (70 - 100%) of WT137-45-specific CD8+ T cells detected 
revealed a naïve phenotype (CD45RA+ CCR7+, Fig. 3.14D).  
These data suggest that the majority of WT137-45-specific CD8+ T cells in an individual are of 
naïve phenotype. 
 
Figure 3.14: MHCI tetramer+ cell enrichment reveals naïve phenotype of most WT137-45-specific 
CD8+ T cells. WT137-45-MHCI tetramer+ cells have been enriched from 0.8 – 1.2x108 Pan T cells using 
anti-PE-MB. (A) Workflow for WT137-45-MHCI tetramer+ cell enrichment. (B) Representative dot plots of 
WT137-45-MHCI tetramer+ cell enrichment. Dual staining with WT137-45-MHCI tetramer is shown, cells 
were gated on CD8+ or CD4+ as internal control for specificity (percentage within CD8+ or CD4+ cells 
and total count of detected double positive cells is given). CD45RA and CCR7 staining of CD8+ 
tetramer+ cells (right). (C) Frequency of detected CD8+ WT137-45-MHCI tetramer+ within total CD8+ cells 
is shown for 10 HLA-A2+ donors (6 independent experiments were performed). Mean is given. (D) 
Frequency of CD45RA+ cells within WT137-45-MHCI tetramer+ CD8+ cells is shown (n = 10, 6 
independent experiments were performed).  
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3.2.1.3 Disparity of phenotype in CD4+ and CD8+ T cells specific for WT1  
Ex vivo characterization of CD4+ WT1-reactive T cells using ARTE revealed a high proportion 
of donors exhibiting a memory response against WT1. Ex vivo analysis of CD8+ WT1-specific 
T cells via WT1-MHCI tetramer enrichment proposed a naïve phenotype of WT137-45-specific 
CD8+ T cells. To obtain a reliable determination of the in vivo phenotypic origin of the CD8+ 
WT1-specific T cells, independent of the WT137-45-specificity used for the tetramer+ 
enrichment approach, presorting of the T cell subsets before stimulation was done (Fig. 3.15). 
Sorting of T cell subsets before enrichment of antigen-specific T cells, in addition, 
circumvents problems with ex vivo characterization owing to the exceedingly low frequency, 
especially of CD8+ WT1-reactive T cells, in healthy donors. Furthermore, this assay allowed 
for co-detection of CD8+ and CD4+ WT1-reactive T cells simultaneously in one sample. To 
this end, naïve T cells (CD45RA+ CCR7+) and memory T cells (CD45RO+) were sorted by 
magnetic cell separation in an untouched manner from PBMC of five healthy donors. Purities 
of sorted T cell subsets were >99% within CD3+ cells (Fig. 3.15B). Subsequently, 0.5-1x108 
pure, presorted naïve and memory T cells were separately stimulated with WT1 peptide pool 
and autologous, CD3-depleted cells for 36 h and CD137+ cells were enriched and expanded 
for nine days.  
Three of the five donors included were HLA-A2 positive (Donor 2, 4, and 5) and allowed for 
analysis of the presence of WT1-specific T cells using WT1-peptide loaded MHCI tetramers 
after expansion. Interestingly, in the T cell cultures obtained from naïve T cells a tetramer-
staining was detectable in all three tested donors, whereas the memory sorted T cell culture 
did not show a staining, suggesting that WT137-45-specific T cells in those three donors were 
derived exclusively from the naïve T cell repertoire (Fig. 3.15C). In the non-sorted fraction, 
which was also stimulated and enriched for CD137+, WT1-specific T cells could also be 
detected with the WT1-MHCI tetramer-mix (Fig. 3.15C). Notably, WT1-MHCI tetramer+ cells 
cannot be detected in either T cell fraction without the enrichment step, since frequencies are 
below the detection limit. These data confirm the naïve phenotype of WT1-reactive CD8+ T 
cells in healthy donors. 
Investigation on the phenotype of both CD4+ and CD8+ WT1-reactive T cells side-by-side 
was done via restimulation assays after expansion of both CD4+ and CD8+ T cells. T cells of 
four out of five donors (donor 1, 3, 4 and 5) were expanded and restimulation assays 
revealed that the highest frequencies of WT1-reactive CD8+ T cells were detected in the 
samples derived from naïve T cells. Only one sample (donor 3) exhibited WT1-specific CD8+ 
T cells in the memory fraction in addition to the WT1-specific T cells detected in the cells 
derived from the naïve fraction (Fig. 3.15E, left graph). For donor 1, CD8+ WT1-reactive T 
cells were detected in none of the fractions. In the three other samples also CD8+ WT1-
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reactive T cells were detected in the non-sorted sample. These results reflect the results 
obtained by tetramer detection, namely that in vivo occurring CD8+ WT1-specific T cells are 
of naïve phenotype (Fig. 3.15C). 
The CD4+ T cell compartment, however, revealed a strikingly different pattern as highest 
frequencies of WT1-reactive CD4+ T cells were detected in the cells derived from the 
memory compartment in three out of four cases (Fig. 3.15D, E and F), confirming the 
phenotype detected directly ex vivo (Fig. 3.13). In each case also reactive CD4+ WT1-
specific T cells were detected in the non-sorted sample (Fig. 3.15E).  
In summary, these results confirm the data obtained by the ex vivo analysis approaches, as 
they suggest a memory T cell population of WT1-reactive CD4+ T cells (Fig. 3.13) and a 
naïve phenotype of the CD8+ WT1-specific T cells (Fig. 3.14) in the majority of healthy 
donors. Furthermore, as the performed assay allows a side-by-side analysis of antigen-
reactive CD4+ and CD8+ T cells, it reveals that memory CD4+ and naïve CD8+ T cells with 
specificity for the WT1 antigen can co-exist in one individual (Fig. 3.15). 
 
 
 
 
 
 
 
 
 
Figure 3.15 (next page): Disparity of phenotype in CD4+ and CD8+ T cells specific for WT1 in 
most healthy donors. 1x108 presorted (naïve (CD45RA+ CCR7+) or memory (CD45RO+) T cells) or 
unsorted PBMCs were stimulated with WT1 peptide pool for 36 h and CD137+ cells were enriched. (A) 
Workflow for T cell subset sorting and subsequent enrichment of CD137+ cells. (B) Phenotype of T 
cells after subset sorting, shown for donor 5. Gate is set on living CD3+ cells. (C) Analysis of CD8+ 
WT1-MHCI tetramer+ T cells after expansion of the CD137+ enriched T cells obtained from presorted 
or non-sorted PBMC. Cells were stained with a mixture of tetramers loaded with four different WT1 
epitopes. Cells are gated on CD3+ cells. Percentages of tetramer-mix+ cells within CD8+ cells are 
given. Dot plots of donor 4 are shown. (D, E and F) Analysis of cytokine-producing cells by 
intracellular staining after restimulation of CD137 enriched and expanded T cell cultures obtained from 
presorted or non-sorted PBMC as indicated. (D) WT1-specific IFN-γ expression after restimulation of 
expanded cells from one representative donor (donor 4) using either unloaded or differently loaded 
autologous APC or peptide pulsed T2 cells (PTP = peptide pool). (E) Summary of antigen-specific 
CD4+ TNF-α expression and CD8+ IFN-γ expression after restimulation for 4 different donors. (F) 
Summary of antigen-specific responses after restimulation for four different donors. Ratio of naïve to 
memory cytokine response after restimulation calculated for CD4+ and CD8+ cells as well as for 
tetramer+ CD8+ T cells derived from naïve and memory cell populations. 
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Table 3.2: Schematic overview of WT1-specific T cell responses of five different healthy donors. 
Given is the fraction (naïve or memory) in which a WT1-specific T cell response could be detected 
directly after CD137 enrichment (ex vivo) or after expansion (restimulation and tetramer staining). 
Unsorted fractions are not listed. “Highest” marks the fraction showing the highest percentage of WT1-
specific T cells after expansion compared between unsorted, naïve, and memory sorted samples. 
 
 
 
 
3.2.2 In vitro generation of WT1-specific T cell cultures 
Ex vivo analysis revealed that functional WT1-specific T cells are present in virtually all 
healthy donors. In the following, the newly established protocol using CD137 as selection 
marker for propagation of rare TAA-specific T cells was implemented to obtain further 
knowledge on the WT1-specific T cell repertoire in healthy donors, including cytotoxic 
potential and functional avidity of the T cells. 
 
3.2.2.1 In vitro propagation of WT1-specific T cells by enrichment of CD137+ cells  
For the in vitro propagation of WT1-specific T cells from blood of healthy donors the CD137 
enrichment and expansion approach was implemented (introduced in 3.1.2). 1x108 PBMC 
were stimulated using WT1 peptide pool, CD137+ cells were enriched, and subsequently 
analyzed by flow cytometry (Fig. 3.16). Frequencies of CD4+ CD137+ and CD8+ CD137+ 
within T cells were significantly higher in stimulated samples compared to unstimulated 
control samples (Fig. 3.16B). However, also in the unstimulated control many CD137+ cells 
were enriched, indicating that the background of enriched, non-WT1-specific T cells is high. 
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Figure 3.16: Enrichment and expansion of WT1-specific T cells. 1x108 PBMC were stimulated 
using WT1 peptide pool for 24 – 36 h and CD137+ cells were enriched using anti-CD137-PE and anti-
PE-MB. (A and B) Representative dot plots (as in Fig. 3.9) (A) and frequencies (B) of CD4+ CD137+ 
and CD8+ CD137+ cells with and without WT1 stimulation, before and after enrichment. Significance 
was determined using paired Student’s t-test. (C) Cell count of CD137+ leukocytes after enrichment 
from 1x108 PBMC with and without WT1 stimulation. Significance was determined using paired 
Student’s t-test. (D) Fold expansion of CD3+ cells within 9 days of expansion after enrichment of 
CD137+ cells. (E) Scheme of 9 day expansion protocol. 
 
Cell count after enrichment was between 1x104 and 1x105 leukocytes (mean 3.4x104 
leukocytes). Fold expansion of CD3+ T cells during the 9 day expansion protocol (depicted in 
Fig. 3.16E) was between 30- and 210-fold for WT1 stimulated cultures (mean 102-fold) (Fig. 
3.16D). 
 
3.2.2.2 WT1-specific T cell cultures can be efficiently generated using CD137 enrichment  
After the expansion WT1-specificity was tested by staining with WT1-MHCI tetramers. Four 
MHCI tetramers loaded with either WT137-45, WT1126-134, WT1187-195, or WT1235-243 peptide 
were used (Fig. 3.17). The specificity of the staining was controlled by using a CMV pp65495-
503-MHCI tetramer. In 21 out of 24 expanded T cell cultures from PBMC obtained from HLA-
A2+, healthy donors WT1-MHCI tetramer+ CD8+ T cells were detected with frequencies of 0.5 
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to 38% among CD8+ T cells (Fig. 3.17B), indicating that the WT1 stimulation and CD137 
enrichment approach indeed resulted in an enrichment and expansion of WT1-specific T 
cells. For 3 of these 21 cultures a mixture of the four WT1-MHCI tetramers was used for 
staining. In all of the remaining 18 T cell cultures CD8+ T cells specific for WT137-45 were 
found and was the most abundant fraction of WT1-MHCI tetramer+ cells in 16 T cell cultures. 
Notably, before enrichment no WT1-MHCI tetramer+ cells were detectable in PBMC of those 
24 donors.  
 
 
Figure 3.17: Expanded T cells are WT1-specific. T cell cultures generated by stimulation of 1x108 
PBMC obtained from healthy HLA-A2+ donors with WT1 peptide pool, enrichment of CD137+ cells, and 
9 day expansion were stained using MHCI tetramers that have been loaded with the WT1 epitopes 
WT137-45, WT1126-134, WT1187-195, and WT1235-243 or a mix of all four tetramers. (A) Representative dot 
plots of staining with WT37-45-MHCI and WT1126-134-MHCI tetramer and, as negative control, pp65495-
503-MHCI tetramer. Cells are gated on CD3+ T cells. (B) Frequencies of WT1-MHCI tetramer+ cells 
within CD8+ T cells detected in expanded T cell cultures of 24 donors are given. 
 
3.2.2.3 Expanded WT1-specific T cell cultures are polyfunctional 
Functional characterization of the expanded T cell cultures was done by short-term 
restimulation experiments and subsequent analysis of effector cytokine and activation marker 
expression, and of the cytotoxic potential. 
To this end, expanded T cell cultures were co-cultivated with peptide loaded, autologous 
APC. Co-cultivation with WT1-loaded APC resulted in activation of CD4+ as well as CD8+ T 
cells in the expanded cultures (Fig. 3.18A and 3.18B), measured by expression of effector 
cytokines TNF-α and IFN-γ and upregulation of CD154 and CD137. In contrast, unloaded 
APC and APC loaded with an irrelevant peptide pool did not trigger activation in most T cell 
cultures. Frequencies of cytokine- and activation marker-expressing T cells after incubation 
with unloaded autologous APC were subtracted for the determination of WT-1-specific 
responses.  
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WT1-specific cytokine production was detected in cultures generated from all healthy donors. 
The average antigen-specific TNF-α production was 12.4% within CD4+ T cells (range 2 - 
59%) and 6.4% within CD8+ T cells (range 0.5 - 34%). Frequencies of IFN-γ producing cells 
were 6.0% (range 0.5 - 36%) within CD4+ T cells and 5.1% (range 0.5 - 23%) within CD8+ T 
cells. Notably, in each donor a WT1-induced cytokine production in either CD4+ or CD8+ T 
cells was found, and in more than 80% (25 of 30 donors) both CD4+ and CD8+ WT1-reactive 
T cells were present. Cytokine production correlated with activation marker expression upon 
restimulation with WT1 peptide pool. WT1-specific CD137 expression was observed on 
average in 4.9% (range 0.5% - 35%) within CD4+ and 7.3% (range 0.5% - 45%) within CD8+ 
T cells and CD154 expression in 11.2% (range 1.5% - 50%) on CD4+ and 2.4% (range 0.2% 
- 30%) on CD8+ T cells. Noteworthy, expression levels were measured after 6 h of 
stimulation and not all reactive cells might have upregulated CD137 at this point in time, due 
to the delayed kinetic of CD137 upregulation. Furthermore, CD154 expression on CD8+ T 
cells is rather low on most expanded, restimulated cells, compared to cytokine production, as 
it is described as an activation marker mostly found on CD4+ reactive T cells (Frentsch, 
Arbach et al. 2005), but a special subpopulation of CD8+ T cells was recently described to 
upregulate CD154 upon stimulation (Frentsch, Stark et al. 2013). In some donors, however, 
a distinct population of such CD154 expressing CD8+ T cells was detectable after 
restimulation (Fig. 3.18B). Notably, also in the three samples lacking MHCI-WT1 tetramer+ 
cells (Fig. 3.17B) WT1-specific cytokine production was detected in either CD4+ T cells only 
(one of three donors) or in both CD4+ and CD8+ T cells (two of three donors). 
Release of further cytokines by T cells restimulated with WT1 peptide pool was determined 
using a bead-based cytokine detection assay on cell culture supernatants collected from 
eight donors (Fig. 3.18C). WT1-specific TNF-α, IFN-γ, IL-2, and GM-CSF release was 
determined, clearly indicating that WT1-specific TH1 cells and/or cytotoxic CD8+ T cells 
became activated. In some cultures also WT1-specific IL-4, IL-5, IL-6, and IL-10 release was 
observed, indicating also the presence of functional WT1-reactive TH2 cells. All in all, WT1-
specific immunity in those expanded T cell cultures was skewed towards TH1 and CTL cells. 
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Figure 3.18: Expanded WT1-specific T cells are functional. T cell cultures generated by stimulation 
of 1x108 PBMC obtained from healthy donors with WT1 peptide pool, enrichment of CD137+ cells, and 
9 day expansion were restimulated for 6 h by co-cultivation with autologous APC, which were either 
left unloaded, were loaded with an irrelevant peptide pool, or with WT1 peptide pool. (A) 
Representative dot plots showing intracellular staining of cytokines and CD154 after restimulation, 
gated on CD4+ (left) or CD8+ (right) T cells. Frequencies of positive cells within CD4+ or CD8+ T cells 
are given. (B) Frequencies of WT1-specific expression of IFN-γ, TNF-α, CD137, and CD154 upon 
restimulation within CD4+ (left) and CD8+ (right) T cells. Frequencies detected in co-cultures with 
unloaded APC have been subtracted. Mean of 30 T cell cultures obtained from different healthy 
donors is given. (C) Cytokine concentrations detected in supernatants of WT1-restimulated T cell 
cultures. Concentrations detected in T cell cultures co-cultivated with unloaded APC were subtracted. 
2.5x105 T cells obtained from eight donors were used. Bar represents mean of triplicate 
measurements, standard deviation is given. 
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WT1-specific cytotoxic potential of the expanded T cells was demonstrated by detection of 
CD107a expression upon stimulation. CD107a is the lysosome-associated membrane 
protein (LAMP) and is a marker for T cell degranulation and therefore commonly used as a 
surrogate marker for cytotoxic activity (Betts, Brenchley et al. 2003). WT1-specific 
upregulation of CD107a was observed in all tested T cell samples, remarkably both within 
CD4+ and CD8+ T cells (1.0 to 19.5% and 2.4 to 42.0% within CD4+ and CD8+ T cells, 
respectively) (Fig. 3.19A). Additionally, direct WT1-specific cytotoxicity was detected by 
killing of WT1-loaded T2 cells by expanded T cell cultures in co-culture (Fig. 3.19B). Target 
cell killing was MHC-mediated as MHCI-blocking lead to decreased killing. Unloaded T2 cells 
were not killed and T cells specific for HPV16 did not kill WT1-loaded T2, clearly proving 
WT1-specific cytotoxicity and low off-target activity of the expanded T cells. Of note, effector 
to target ratios were determined for overall T cells used for the assay, however, the T cell 
culture used for the depicted cytotoxicity experiment displayed 14.6% WT1-MHCI tetramer+ 
cells within CD8+ (3% among CD3+) T cells and 7.5% WT1-specific TNF-α expression within 
CD8+ T cells. The given effector to targets ratios might therefore be drastically overestimated 
and in fact be approximately 35-fold lower. 
 
Figure 3.19: Expanded WT1-specific T cells exhibit cytotoxic potential. (A) Representative dot 
plots of CD107a expression of expanded T cells after 6 h co-cultivation with unloaded or WT1 peptide 
pool loaded APC, gated on CD4+ or CD8+ T cells. Frequencies of positive cells are given. Graph 
shows WT1-specific CD107a expression, frequencies detected in co-cultures with unloaded APC were 
subtracted. Mean of 14 T cell cultures obtained from different healthy donors is given. (B) Direct 
cytotoxicity of expanded T cell cultures towards WT1 peptide pool loaded T2 cells (black line), 
detected after 4 h of co-cultivation. Different ratios of T cells (effector cells) to T2 cells (target cells) 
were used. As controls blocking with an anti-MHCI antibody (dotted line), cytotoxicity towards T2 cells 
loaded with an irrelevant (HPV16) peptide pool (light grey line), and cytotoxicity of non-specific T cells 
towards WT1-loaded T2 cells (dark grey line) was included. Measurements were done in triplicates 
and standard deviation is given. 
 
Determining the actual rate of WT1-specific T cells within the expanded T cell cultures is 
difficult, as every assay most probably detects only a subpopulation of the specific T cells. 
Frequency of WT1-specific TNF-α and IFN-γ-expressing CD8+ cells was sometimes lower 
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than the frequency of WT1-MHCI tetramer+ cells (Fig. 3.20), indicating that only a subset of 
cells carrying a WT1-specific TCR produced these effector cytokines upon stimulation. WT1-
specific CD107a expression of expanded CD8+ T cells was higher than cytokine expression 
in all T cell cultures tested. Frequencies of CD107a-expressing CD8+ T cells was in the range 
of frequencies of WT1-MHCI tetramer+ cells detected, in the depicted sample 38.9% versus 
40.5% after 9 day expansion and 72% versus 73.4% after 16 day expansion of CD107a-
expressing and WT1-MHCI tetramer+ T cells in CD8+ T cells, respectively. Therefore, 
determining frequencies of cytokine-producing CD8+ T cells after WT1 stimulation might 
underestimate the real frequency of WT1-specific CD8+ T cells in the T cell culture.  
Furthermore the frequencies of WT1-specific T cells within the expanded T cells cultures 
could be increased by a pro-longed expansion phase, shown exemplarily for one donor (Fig. 
3.20). 
Collectively, the data show that the expanded WT1-specific T cells exhibit a multi-functional 
phenotype. 
 
Figure 3.20: Determined frequencies 
of WT1-specific T cells vary using 
different read-outs. Frequencies of 
WT1-specific TNF-α expression and 
CD107a expression within CD8+ T cells 
after restimulation and frequency of 
WT1-MHCI tetramer+ cells within CD8+ 
T cells detected in expanded T cell 
cultures of one HLA-A*02+ donor, either 
after 9 day expansion and after 16 day 
expansion.  
 
3.2.2.4 Expanded WT1-specific T cell cultures show a non-exhausted phenotype 
Differentiation status of expanded WT1-reactive T cell cultures was determined, as T cells 
can acquire an exhausted end-differentiated phenotype during long-term cultivation, 
especially after repetitive stimulation (Wirth, Xue et al. 2010). Non-exhausted effector cells 
have been shown to have a better proliferative capacity and therefore provide a more 
sustained anti-tumor protection when clinically used. The expanded T cell cultures mostly 
showed an effector memory T cell (CD45RO+ CCR7-) phenotype after short-term expansion 
(9 days), only few cultures showed substantial frequencies of terminally differentiated 
(CD45RO- CCR7-) CD8+ T cells (Fig. 3.21A). Furthermore, co-stimulatory markers CD27 and 
CD28 were still highly expressed on the expanded T cells (Fig. 3.21B). In contrast 
exhaustion markers such as CD178 (Fas-L), CD279 (PD-1), and CD57 were only expressed 
on few expanded CD4+ and CD8+ T cells (Fig. 3.21C). Additionally, expression of the IL-7 
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receptor α-chain (CD127) was analyzed, as this marker is described to be an indicator for the 
proliferative capacity of T cells. CD127 was found to be expressed on a substantial fraction 
of expanded CD4+ and CD8+ T cells (Fig. 3.21D). Proliferative capacity of the T cell cultures 
was additionally proven by further expansion (exemplarily shown in Fig. 3.20). 
The profile of expression of the tested markers suggests a non-exhausted phenotype of the 
T cell cultures obtained by short-term expansion.  
 
 
Figure 3.21: Expanded T cells exhibit a non-exhausted phenotype. T cell cultures generated by 
stimulation of 1x108 PBMC obtained from healthy donors with WT1 peptide pool, enrichment of 
CD137+ cells, and 9 day expansion were stained for expression of surface markers on CD8+ (upper 
row) and CD4+ (bottom row) T cells. (A) Differentiation status of T cells divided into naïve (CD45RO- 
CCR7+), central memory (TCM, CD45RO+ CCR7+), effector memory (TEM, CD45RO+ CCR7-), and 
exhausted effector (TEM-RA, CD45RO- CCR7-) T cells. (B) Frequency of CD28- and CD27-expressing T 
cells. (C) Frequency of CD57-, CD279-, and CD178-expressing T cells. (D) Frequency of CD127-
expressing T cells. 
 
3.2.2.5 Expanded WT1-specific CD8+ T cells have a functional avidity comparable to CMV-
specific T cells 
T cells specific bearing a high affinity TCR against a self-antigen are expected to be 
negatively selected during their development in the thymus to protect the body from severe T 
cell mediated autoimmunity. However, recently the notion emerged that this negative 
selection might be incomplete for some antigens. The affinity of the generated WT1-reactive 
T cells might be crucial for the cells’ clinical potential against malignant cells. Therefore, we 
tested the functional avidity of expanded WT137-45-specific CD8+ T cells derived from eight 
different donors by restimulation using T2 cells loaded with titrated amount of WT137-45 
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peptide (Fig. 3.22). The half maximal effective concentration (EC50) for TNF-α release upon 
restimulation was calculated to range between 4 nM and 2 µM (Fig. 3.22A). However, in four 
of these T cell cultures also WT1-specific CD107a upregulation was tested and resulted in 
lower EC50 rates (9 nM to 50 nM) for three of the four donors compared to EC50 rates 
calculated based on TNF-α expression (Fig. 3.22B). That different read-outs can result in 
different EC50 values is demonstrated for one T cell culture, comparing TNF-α expression 
(EC50 = 2.3 µM) to CD107a expression (Fig. 3.22C, EC50 = 50 nM) and CD137 expression 
(Fig. 3.22D, EC50 = 3.3 nM). 
 
Figure 3.22: Expanded WT137-specific T cells show a high functional avidity. T cell cultures 
generated by stimulation of 1x108 PBMC obtained from healthy donors with WT1 peptide pool or 
WT137-45 peptide, enrichment of CD137+ cells, and 9 day expansion were co-cultivated with autologous 
APC loaded with titrated amounts of WT135-45 peptide for 6 h. (A) WT1-specific TNF-α expression 
within CD8+ T cells expanded from PBMC of eight donors. (B) WT1-specific CD107a expression within 
CD8+ T cells expanded from PBMC of four donors. (C) WT1-specific TNF-α (circles) and CD107a 
(squares, left) and CD137 (triangles, right) expression within CD8+ T cells expanded from PBMC of 
one donor. Curves represent non-linear regression curves, based on which EC50 values were 
calculated. Lines illustrate determined EC50 values. Open symbols mark values which have not been 
included in calculation of EC50. 
 
For this reason it might be difficult to compare determined EC50 values to EC50 values for 
WT1-specific T cells reported in the literature, as mostly cytotoxicity was used as read-out 
(Rosenberg). To get a more reliable value to compare the obtained data to, we determined 
EC50 values for CMV pp65495-503-specific T cells using the same experimental setting (Fig. 
3.23). CMV-specific T cells are expected be of high affinity, as CMV represents a viral 
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antigen and T cells specific for foreign antigens should not be affected by negative selection 
in the thymus. Functional avidity of pp65495-503-specific CD8+ T cells can be determined 
directly ex vivo as frequencies for these cells are high in some donors (2.1% among CD8+ T 
cells for the depicted donor). Two donors were tested and ex vivo EC50 were as low as 1.2 
nM and 8.4 nM for pp65495-503-specific TNF-α expression and CD137-expression, respectively. 
To test whether the enrichment and expansion protocol has any influence on measured 
functional avidity the functional avidity of pp65495-503-specific CD8+ T cells after enrichment 
and 9 day expansion was also determined. Indeed, the calculated EC50 values after 
expansion were much higher when determining TNF-α release (2 µM), but, interestingly, not 
when using CD137 expression as read-out (EC50 = 6 nM). These data indicate that the 
enrichment and expansion protocol probably does not per se lead to expansion of low avidity 
clones, but that the functional characteristics of the T cells might change during the 
expansion phase. The determined EC50 values after expansion were similar for WT137-45-
specific (determined for 4 T cell cultures) and pp65495-503-specific (determined for two T cell 
cultures) CD8+ T cells. Thus, we conclude that the functional avidity of WT137-45-specific T 
cells was not strikingly lower than the functional avidity of virus-specific T cells. 
 
 
Figure 3.23: Expansion influences read-out but not functional avidity of pp65495-specific T cells. 
(A and B) PBMC of a CMVpos donor were co-cultivated with autologous APC loaded with titrated 
amounts of pp65495-503 peptide for 6 h either (A) directly ex vivo or (B) after stimulation of 1x108 PBMC 
with pp65495-503 peptide, enrichment of CD137+ cells, and 9 day expansion. pp65-specific TNF-α 
(circles) and CD137 (triangles, right) expression within CD8+ T cells expanded from PBMC of one 
donor is shown. Curves represent non-linear regression curves, based on which EC50 values were 
calculated. Open symbols mark values which have not been included in calculation of EC50. 
 
Collectively, the data show that functional WT1-reactive CD4+ and CD8+ T cells are present 
in peripheral blood of virtually all healthy donors. WT1-reactive T cell populations can be 
efficiently generated by using an CD137 enrichment and short-term expansion protocol. 
Furthermore, evidence is provided that the in vitro propagated WT1-specific T cells possess 
a functional and non-exhausted phenotype, exhibit cytotoxic potential and a high or 
intermediate avidity towards WT1-loaded target cells. 
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3.3 Characterization of the HPV16-specific T cell immunity in HNSCC patients 
Immunity in HNSCC, so far, was mostly studied by immunohistochemistry staining of tumor 
slices and evaluating strength and quality of overall T cell infiltration, however only few 
studies have dealt with HPV16-specific immunity in HNSCC. First hints on the presence of 
systemic and local HPV16-directed T cell responses in some HPV16pos HNSCC patients 
have been provided recently (Heusinkveld, Goedemans et al. 2012). We aimed at a more 
precise and detailed characterization of HPV16-specific T cell responses both in the blood 
and the tumor of HPV16pos HNSCC patients using the highly sensitive method of enrichment 
and multi-parametric flow cytometry. 
 
3.3.1 Magnitude of HPV16-specific immunity in blood of HPV16pos HNSCC patients 
varies 
To overcome possible detection limits and facilitate an in-depth characterization of 
presumably rare HPV16-reactive CD4+ T cells directly ex vivo, the antigen-reactive T cell 
enrichment (ARTE) approach (Bacher, Schink et al. 2013) was utilized, which was described 
already in this work for the analysis of WT1-reactive T cells (Section 3.2.1). For ex vivo 
characterization PBMC of HPV16pos and, as control, HPV16neg HNSCC patients were used. 
Blood samples were taken directly at time of primary tumor resection before treatment 
(surgery patients) or taken during a follow-up visit 1 to 57 months after tumor resection 
(follow-up patients). Details on tumor entities and pre-treatment of patients are given in 
tables 2.1 and 2.2. PBMC were stimulated using HPV16 E6 and E7 peptide pools for 7 h, 
CD154+ cells were enriched and analyzed by flow cytometry. In all nine tested HPV16pos 
HNSCC patients (four follow-up patients and five patients at tumor resection) HPV16-reactive 
CD4+ T cells could be detected in frequencies ranging from 2.0x10-6 to 8.0x10-5 within CD4+ 
T cells. Intriguingly, five of these nine HPV16pos HNSCC patients revealed frequencies of 
>2x105 HPV16-reactive cells within CD4+ T cells (Follow-up patients 17 and 19 and surgery 
patients 8, 23, and 25, ranging from 2.5x10-5 to 8.0x10-5 within CD4+ T cells, Fig. 3.24A and 
B), which are significantly higher compared to frequencies detected in PBMC of healthy 
donors and HPV16neg HNSCC patients. The five HPV16pos patients bearing this high level of 
CD4+ HPV16-reactive T cells in the blood will be referred to as high responders, the other 
four patients as low responders in the course of this thesis. In contrast, only in 23 of 30 
tested healthy individuals (=72%) and 7 out of 9 HPV16neg HNSCC patients (=78%) HPV16-
reactive T cells could be detected with the ARTE protocol. Frequencies of HPV16-specific 
CD4+ T cells detected in HPV16neg HNSCC patients (range 1.7x10-6 to 1.0x10-5 within CD4+ T 
cells) did not differ significantly from frequencies detected in healthy individuals (range 
6.0x10-6 to 3.4x10-5 within CD4+ T cells) (Fig. 3.24B). 
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Figure 3.24: High frequencies of HPV16-reactive T cells exist in blood of a subgroup of 
HPV16pos HNSCC patients. PBMC were stimulated using HPV16 E6 and E7 peptide pools (HPV16) 
or left unstimulated (w/o) for 7 h and CD154+ cells were enriched. (A) Dot plots of positive fractions of 
CD154 enrichment of PBMC obtained from a HPV16pos HNSCC patient (Patient 8), sequentially gated 
on lymphocytes, singlets, CD3+ cells, and CD4+ CD154+ or CD4- CD154+ cells. (B) Frequencies of 
HPV16-reactive CD4+ CD154+ T cells within the CD4+ T cell populations were calculated by first 
subtracting CD4+ CD154+ cell count in unstimulated sample from CD4+ CD154+ cell count in HPV16 
stimulated sample and subsequent division by absolute count of total used CD4+ T cells. Frequencies 
of HPV16-reactive CD154+ T cells within the CD4+ T cells for PBMC from healthy donors (n = 30), 
HPV16neg HNSCC (n = 3) and HPV16pos HNSCC follow-up patients (n = 4), HPV16neg HNSCC patients 
(n = 6) and HPV16pos HNSCC patients (n = 5) at time of tumor resection (surgery) are given. (C) 
Frequencies of HPV16-reactive CD4- CD154+ T cells were determined according to (B), shown for 
healthy donors (n = 30), HPV16neg HNSCC (n = 3) and HPV16pos HNSCC follow-up patients, HPV16neg 
HNSCC patients (n = 6) and HPV16pos HNSCC patients (n = 5) at time of tumor resection (surgery). 
Significance was determined using unpaired Student’s t-test. 
 
To investigate also on the presence of CD8+ HPV16-reactive T cells, CD3+ CD4- CD154+ 
cells were determined after enrichment. HPV16-reactive CD3+ CD4- T cells were found in six 
out of nine HPV16pos HNSCC patients (Fig. 3.24C; range 5x10-7 to 3.8x10-5 within CD4- cells, 
follow-up patients 17 and 21 and surgery patients 8, 15, 16, and 23). Patient 8 showed 
exceedingly high frequencies (3.8x10-5 within CD4- cells, Patient 8). We assume that those 
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CD3+ CD4- CD154+ cells are indeed CD8+ T cells, as detection of CD8+ CD154+ cells was 
shown before (Fig. 3.1). 
To determine the differentiation status of HPV16-reactive T cells, expression of the 
differentiation markers CD45RO and CCR7 on CD154+ T cells was determined (Fig. 3.24). 
The majority of HPV16-reactive T cells detected in the high responder surgery patients at 
tumor resection are effector memory T cells (CD45RO+ CCR7-) (Fig. 3.25B). In the low 
responder HPV16pos surgery patients HPV16-reactive CD4+ T cells are central memory 
(CD45RO+ CCR7+) and effector memory (CD45RO+ CCR7-) T cells (Fig. 3.25B). This is in 
contrast to HPV16-reactive CD4+ T cells detected in healthy individuals. Among the 30 
healthy donors, 15 showed no HPV16-reactive memory T cells, but only naïve HPV-specific 
T cells. In the 12 of 15 healthy donors showing a memory response, the naïve HPV16-
specific precursor cells make up the majority of the total detected cells (Fig. 3.25D). Apart 
from the fact that the high responders clearly show a strong effector memory response 
against HPV16, also the low responder patients, who do not have a stronger HPV16-directed 
CD4+ T cell response in terms of frequency, do indeed show a memory response, which is 
distinctly different from the majority of healthy individuals. In contrast, in one of the two 
follow-up high responder patients HPV16-reactive CD4+ T cells showed an exhausted TEM-RA 
(CD45RO- CCR7-) phenotype (Fig. 3.25C, Patient 19). HPV16-specific T cells in low 
responder follow-up patients were of central memory (CD45RO+ CCR7+) and naïve 
(CD45RO- CCR7+) phenotype, similar to healthy donors (Fig. 3.25C). 
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Figure 3.25: HPV16-specific T cells in blood of HPV16pos HNSCC patients are memory T cells. 
(A) Dot plots of positive fractions of CD154 enrichment of PBMC obtained from a HPV16pos HNSCC 
patient (Patient 8), sequentially gated on lymphocytes, singlets, CD3+ cells, and CD4+ CD154+ or CD4- 
CD154+ cells. Frequencies and total cell counts of CD154+ naïve (CD45RO- CCR7+), central memory 
(CD45RO+ CCR7+), effector memory (CD45RO+ CCR7-), and exhausted effector (CD45RO- CCR7-) T 
cells among CD154+ cells are depicted. (B to C) Contribution of T cell subsets to total HPV16-reactive 
CD4+ T cells: naïve (CD45RO- CCR7+, white bars), central memory (CD45RO+ CCR7+, light grey bars), 
effector memory (CD45RO+ CCR7-, dark grey bars) and exhausted effector (CD45RO- CCR7-, black 
bars) T cells, shown for HPV16pos HNSCC patients (B) at time of tumor resection and (C) follow-up 
patients and (D) healthy donors bearing a memory response. Bars represent mean. 
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Although all HPV16pos HNSCC patients showed a HPV16-reactive memory response the 
question remains why some donors show a strikingly stronger effector memory response 
than others? Recently, it was shown for epitopes of Bacillus anthracis that the number of 
naïve precursor T cells can determine the strength of memory T cells response after 
vaccination (Kwok, Tan et al. 2012). Therefore, frequencies of naïve HPV16-specific T cells 
in the HPV16pos HNSCC surgery patients were checked. Higher frequencies of HPV16-
specific precursors were found in high responders (3.6x10-6 to 5.0x10-6 within CD4+ T cells) 
compared to low responders (6.6x10-7 to 7.0x10-7 within CD4+ T cells, Fig. 3.26B). The 
detected frequencies of naïve HPV16-reactive CD4+ T cells for both groups, the high and low 
responders, lie within the range of healthy donors (4.4x10-7 to 7.7x10-6 within CD4+ T cells, 
Fig. 3.26A). For the five HPV16pos HNSCC surgery patients included in this study a positive 
correlation between HPV16-specific T cell precursor numbers and memory formation in 
HPV16pos HNSCC patients was found (Fig. 3.26C). 
These data reveal that all nine HPV16pos HNSCC patients included in this study show a clear 
memory T cell response against HPV16 in the blood. However, the magnitude and 
phenotype of this HPV16-directed CD4+ T cell response varies dramatically between 
individual HPV16pos HNSCC patients. 
 
 
Figure 3.26: Frequencies of naïve and memory HPV16-specific T cells correlate. Frequencies of 
CD4+ CD154+ HPV16-reactive among naïve and memory T cells determined according to Fig. 3.25, 
shown for (A) healthy donors (n = 23) and (B) HPV16pos HNSCC patients (n = 5). (C) Correlation of 
frequency of naïve CD4+ CD154+ HPV16-reactive T cells to frequency of memory CD4+ CD154+ 
HPV16-reactive T cells for HPV16pos HNSCC patients (n = 5). Correlation was determined by Pearson 
correlation coefficients. 
 
3.3.2 HPV16-reactive T cells detected in high responder HPV16pos HNSCC patients 
are highly functional 
To investigate on the functionality of blood CD4+ HPV16-reactive T cells, the production of 
effector cytokines, such as TNF-α and IFN-γ, by HPV16-specific T cells detected with the 
ARTE protocol produced was tested (Fig. 3.27A). Nearly 100% of the CD4+ HPV16-reactive 
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T cells detected in the high responders (Patient 8, 23, and 25) at time of surgery produced 
TNF-α (range from 89.6% to 96.7%, Fig. 3.27B) and a substantial proportion of HPV16-
reactive T cells also IFN-γ (range from 27.6% to 50.0%, Fig. 3.27C). The low responders 
within the HPV16pos HNSCC patients (Pat 15 and 16) at time of surgery contained smaller 
proportions of TNF-α producing cells (22% and 31%), which was in the range also observed 
for HPV16neg HNSCC patients and healthy individuals (up to 63%) and hardly any co-
produced IFN-γ. HPV16-specific T cells detected in follow-up patients showed cytokine 
expression in one of the high responder patients (patient 17, 85% TNF-α- and 15% IFN-γ-
producing T cells), whereas the patient exhibiting high frequencies of CD4+ TEM-RA cells 
(Patient 7) hardly produced any cytokines, the same was true for HPV16neg HNSCC follow-up 
patients. Additional information on the cytokine profile of the HPV16-specific T cells could be 
obtained for HPV16pos patients 8 where the cytokines IL-2, IL-17, and IL-10 could be co-
stained as enough cells were available, 41% of HPV16-reactive CD4+ T cells produced IL-2 
and 1.5% IL-10. No IL-17 producers were detected within the HPV16-reactive T cells (data 
not shown). CD4- HPV16-reactive T cells from patient 8 also produced effector cytokines 
(79% TNF-α, 88% IFN-γ and 87% IL-2 within HPV16-specific CD154+) (Fig. 3.27D and E). 
Analysis of ex vivo HPV16-specific release of cytokines is available for high responder 
patients 17 and 23 (Fig. 3.27F) and reveals a HPV16-specific production of IL-10, IL-12, IL6, 
and IL-9 in addition to TNF-α and IFN-γ production of the stimulated PBMC of patient 23. 
These data show that indeed highly functional HPV16-reactive TH1 effector memory cells 
exist in the blood of a subgroup of HNSCC patients bearing an HPV16pos HNSCC tumor.  
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Figure 3.27: Functional HPV16-reactive TH1 cells exist in blood of HPV16pos HNSCC patients. 
PBMC were stimulated using HPV16 E6 and E7 peptide pools (HPV16) or no peptide pool (w/o) for 7 
h and CD154+ cells were enriched. (A) Dot plots of positive fraction after CD154 enrichment of PBMC 
obtained from a HPV16pos HNSCC patient (Patient 8), gated on lymphocytes, singlets, CD3+, and 
CD4+ CD154+ or CD4- CD154+ cells. Cell count is given. (B to E) Percentage of (B) TNF-α and (C) 
IFN-γ producing T cells within the HPV16-reactive CD4+ CD154+ T cells and percentage of (D) TNF-α 
and (E) IFN-γ producing T cells within the HPV16-reactive CD4- CD154+ T cells shown for PBMC from 
healthy donors, HPV16neg HNSCC (n = 3) and HPV16pos HNSCC follow-up patients, HPV16neg 
HNSCC patients (n = 6) and HPV16pos HNSCC patients (n = 5) at tumor resection (surgery). 
Significance was determined using unpaired Student’s t test. Significances for CD4- cells were not 
determined as in many donors no HPV16-reactive CD4- T cells were detected. (F) Cytokine 
concentrations detected in PBMC supernatants after 7 h of stimulation using HPV16 E6 and E7 
peptide pools (HPV16), concentrations detected in unstimulated samples were subtracted. Shown for 
two high responder HPV16pos HNSCC patients (patient 17 and 23). Bar represents mean of triplicates, 
standard deviation is given. 
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3.3.3 Favorable cell composition of the tumor tissue in high responder HPV16pos 
HNSCC patients 
For HPV16pos cervical carcinoma it has been suggested that patients bearing a systemic 
HPV16-directed CD4+ immune response have a higher CD8+ T cell infiltration and a higher 
CD8+ to Treg ratio and both this is correlated to less metastases and hence a better prognosis 
(Piersma, Jordanova et al. 2007). To test whether or not there are differences in infiltration of 
the tumor by T cells between the high and low responder HPV16pos HNSCC patients and 
between HPV16pos and HPV16neg HNSCC patients, the presence of different T cell subsets in 
freshly dissociated tumor material was analyzed. No significant difference both between 
HPV16neg and HPV16pos and between tumors of low and high responder patients for CD3+ T 
cells, CD4+ T cells, CD8+ T cells, and CD4+ FoxP3+ cells was detected, indicating that the 
overall T cell infiltration is not substantially varied (Fig. 3.28A). However, when we 
determined the CD8+ to Treg ratio in these tumors, the three high responding patients (but 
also one of the low responding) HPV16pos patients had higher ratios compared to HPV16neg 
tumors (Fig. 3.28B), although not statistically significant. Still, these data hint at a favorable T 
cell composition in the high responder patients. 
Furthermore, the activation status of TIL was analyzed. To this end, expression of the 
activation markers CD137 and CD279 was determined, which were recently reported to mark 
TIL with anti-tumor function, especially CD137 identifying a subpopulation of highly tumor-
reactive T cells (Gros, Robbins et al. 2014, Ye, Song et al. 2014). Additionally, high levels of 
PD-1+ TIL are correlated to a good prognosis in HNSCC (Badoual, Hans et al. 2013). 
HPV16pos high responders had rather high populations of CD137-expressing (6.9% to10.6% 
within CD3+ cells) and PD-1-expressing (52.5% to 75.6% within CD3+ cells) T cells, indicating 
an activated status of the TIL. However, no significant difference was found both between 
HPV16neg and HPV16pos and between tumors of low and high responder HPV16pos patients 
(Fig. 3.28C) for CD279 and CD137 expression.  
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Figure 3.28: T cell infiltration and MHC class I expression in HNSCC tumors. Freshly dissociated 
tumor material of HPV16pos and HPV16neg HNSCC patients was analyzed by flow cytometry. (A, B) 
The number of T cells (CD3+ cells among all living cells), CD4+ and CD8+ cells (within CD3+ cells), and 
CD25+ FoxP3+ Treg cells (within CD4+ cells) was determined by flow cytometry. Significance was 
determined using unpaired Student t test. (C) Percentage of CD137 and CD279 expressing CD3+ cells. 
(D) Percentage of MHC class I expressing CD44+ and CD326+ tumor cells.  
 
HPV16 induced tumors are known to interfere with the antigen-presentation machinery in 
host (tumor cells), thereby preventing activation of effector T cells. We checked for MHC 
expression on tumor cells and detected significantly elevated levels of MHC class I 
expression on the tumor cells of the high responder patients on both CD326 epithelial cells 
and a subpopulation of CD44+ putative cancer stem cells (Prince, Sivanandan et al. 2007) 
(Fig. 3.28D). 
Although the strength of overall T cell infiltration in the tumor tissue was not strikingly 
different in the tested patients, the higher expression of MHC class I and the higher CD8+ to 
Treg ratios detected in the tumor of high responder HPV16pos patients hint at an on-going 
HPV16-directed anti-tumor response in those patients compared to the HPV16neg and low 
responder HPV16pos patients.  
 
3.3.4 HPV16-directed T cell immunity in blood of HNSCC patients reflects 
intratumoral immunity 
To investigate the HPV16-specific immunity at the tumor site and to compare HPV16-
reactivity in the periphery to intratumoral immunity, T cell cultures from PBMC and tumor 
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tissue of HNSCC patients were expanded. HPV16-reactive T cell cultures from patient 
material were generated by utilizing enrichment via the activation marker CD137. PBMC of 
HNSCC patients were stimulated directly ex vivo with HPV16 E6 and E7 peptide pools and 
CD137+ cells were enriched. To expand HPV16-reactive tumor-infiltrating lymphocytes (TIL) 
fresh tumor pieces were dissociated and likewise stimulated and enriched for CD137-
expressing cells. In parallel, direct TIL expansion from tumor fragments without enrichment 
was performed, adapted to established protocols (Dudley, Wunderlich et al. 2003) (Fig. 
3.29A). Starting cell numbers were between 0.8x107 and 6x107 for PBMC and 1x106 to 4x106 
total cells obtained after tumor dissociation. Obtained total cell counts after expansion ranged 
between 4.3x105 to 1.4x107 for cells obtained from PBMC, between 2.8x104 to 5.0x106 for 
cells obtained by CD137 enrichment of dissociated tumor material and between 2.7x106 to 
1.5x107 for cells grown from tumor pieces (Fig. 3.29B).  
 
Figure 3.29: Expansion 
of peripheral blood T 
cells, tumor-infiltrating 
T cells. (A) Scheme of 
expansion strategy. (B) 
Cell count at day 12 or 
day 19 is depicted. 
 
 
 
 
 
 
 
 
 
 
Expanded T cell cultures were tested for HPV16 reactivity by co-cultivation with autologous 
CD3-depleted PBMC, which have been either loaded with HPV16 peptide pools or left 
unloaded (Fig. 3.30). HPV16-specific TNF-α expression was determined via intracellular 
staining and flow cytometric analysis after 6 h of co-cultivation. In all five tested HNSCC 
patients bearing an HPV16-positive tumor TNF-α-producing HPV16-reactive T cells could be 
generated from blood and tumor material by using the enrichment strategy (Fig. 3.30B), 
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clearly indicating that potentially functional HPV16-directed T cells exist in these patients. 
CD4+ HPV16-reactive T cells were detected in all five cultures derived from PBMC (range 
HPV16-specific TNF-α production 3.6 – 20% within CD4+ T cells), in four of five cultures 
derived from CD137-enriched tumor material (range HPV16-specific TNF-α production 6.6 – 
23% within CD4+ T cells, no data for patient 15) and weakly in one culture directly expanded 
from tumor pieces (HPV16-specific TNF-α production 2.3% within CD4+ T cells). CD8+ 
HPV16-reactive T cells were detected in all five cultures derived from PBMC (range HPV16-
specific TNF-α production 1.0 – 7.2% within CD8+ T cells), in four of five cultures derived 
from CD137-enriched tumor material (range HPV16-specific TNF-α production 0.5 – 27% 
within CD8+ T cells, no data for patient 15), and in one culture (patient 8) directly expanded 
from tumor pieces (HPV16-specific TNF-α production 15.2% within CD8+ T cells). Except 
from patient 8 the HPV16-directed T cell immunity in the tested patients seems to be skewed 
to CD4+ T cells within the blood. Expansion of the CD137-negative fraction did not result in 
expansion of HPV16-specific T cells (data not shown), indicating that this approach selects 
for HPV16-reactive T cells. In HNSCC patients bearing an HPV16-negative tumor HPV16-
specific T cells could be generated from PBMC in three out of four donors, but not from 
tumor material, indicating that HPV16-specific T cells selectively infiltrate the tumor tissue of 
HPV16pos patients. 
The HPV16-reactivity of the T cell cultures was investigated in more depth by determining 
the reactivity against each of the used HPV16 antigens separately (Fig. 3.30C). In the T cell 
cultures obtained from blood and tumor by CD137 enrichment the same protein specificities 
could be detected for each patient. Four donors (patient 8, 15, 23, and 25) showed CD4+ T 
cell reactivity both against HPV16 E6 and E7 and CD8+ T cell reactivity against HPV16 E7. 
Patient 16 showed CD4+ T cell reactivity only against HPV16 E6 and also CD8+ T cell 
reactivity against HPV16 E6. The distribution of CD4+ and CD8+ T cell reactivity and also the 
distribution of E6 and E7 protein responses vary remarkably between T cell cultures obtained 
from blood and tumor in most donors. Nonetheless, concerning the presence of protein 
specificities in the CD4+ and CD8+ T cell compartment, the HPV16-directed T cell immunity 
detected in the blood seems to reflect the tumor resident HPV16-reactive T cells. 
In the cell cultures expanded from both PBMC and tumor tissue the dominant HPV16-
specifically released cytokines were IL-2, TNF-α, and IFN-γ (Fig. 3.30D). 
For the high responding patients 8, 23, and 25 the ex vivo data obtained with the ARTE 
approach (Fig. 3.24) reflect the data obtained by CD137 enrichment and expansion (Fig. 
3.30). In patient 8 a strong CD4+ and CD8+ HPV-reactivity was detected ex vivo as well as 
after expansion of both PBMC and enriched TIL. In contrast, patients 23 and 25 seem to 
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have a CD4+ skewed HPV16 response, detectable both ex vivo and after expansion of 
PBMC and enriched TIL.  
 
 
 
 
Figure 3.30 (A – C): For figure legend see next side.  
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Figure 3.30: HPV16-specific reactivity of expanded T cells from blood and tumor. T cells 
expanded from PBMC or dissociated tumor material of five HPV16pos HNSCC patients. PBMC (PBMC 
CD137) and dissociated tumor material (TIL CD137) were stimulated using HPV16 E6 and E7 peptide 
pools, subsequently CD137+ cells were enriched, and expanded for 19 days. In parallel T cells from 
tumor pieces (TIL) were expanded without stimulation and enrichment. HPV16-specific TNF-α 
production was determined after 6 h co-cultivation of T cell cultures with autologous antigen-
presenting cells either loaded with HPV16 E6 or HPV16 E7 peptide pool or both peptide pools, 
additionally as controls APC loaded with an irrelevant peptide pool and unloaded APC were used. (A) 
Dot plots of restimulated T cell cultures obtained from patient 8. Gated on CD8+ T cells (top) or CD4+ T 
cells (bottom). (B) HPV16-specific TNF-α production of expanded overall CD3+ (left), CD4+ (middle), 
and CD8+ (right) T cells. (C) Composition of CD4+, and CD8+ T cell responses against E6 and E7 
peptide pools, shown for all five HPV16pos HNSCC patients’ T cell cultures. (D) Cytokine 
concentrations in supernatants after restimulation using HPV16 E6 and E7 peptide pools, 
concentrations detected in unstimulated samples were subtracted. Shown for T cell culture obtained 
from PBMC (black) and tumor tissue (grey) of one high responder HPV16pos HNSCC patients (patient 
25). Bar represents mean of triplicates, standard deviation is depicted. 
 
In summary, these results show that functional HPV16-reactive T cells can be generated 
from all HPV16-positive HNSCC patients, both from blood and tumor tissue, independent of 
the magnitude of HPV16-directed T cell immunity in the periphery. 
 
3.3.5 T cells expanded from blood and tumor tissue exhibit a similar phenotype 
To further investigate whether HPV16-specific T cells from one particular source, blood or 
tumor tissue, have favorable characteristics for potential clinical use, expression of co-
stimulatory markers and exhaustion markers and differentiation status of the expanded T 
cells was determined. After expansion of T cells no striking difference in the expression of 
the co-stimulatory markers CD27, CD28, and the IL-7 receptor α-chain (CD127), which 
marks a putative stem T cell population, was detected both for CD4+ and CD8+ T cells 
between HPV16-reactive T cell cultures expanded from blood or tumor tissue of HPV16pos 
HNSCC patients (Fig. 3.31). Likewise, the exhaustion markers CD57, CD279, and TIM-3 
were not differentially expressed. The majority of expanded T cells exhibited a CD45RO+ 
CCR7- TEM differentiation status. So overall, no striking differences in terms of expression 
profile of the tested phenotypic markers was observed depending on which source, blood or 
tumor, was used for the generation of HPV16-reactive T cell cultures. A cluster analysis 
revealed that the difference between donors were more profound than differences of T cell 
cultures derived from different sources of one donor (cluster analysis not depicted). 
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Figure 3.31: Surface marker expression of expanded T cells from blood and tumor. Heat map 
analysis of flow cytometric analysis of expression of surface markers in expanded T cells obtained 
from blood (PBMC CD137) and tumor tissue (TIL CD137), shown for CD4+ T cells (left) and CD8+ T 
cells (right). Black indicates 0% of T cells express the respective marker and red indicates 100% of T 
cells express the respective marker. Differentiation status was distinguished as CD45RO- CCR7- (TEM-
RA), CD45RO+ CCR7- (TEM), CD45RO+ CCR7+ (TCM) and CD45RO- CCR7+ (naïve). Analysis was done 
using TIGR Multi Experiment Viewer 4.9. 
 
3.3.6 T cells expanded from blood and tumor tissue show HPV16-specific cytotoxic 
potential 
To check for cytotoxic potential, CD107a expression after restimulation of expanded T cell 
cultures from HPV16pos HNSCC patients with HPV16 peptide loaded autologous APC was 
determined (Fig. 3.32). HPV16-specific CD107a expression was observed on CD8+ and, 
although with lower mean fluorescence intensity, also on CD4+ T cells in all five cultures 
derived from PBMC (range HPV16-specific CD107a expression 6.8 – 16% within CD4+ T 
cells, 2.4 – 19.2% within CD8+ T cells) and in four of five cultures derived from CD137-
enriched tumor material (range HPV16-specific CD107a expression 2.5 – 16.7% within CD4+ 
T cells, 0.2 – 41% within CD8+ T cells, no data for patient 15).  
To investigate on cytotoxicity against tumor cells, CD107a expression after co-cultivation with 
cultivated autologous, primary tumor cells was determined (Fig 3.32C) for T cell cultures 
obtained from HPV16pos HNSCC patients. In vitro expansion of autologous tumor cells was 
successful only for tumors of patients 23 and 25. MHC class I expression on CD324+ CD326+ 
was observed after expansion of autologous tumor cells, allowing recognition by specific 
CD8+ T cells (Fig. 3.32C). Both T cell cultures showed tumor cell-specific CD107a expression 
on CD8+ T cells (shown for patient 23 in Fig. 3.32D). For patient 23 5.3% of CD8+ T cells 
obtained from PBMC and 1.5% of CD8+ T cells expanded from tumor tissue showed tumor 
cell-specific expression of CD107a, for patient 25 2.5% and 3.5%, respectively. As negative 
control unloaded APC and autologous fibroblast cultures were used (not shown). The 
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obtained results indicate that the expanded T cell cultures exhibit cytotoxic potential against 
autologous tumor cells.  
 
 
 
Figure 3.32: HPV16-specific T cells from blood and tumor exhibit cytotoxic potential. T cell 
cultures were generated according to Fig. 3.29. HPV16-specific expression of CD107a was tested 
after 6 h of co-cultivation. (A) Dot plots of CD107a expression of T cell cultures derived from PBMC 
(PBMC CD137) and tumor tissue with enrichment (TIL CD137) and without enrichment (TIL) of patient 
8. Gated on CD8+ (left) and CD4+ (right) T cells. (B) CD107a expression of CD4+ (left) and CD8+ (right) 
T cells upon co-cultivation with antigen-loaded APC, shown for the five HPV16pos HNSCC patients. (C) 
CD107a expression of CD8+ T cells obtained from PBMC and tumor tissue of patient 23 upon co-
cultivation with autologous tumor cells (left). (D) HLA-ABC expression on a tumor cell line from patient 
23. Dead cells, CD45+, CD31+ cells, and fibroblasts were excluded from the analysis (right). 
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3.3.7 Immunosuppressive tumor microenvironment in HPV16pos HNSCC impairs T 
cell functions 
To test intratumoral HPV16-directed T cell activity for HPV16pos patients, the cytokine profile 
of freshly dissociated tumor MNC after 24 h of cultivation ex vivo with addition of HPV16 
peptide pool was analyzed (Fig. 3.33). As the number of cells available from the patients 
varied, direct comparison of cytokine concentrations between the patient samples is difficult, 
however it became obvious that not only pro-inflammatory cytokines, such as IFN-γ, are 
prominent, but also the suppressive cytokine IL-10 was detected in high amounts. Elevated 
IFN-γ to IL-10 ratios were detected for two of the high responder HPV16pos patients 
compared to the two low responder HPV16pos patients (Fig. 3.33B). These data indicate that 
there are either differences in the strength of immunosuppression, e.g. by IL-10 release, or a 
difference in the strength of HPV16-directed T cell reactivity. In either case the data imply a 
stronger anti-tumor response in the high responder HPV16pos patients. Unfortunately for 
three of these four donors an unstimulated control sample is not available to judge on the 
strength of non-HPV16-specific background activation. 
That immunosuppression is a prominent feature also of HPV16pos high responder tumors was 
manifested by an experiment in which CD25+ cells were depleted from the tumor MNC before 
stimulation and enrichment of CD137+ cells (Fig. 3.33C). Depletion of CD25+ cells lead to a 
strong increase of HPV16-specific IFN-γ (5-fold) and IL-2 (45-fold) release and decrease of 
IL-10 (2-fold) release of the tumor MNC (Fig. 3.33B and D). As the IFN-γ concentrations 
detected in the unstimulated sample were low these data indicate an increased functionality 
of HPV16-directed T cells after depletion of immunosuppressive cells from the tumor tissue. 
Interestingly, also the expansion of CD137 enriched TIL increased 6-fold when CD25+ cells 
were depleted before stimulation (Fig 3.33E). This reflects the prominent role of suppressive 
cells in impairing HPV16-specific T cell activation in the tumor.  
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Figure 3.33: Suppressive cytokine milieu present in HNSCC tumors. Dissociated HNSCC tumor 
material was cultivated for 24 h with addition of HPV16 peptide pools and cytokine concentrations in 
the supernatants were determined. (A) Cytokine concentrations in HPV16 stimulated samples of 
dissociated HPV16pos tumors. Between 1x106 and 4x106 total cells were stimulated. Cytokine 
measurements were done in triplicates, standard deviation is depicted. (B) Ratio of IFN-y to IL-10 
concentrations of two low responders (patients 15 and 16, dark squares), high responders (patients 23 
and 25, white squares) (left), and patient 25 with CD25+ cell pre-depletion before cultivation (right). (C) 
Frequency of CD25+ FoxP3+ cells within CD4+ T cells in dissociated tumor material of patient 25, 
before (top) and after (bottom) depletion of CD25+ cells. (D) IFN-γ, IL-2, and IL-10 concentration for 
patient 25 without HPV16 stimulation and with HPV16 stimulation, both with and without CD25+ cell 
pre-depletion. (E) Expansion rate of CD137 enriched TIL with and without pre-depletion of CD25+ cells.  
 
Strong immunosuppressive mechanisms impair the HPV16-directed T cell immunity in the 
tested HNSCC tumor. A release of some of these immunosuppressive features, as shown for 
CD25+ cell depletion, or the removal of the T cells from the suppressive microenvironment, 
as shown by expansion experiment (Fig. 3.30), restores the functionality of the HPV16-
directed tumor-resident T cells. 
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4 Discussion 
 
4.1 Establishment of activation marker-based enrichment strategies for the 
detection of rare antigen-specific T cells 
In this study, an in-depth analysis of the full repertoire of rare TAA-specific T cells is provided. 
Magnetic cell enrichment strategies were implemented to overcome sensitivity hurdles of 
conventional methods. By using enrichment based on activation marker expression after 
antigenic stimulation using peptide pools, the full-repertoire of both CD4+ and CD8+ naïve 
and memory T cells was investigated. Subsequent multi-parametric flow cytometry enabled 
an in-depth analysis of the TAA-specific T cells in terms of prevalence, functionality, and 
differentiation status. Such an in-depth characterization of TAA-specific T cell repertoires is 
valuable for diagnostic, prognostic, and also therapeutic intervention strategies. 
Ex vivo detection and comprehensive characterization was achieved by stimulation of 
primary peripheral blood cells and enrichment of CD154+ cells. Propagation of TAA-specific T 
cell cultures from blood and tumor tissue was established by in vitro stimulation, enrichment 
of CD137+ cells, and subsequent short-term expansion. With the help of the newly 
established, highly sensitive methods novel, comprehensive insights in both the WT1- and 
HPV16-specific T cell repertoire were obtained. 
 
4.1.1 Ex vivo enumeration and characterization of rare antigen-specific T cells via 
CD154 enrichment 
Presence and functionality of presumably rare TAA CD4+ T cells was investigated directly ex 
vivo with the help of the antigen-reactive T cell enrichment (ARTE) approach. ARTE 
facilitates ex vivo analysis of the complete antigen-specific Th cell compartment regarding 
their cytokine expression profile and expression of cell surface markers down to frequencies 
of 10-5 to 10-6 specific T cells within 107 to 108 PBMC after magnetic enrichment of antigen-
activated, CD154+ cells (Bacher, Schink et al. 2013). CD154 enrichment was established for 
detection of T cells specific for recall antigens. By the use of 15-mer peptide pools for 
stimulation, CD4+ TH cells were activated independent of their HLA status. Thus, this 
approach allows for the detection of the full-repertoire of antigen-specific T cells without any 
epitope restriction. Besides CD4+ TH cells also antigen-activated CD8+ T cells were detected. 
It was recently reported that those CD154-expressing CD8+ T cells can compose up to 25% 
of the total CD8+ compartment and that these cells probably bear helper functions 
comparable to TH cells (Frentsch, Stark et al. 2013). A reliable enumeration of antigen-
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specific CD4+ T cells is feasible via 15mer peptide pool stimulation, enrichment of CD154+ 
cells, and subsequent flow cytometric analysis. 
In a next step, the established system was transferred to less frequent antigen-specificities. 
In principle, the CD154 enrichment strategy is a suitable method for detection of rare TAA-
specific T cells in healthy donors. Due to the enrichment step the sensitivity of the method is 
10- to 100-fold higher compared to commonly used methods, such as direct pHLA tetramer 
staining and also ELISPOT. However, at least 5x107 PBMC should be used as input when 
low frequent T cells are to be detected, as their frequencies lie between 1x10-7 and 1x10-5 
within T cells.  
The ARTE approach combined with analysis via multiparametric flow cytometry allows direct 
functional and/or phenotypical analysis of the enriched T cells. However, for rare cells an 
educated gating strategy has to be implemented to identify the right cells by exclusion of 
debris and non-target cells and requires at least four detection channels in flow cytometry. 
With the instruments used in this study eight different fluorophores could be detected, leaving 
four channels for the markers of interest. Co-staining of the effector cytokines TNF-α, IFN-γ, 
and IL-2 was feasible and allowed for functional characterization of the enriched antigen-
specific T cells.  
Furthermore, the differentiation status of the enriched, antigen-specific T cells can be 
determined via co-staining of CCR7 and CD45RO, clearly indicating that both naïve and 
memory T cells can be detected with ARTE. Naïve cells can have slower kinetics of cytokine 
production compared to memory T cells (Bachmann, Barner et al. 1999), nonetheless, also 
naïve TNF-α-producing T cells were detected after antigen-specific stimulation. 
 
4.1.2 Detection of rare antigen-specific T cells via CD137 enrichment 
CD137 has been described as a marker of activated T cells upon TCR engagement (Pollok, 
Kim et al. 1993) and was previously used to detect antigen-specific memory and naïve CD4+ 
and CD8+ T cells (Wolfl, Kuball et al. 2007, Wolfl, Kuball et al. 2008). Detection of antigen-
specific T cells after CMV peptide stimulation was confirmed, as CD137 was co-expressed 
with other established T cell activation markers. However, several feature of CD137 hinder 
an accurate ex vivo characterization of rare antigen-specific T cells using this activation 
marker. Firstly, for rare antigen-specific T cells an enrichment step has to be implemented, 
which results in relatively high background of pre-activated, CD137-expressing cells in both 
antigen-stimulated and unstimulated control samples. This background of pre-activated 
CD137+ T cells hinders an accurate enumeration of rare antigen-specific T cells. Secondly, 
prolonged stimulation times lead to changes in the expression of differentiation markers, 
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consequently accurate phenotyping is hardly possible. Thirdly, co-staining of cytokines holds 
also limited capacity due to the fact that stimulation times >12 h are needed for expression of 
CD137 on the surface of activated effector T cells. Expression of effector cytokines in 
memory T cells, in contrast, peaks at approximately 6 h of stimulation (Pala, Verhoef et al. 
2000). Simple addition of a secretion inhibitor to allow for accumulation of cytokines in the 
cell to enhance fluorescent signals for detection, as done for CD154 enrichment, is not 
possible as it hinders CD137 expression. Hence, CD137 was chosen as a marker to 
generate TAA-specific T cell cultures, but was not used for ex vivo characterization.  
 
4.1.3 Influence of Treg on enrichment of antigen-specific effector T cells via CD137  
CD137 is not only upregulated on Teff, but also on Treg, even with a faster kinetic upon 
antigen stimulation (Schoenbrunn, Frentsch et al. 2012). Indeed, FoxP3-expressing cells 
were enriched via CD137 enrichment after 24 – 36 h of stimulation. In experiments in which 
Treg (CD25+ cells) were depleted before stimulation and CD137 enrichment, indeed a lot of 
these CD4+ FoxP3+ CD137dim cells were lost. We assume that those T cells are Treg, but most 
likely not antigen-specific Treg. The hypothesis that those CD137dim cells are most likely no 
antigen-specific Treg is based on the following findings. Firstly, this phenomenon was 
especially pronounced when recall antigens were used for stimulation and many antigen-
specific effector T cells were activated. Secondly, far higher “antigen-specific” CD4+ 
CD137dim cell numbers were detected compared to CD4+ CD137+ cells after depletion of 
CD25+ cells, presumably suggesting a dominance of antigen-specific Treg. However, this is 
highly unlikely, as previous studies clearly show that antigen-specific Treg to Teff ratios usually 
lie below one. Even for particular antigens for which rather high Treg frequencies have been 
reported, presumably to prevent allergies or autoimmune diseases, the Treg to Teff ratios lay 
close to one (Belkaid and Tarbell 2009, Bacher, Kniemeyer et al. 2014). Thirdly, it was found 
that the CD137high fraction contained much higher frequencies of antigen-specific T cells, 
when antigen-specificity of CD137dim and CD137high cells was investigated after sorting of 
both fractions and expansion (personal communication Anne Schoenbrunn, Charité, Berlin). 
Therefore, we hypothesize that the CD4+ FoxP3+ CD137dim cells get dimly activated via 
bystander mechanisms, probably mediated by soluble factors, and are not antigen-specific 
Treg.  
Antigen-specific Treg might also be present, but not in such a high magnitude. Indeed, pre-
depletion of CD25+ cells in some cases led to higher numbers of activated Teff. Indicating that 
the activation of antigen-specific Teff in some cases is diminished by antigen-specific Treg. 
However, such differences were only detected in the experiments where T cell specific for 
recall antigens were stimulated, but not for rare antigen-specific T cells. Indicating either that 
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the effect is just not strong enough to be visible in the rare T cell setting or that higher 
amount of antigen-specific Treg exist for recall antigens to provide a natural balance between 
activation and regulation of a T cell response under inflammatory conditions (Belkaid and 
Tarbell 2009). 
However, efficiency of WT1- and HPV16-specific T cell generation was not altered by CD25+ 
cell depletion, as expansion rates and frequencies of antigen-specific T cells was similar to 
unsorted PBMC. So both the activation and proliferation efficiency were obviously not 
altered; indicating that the numbers of antigen-specific Treg indeed is low for those TAA-
specific T cells in healthy donors and the conditions for expansion were favorable for Teff, not 
Treg. 
 
4.1.4 Generation of TAA-specific T cell cultures 
In contrast to existing protocols for the expansion of TAA-specific T cells, which are mainly 
based on repetitive antigen stimulation cycles and subsequent cloning of T cells, this study 
introduces a rapid and efficient protocol based on enrichment of rare antigen-specific T cells 
and short-term expansion. 
Traditionally, T cells were expanded in vitro by addition of IL-2, which is the main cytokine 
responsible for overall T cell proliferation. However, in the last decade, there have been 
multiple reports stating that extensive in vitro culturing, especially in high doses of IL-2, leads 
to an exhausted phenotype of obtained T cells. At the same time studies proved the 
favorable characteristics of other cytokines for T cell expansion for clinical purposes. IL-15 
has been reported to maintain functional CD8+ T cells with enhanced in vivo anti-tumor 
activity compared to T cells expanded using IL-2 in a mouse model (Klebanoff, Finkelstein et 
al. 2004). Additionally, IL-15 was found to rescue anergic T cells and restore their activity 
against TAA (Teague, Sather et al. 2006). IL-21 was reported to promote the expansion of 
cytotoxic TIL, which retain expression of the co-stimulatory molecules CD27 and CD28 
(Santegoets, Turksma et al. 2013). Several groups than used these and other cytokines in 
combination to generate T cells with a non-exhausted phenotype in short-term expansion 
approaches. In this study the cytokine replenishment was adapted from Wölfl et al. (Wolfl, 
Merker et al. 2011), where tumor-reactive multifunctional CD8+ T cells were generated 
specific for the TAA MART-1 using IL-7, IL-15, and IL-21, and the expanded CD8+ T cells 
retained a non-exhausted CD62L+ CCR7+ CD28+ phenotype. Indeed, by using IL-7, IL-15, 
and IL-21 for the expansion of TAA stimulated and CD137 enriched T cell cultures 
expressing co-stimulatory markers CD27 and CD28 at a high level were obtained both within 
the CD4+ and CD8+ T cell compartment. In addition, surface markers indicating T cell 
exhaustion or senescence were not profoundly upregulated by the implemented expansion 
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protocol. Expression of CD57, a marker indicating limited proliferative ability (Brenchley, 
Karandikar et al. 2003), remained low. Likewise, CD279 (PD-1) expression was observed 
only on a minority of both CD4+ and CD8+ T cells after expansion. CD279 is a co-inhibitory 
molecule and can be upregulated after prolonged antigen encounter, presumably in vivo in 
chronic infections or cancer and during in vitro culturing. PD-1 can actively suppress T cell 
functionality when binding to its ligand PD-L1 (Barber, Wherry et al. 2006). 
The used cytokine panel did not drive the expansion of Treg, as no Treg were detected after 9 
day expansion, although Treg were clearly also enriched via CD137 enrichment. This is in line 
with published reports stating that IL-7 does not promote Treg expansion, as Treg commonly 
have only low expression level of the IL-7 receptor α-chain (CD127) (Liu, Putnam et al. 2006, 
Seddiki, Santner-Nanan et al. 2006). IL-2, in contrast, clearly drives the expansion of Treg (de 
la Rosa, Rutz et al. 2004). 
Therefore, it is assumed that TAA-specific T cells generated by peptide pool stimulation, 
CD137 enrichment and expansion under supplement of IL-7, IL-15, and IL-21 bear favorable 
features in terms of functionality and in vivo persistence for a potential clinical use of the 
expanded T cell product. Furthermore, the introduced protocol can be easily transferred to 
GMP-conform conditions, as all needed reagents are available at clinical grade quality.  
Percentage of CD4+ T cells directly after enrichment step was strongly increased, due to high 
unspecific background expression of CD137 on CD4+ T cells (discussed in 4.1.3). However, 
the enriched antigen-specific T cells received a proper TCR trigger and therefore were driven 
into proliferation in contrast to dimly activated or non-activated T cells. Therefore, enriched 
unspecific or non-activated T cells did not attenuate expansion of antigen-specific T cells. 
After expansion the ratio of CD4 to CD8 T cells was highly variable, probably depending on 
the repertoire of naïve and memory antigen-specific T cell of the individual donor. But no 
general bias to propagation of either CD4+ or CD8+ T cells was observed with the used 
enrichment and expansion conditions. 
 
4.1.5 Peptide pools for stimulation of the full repertoire of antigen-specific T cells  
According to basic literature only professional APC, such as DC, are able to prime naïve 
antigen-specific T cells as they provide the right co-stimulatory molecules. Until now, peptide 
stimulation of T cells in vitro was done with peptide loaded DC. These DC have to be 
prepared using a laborious protocol, commonly from peripheral blood monocytes, as DC 
mainly reside in the tissue in vivo and only few are found in the circulation. Furthermore, it is 
believed that cross-presentation of extracellular peptides onto MHC class I to CD8+ T cells is 
a feature unique to DC. In contrast to these classical beliefs, the activation of both naïve and 
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memory antigen-specific T cells was possible using peptide pools of overlapping 15-mers 
without separate preparation of DC, simply by adding the 15-mers to isolated PBMC.  
Additionally, an efficient stimulation of CD4 and CD8 T cells was feasible, indicating that 
antigen-presentation, presumably including antigen-processing and cross-presentation, was 
fully functional even without separately matured DC. When the described method was 
established experiments using separately matured DC, loaded with the peptide pools, were 
also included, but did not lead to a striking difference in efficiency of propagation of rare 
antigen-specific T cell. As no direct comparison of both protocols, with and without separate 
DC preparation, was done the results are not shown. Thus, peptide pool stimulation and 
enrichment of activation marker-expressing cells presents a straightforward and easy 
approach, which allows for the detection of the full-repertoire of antigen-specific T cells 
without separate DC preparation and without any epitope or HLA restriction. 
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4.2 WT1-specific T cell repertoire in healthy donors 
This study gains comprehensive insight into the naturally existing WT1-specific T cell pool in 
healthy individuals. The key findings are: (i) WT1-specific T cells are present in the vast 
majority of healthy donors; (ii) WT1-specific CD4+ T cells are commonly present in the 
memory pool; (iii) WT1-specific CD8+ T cells reside primarily in the naïve pool; and (iv) WT1-
specific memory CD4+ and naïve CD8+ T cells can co-exist in the same individual, which 
implies that distinct mechanisms control the differentiation of the auto-reactive WT1-specific 
CD4+ and CD8+ T lymphocytes from naïve into memory cells; (v) functional WT1-specific T 
cell lines can efficiently be generated in vitro. Collectively, the obtained data argue for the 
usage of the natural WT1-reactive T cell repertoire for immune therapy, such as vaccination 
or adoptive T cell transfer, of WT1-expressing cancers. 
 
4.2.1 Prevalence and functionality of WT1-specific T cells 
Ex vivo detection of the naturally existing WT1-specific T cell pool in healthy individuals 
revealed frequencies as low as 10-6 to 10-5 within the T cell compartment. Additionally, 
functionality of the WT1-specific T cells was proven and their phenotype was determined. 
Notably, the first evidence of co-existence of both memory CD4+ T cells and naïve CD8+ T 
cells with the same self-antigen-specificity within one individual donor is provided. 
Functional CD4+ WT1-specific T cells in healthy donors were detected by enrichment of 
CD154+ T cells (ARTE) after WT1-specific short-time stimulation. By utilizing ARTE, CD4+ 
WT1-specific T cells could be characterized directly ex vivo, comprising determination of 
frequency, phenotype, and functionality. The ARTE method was highly reproducible and thus 
reliable, even if the number of detected activated cells after WT1 stimulation in some 
samples was elevated only by as few as 30 CD154+ T cells compared to the unstimulated 
control (range 30 – 370 WT1-reactive CD154+ T cells above background). Frequencies of 
WT1-specific T cells in healthy donors ranged from 10-6 to 10-5 within CD4+ T cells. These 
determined frequencies are in consistency with published data, both for WT1-specific CD4+ T 
cells (Bacher, Schink et al. 2013), which have been detected using the same method, as well 
as CD4+ T cells specific for other self- or neo-antigens (gp100, fibrinogen, preproinsulin (Su, 
Kidd et al. 2013) and Bacillus anthracis (Kwok, Tan et al. 2012), detected with MHCII 
tetramer enrichment strategies.  
CD8+ WT1-specific T cells, detected with the help of WT1-MHC tetramer enrichment, were 
determined to be present in approximately one magnitude lower frequencies (10-7 to 10-5 
within CD8+ T cells) than CD4+ WT1-specific T cells detected via ARTE, keeping in mind that 
MHCI tetramer enrichment only covers one epitope-specificity, whereas for the ARTE 
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approach a pool of peptides spanning the whole WT1 protein was used to activate and 
identify WT1-reactive CD4+ T cells. The determined frequencies of naïve CD8+ WT137-45-
specific T cells are comparable to frequencies reported for self- or unexposed viral antigens 
(NY-ESO  (10-6 – 10-5), HIV (10-7 – 10-5)) (Alanio, Lemaitre et al. 2010). 
T cells specific for the self-antigen WT1 exist in virtually all healthy donors. There is evidence 
that the WT1-specific CD8+ T cells are of quite high avidity (see section 3.2.2.5 and (Chapuis, 
Ragnarsson et al. 2013). The presence of high-avidity WT1-specific T cells in peripheral 
blood of healthy donors argues for an incomplete negative selection of these self-antigen 
specific T cells, as high-affinity clones against self-antigens are classically believed to be 
deleted during their development in the thymus in a mechanism known as central tolerance 
(Wiegers, Kaufmann et al. 2011). Therefore, the question arises why those WT1-reactive T 
cells have not been negatively selected in the thymus? There are several mechanisms 
reported that can lead to high levels of auto-reactive T cells because of insufficient negative 
selection in thymus: (1) very low expression of the antigen in mTEC as reported for the 
myosin heavy chain 6 in autoimmune myocarditis (Lv, Havari et al. 2011) and the glutamate 
decarboxylase 2 (GAD2) in type I diabetes (Gotter, Brors et al. 2004); (2) differential splicing 
or mis-initiation of transcription in mTEC reported for MART-1 (Klein, Klugmann et al. 2000, 
Pinto, Sommermeyer et al. 2014); (3) missing post-translational modifications of antigens in 
mTEC as shown for aggrecan and vimentin in rheumatoid arthritis (Scally, Petersen et al. 
2013) or insulin in type I diabetes (Van Lummel, Duinkerken et al. 2014) (List taken from 
(Klein, Kyewski et al. 2014)). Whether any of these mechanisms is involved in the 
development of WT1-specific T cells remains matter of future investigation. However, it was 
shown that activation of self-reactive T cells can also occur in the absence of any defects in 
negative selection and in the presence of functional Treg (Enouz, Carrie et al. 2012). T cells 
that escape negative selection, as their avidity is below negative selection threshold, are 
quiescent due to sustained encounter of antigen, which can render mature T cells tolerant to 
the antigen by constant signals through their T cell receptors. These auto-reactive T cells are 
therefore ignorant to self under steady-state conditions in the periphery. Such tolerant T cells 
can be activated, e.g. during an infection due to cross-reactivity to foreign antigens or when 
their threshold for activation is lowered by co-activating factors. One such stimulus could be 
infection or in case of TAA-specific T cells tumor formation accompanied by inflammatory 
conditions. Self-reactive T cells can then cause autoimmunity resulting in tissue destruction 
or, in the case of WT1-specific T cells, in tumor cell destruction. WT1-specific T cells can at 
least ex vivo clearly be activated by stimulation with WT1 peptides, as shown in this study, 
indicating that the T cells are not anergic. So far, no autoimmune complications were 
reported emerging from WT1-specific T cells, although WT1 is expressed on CD34+ 
hematopoietic precursors. This could be due to the fact, that expression levels of WT1 are 
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just too low on normal cells compared to tumor cells. WT1 expression levels have been 
reported to be comparable to leukemic cells in about 1% of CD34+ hematopoietic precursors, 
the vast majority of cells expressing far lower levels (Hosen, Sonoda et al. 2002). Therefore, 
normal WT1-expressing cells seem to not provide a stimulus, which is above the activation 
threshold of WT1-specific T cells. Severe autoimmunity resulting in leukopenia has been 
observed after vaccination with WT1126-134 peptide in myelodysplastic syndrome (MDS) 
patients (Oka, Tsuboi et al. 2003). This leukopenic effect is a sign of the anti-tumor 
functionality of WT1-specific T cells rather than a safety concern, as this side-effect was so 
far only observed in MDS patients, but not in other patients treated (Oka, Tsuboi et al. 2004). 
MDS patients have only a few normal hematopoietic precursors as this disorder is marked by 
mutations already in the stem cells in bone marrow, which give rise to all blood cells. 
The ARTE assay revealed that CD4+ WT1-reactive memory T cells exist in over 60% of 
healthy donors in addition to the prevalent naïve WT1-specific T cell pool. These memory 
CD4+ T cells could be shown to have a functional phenotype as they readily expressed the 
effector cytokine TNF-α and partially also IFN-γ. 
 
4.2.2 Discrepancy in differentiation status of CD4+ and CD8+ WT1-specific T cells 
This work comprises, for the first time to my knowledge, phenotyping of both CD4+ and CD8+ 
T cells with the same antigen-specificity. This study discovers, via the ARTE assay, that over 
60% of healthy donors exhibit a CD4+ memory T cell response additionally to CD4+ T cells of 
naïve phenotype specific for WT1. In contrast, virtually all WT137-45-specific CD8+ T cells, 
detected by pMHCI tetramer, are of naïve phenotype. Additionally, a direct discrepancy in 
CD4+ and CD8+ phenotype of WT1-specific T cells was identified in four out of five tested 
donors using presorted naïve or memory T cell subsets. In all five donors included in this 
assay CD4+ WT1-specific memory T cells were identified, whereas detected CD8+ WT1-
specific T cells arose solely from the naïve T cell compartment in four of the five tested 
donors. Such a discrepancy in phenotype of CD4+ and CD8+ T cells with the same antigen-
specificity is in sharp contrast to the classical model of antigen-specific T cell memory 
formation. The classical model states that antigen-specific T cell memory is formed solely 
after recent exposure to the antigen to protect the body from a potential re-encounter with the 
particular specimen. Such an exposure would presumably trigger the formation of both CD4+ 
and CD8+ memory T cells. Recent data introduced alternative ways of memory generation 
into the T cell field, indicating that T cell memory must not necessarily be a result of previous 
cognate antigen encounter. On the one side, memory-like CD8+ antigen-specific population 
were reported in unexposed mice. These memory CD8+ T cells were generated by 
homeostatic mechanisms and were named “virtual memory” (Haluszczak, Akue et al. 2009, 
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Lee, Hamilton et al. 2013). On the other side, Su et al. (Su, Kidd et al. 2013) recently 
introduced a distinct mechanism of memory formation of human virus-specific CD4+ T cells 
by demonstrating their cross-reactivity against common environmental antigens. Our results 
would fit to the latter model, i.e. in the case of the self-antigen WT1, CD4+ memory T cells 
might be a result of cross-reactivity. One reason for this assumption is the absence of CD8+ 
WT1-specific memory seen in the experiments, which argues for the absence of a previous 
systemic WT1-specific T cell response, e.g. due to tumor cell growth. Furthermore, formation 
of a so-called “virtual memory” CD4+ T cells is contradicted by two facts. Firstly, effector 
cytokines were readily produced upon antigen encounter of those T cells. Secondly, the fact 
that they represent a major part of CD4+ WT1-specific T cells (ratio of memory to naïve WT1-
specific CD4+ detected was in a range of 0.6 to 5.2), in contrast to virtual memory T cell 
repertoire, which was reported to comprise only 5-20% of the respective antigen-specific 
population (Haluszczak, Akue et al. 2009, Lee, Hamilton et al. 2013). Intriguingly, the 
existence of memory T cells specific for self-antigens, including WT1, was demonstrated 
recently (Bacher, Schink et al. 2013, Su, Kidd et al. 2013). However, prove for cross-
reactivity as the reason for memory formation of such self-antigen specific T cells remains 
elusive. For CD8+ T cells specific for viral antigens cross-reactivity has been demonstrated to 
exist (Wedemeyer, Mizukoshi et al. 2001, Clute, Watkin et al. 2005). However, CD8+ T cells 
specific for self-antigens (NY-ESO, MART-1) have been reported to exhibit a naïve 
phenotype in the periphery (Zippelius, Pittet et al. 2002, Alanio, Lemaitre et al. 2010). The 
findings presented here indicate that memory formation due to cross-reactivity does not 
occur as frequently for WT1-reactive CD8+ T cells as for CD4+ T cells. The hypothesis that 
cross-reactivity might be more abundant in the CD4+ T cell compartment than in the CD8+ T 
cell compartment was already raised by others in the past (Wilson, Wilson et al. 2004, Welsh, 
Che et al. 2010), however, until now, conclusive evidence is missing. 
The lack of CD8+ WT1-specific memory T cells could also be a result of a more effective 
central tolerance for CD8+ T cells compared to CD4+ T cells, as it has been suggested for 
p53 in mice (Lauwen, Zwaveling et al. 2008). Such a more stringent negative selection of 
CD8+ T cells could serve as a safety mechanism to prevent autoimmunity caused by self-
reactive cytotoxic T cells. However, although a recent study provided interesting insights into 
the human thymic peptide repertoire, such as differences between epitopes and individuals, 
clear prove for such a systemic difference in tolerance induction for CD8+ and CD4+ T cells 
has not been provided for humans (Adamopoulou, Tenzer et al. 2013).  
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4.2.3 In vitro generation of WT1-specific T cell lines 
Enrichment of T cells expressing CD137 out of PBMC obtained from healthy donors after in 
vitro WT1 peptide pool stimulation allowed for the generation of oligoclonal WT1-reactive T 
cell cultures within ten days. The generated T cell populations consisted of CD4+ and CD8+ T 
cells, which produced effector cytokines upon restimulation with WT1 peptides, thus arguing 
for the existence of a functional WT1-specific immunity in virtually all healthy donors, which 
can potentially be utilized for immunotherapeutic approaches. Possible areas of application 
for WT1-specific T cells are, on the one hand, adoptive T cell transfer, preferentially in 
leukemia, and, on the other hand, therapeutic vaccination for numerous tumor entities.  
To judge the therapeutic potential of natural WT1-specific T cells, knowledge about their 
avidity is crucial, as it might determine in vivo anti-tumor efficacy (Pedersen, Sorensen et al. 
2013). The process of clonal deletion during central tolerance was shown to be TCR-affinity 
dependent (Starr, Jameson et al. 2003), suggesting that WT1-specific T cells might be of 
rather low or intermediate affinity towards their antigen. Intriguingly, other groups have 
reported the generation of CD8+ WT1-specific T cell clones of high avidity. These results 
have been obtained by using different assays. Weber et al. (Weber, Karbach et al. 2009) 
reported EC50 values of 0.1 nM for a WT137-45-specific T cell clone and Chapuis et al. 
(Chapuis, Ragnarsson et al. 2013) reported even higher functional avidities. In contrast to the 
approach used in this study, published results were obtained by testing the specific lysis of 
T2 cells of a WT1-specific single cell clone. However, cytotoxicity of T cells can be triggered 
at 10- to 100-fold lower peptide concentrations than needed for cytokine production (Betts, 
Price et al. 2004). Indeed, in this study, discrepancies in determined EC50 values were 
discovered depending on whether cytokine production or CD107a upregulation, a surrogate 
marker for cytotoxicity, was used as read-out. Studying the functional avidity of CMV pp65495-
503-specific T cells ex vivo and after CD137 enrichment and expansion revealed that T cells 
might change certain activation properties during in vitro culture. Unfortunately, determination 
of functional avidities of WT1-specific T cells ex vivo is hindered owing to their exceedingly 
low frequencies. However, the comparison of functional avidities of CMV- and WT1-specific 
T cells after expansion indicated that WT137-45-specific T cells were indeed not of low avidity, 
as one might expect due to negative selection of high avidity clones during development, but 
had similar functional avidities to CMV-specific T cells. Weber et al. (Weber, Karbach et al. 
2009) proved sufficient avidities of generated WT1-specific T cells towards leukemia cell 
lines, which express WT1 endogenously. Reactivity against natural targets such as primary 
tumor cell killing could, unfortunately, not be tested in this study. Further support for the 
therapeutic capacity of natural existing WT1-specific immunity comes from immunmonitoring 
studies. Here, an induction of WT1-specific CD8+ T cell response after alloSCT and or donor 
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lymphocyte infusion (DLI) clearly proved the immunogenicity of WT1 in cancer patients. 
Moreover, the induced WT1-specific T cells presumably mediated graft versus leukemia 
effects in leukemia patients, demonstrating their therapeutic potential (Rezvani, Yong et al. 
2007, Kapp, Stevanovic et al. 2009, Tyler and Koehne 2013). Vaccination strategies, which 
naturally rely on exploiting the pre-existing WT1-specific T cell pool for therapy, likewise 
showed promising results in several clinical studies, reporting clinical response rates of 63% 
in hematological diseases (Van Driessche, Berneman et al. 2012).  
In the past, several studies already established WT1-specific T cell cultures. However, all of 
them used in vitro priming approaches including DC preparation and loading, repetitive 
stimulation cycles using WT1 peptide-loaded DC in some studies followed by cloning of 
single CD8+ T cells (Weber, Karbach et al. 2009, Krishnadas, Stamer et al. 2011, Weber, 
Gerdemann et al. 2013). The described protocols demand laborious DC preparation and  
take several weeks of expansion time. Krishnadas et al.(Krishnadas, Stamer et al. 2011) for 
the first time included an enrichment step, however, enrichment was done after several 
weeks of repetitive stimulation cycles and the obtained T cell culture only contained 3 - 5% of 
WT1 tetramer+ T cells. In this study, a new, improved protocol for the efficient generation of 
WT1-specific T cell cultures via CD137 enrichment and short-term expansion is introduced, 
which has several advantages over established protocols: (i) The protocol avoids prolonged 
in vitro culture, which typically results in an exhausted T cell phenotype associated with 
limited in vivo efficacy (as discussed in 4.4.5). With the efficient protocol used in this study 
functional, non-exhausted T cells cultures were obtained. (ii) The expanded T cell cultures 
contain high frequencies of WT1-specific T cells, up to 60% of WT1-reactive T cells. (iii) The 
described protocol employs the full-repertoire of WT1-specific T cells instead of using clonal 
culture specific for only one particular epitope. Multi-epitope-specificity can be beneficial for 
in vivo efficacy of the T cell product. (iv) The protocol includes enrichment and expansion of 
both CD4+ and CD8+ WT1-specific T cells. In order to provide optimal anti-tumor efficacy it is 
desirable to include CD4+ T cells, as it has been shown that CD4+ T cells can be powerful 
anti-tumor effector cells in mouse (Perez-Diez, Joncker et al. 2007, Xie, Akpinarli et al. 2010, 
Goldstein, Varghese et al. 2011) and human (Tran, Turcotte et al. 2014). The importance of 
CD4+ T cell inclusion has been supported by studies demonstrating that CD4+ T cell help is 
crucial for a maintained CD8+ T cell functionality (Bourgeois, Veiga-Fernandes et al. 2002, 
Shedlock and Shen 2003, Sun and Bevan 2003) and also by studies proving an in vivo anti-
tumor effect of adoptively transferred CD4+ tumor-specific T cells (Tran, Turcotte et al. 2014). 
To this end, utilizing the broad repertoire of pre-existing CD4+ and CD8+ might be beneficial. 
The generation of such WT1-specific CD4+ and CD8+ mixed T cell cultures has been proven 
to be feasible by using a 15mer peptide pool of WT1 (Krishnadas, Stamer et al. 2011), our 
data). (v) Our simplified protocol does not require laborious isolation and maturation of DC.  
Discussion 
90 
 
Therefore, the protocol for propagation of WT1-specific T cell cultures, based on in vitro 
stimulation using 15mer peptide pools and enrichment of CD137+ cells, established in this 
study is superior to previously used protocols for the generation of WT1-specific T cells in 
terms of production efficiency and quality of the T cell product. Notably, the introduced 
protocol could be easily transferred to GMP-conform conditions as all needed reagents are 
available at clinical grade. 
 
4.2.4 Expanded WT1 specific T cells for adoptive anti-cancer therapy 
The generation of such WT1-specific T cells out of the natural existing pool has been of great 
interest for therapeutic approaches, such as adoptive therapy and vaccination. A compelling 
opportunity for which the research results presented here could directly be implemented is 
the use of WT1-specific T cells as DLI after HSCT of leukemia patients. DLI, consisting of 
total lymphocytes of the stem cell donor, is a routine treatment when relapse occurs after 
HSCT and does successfully fight small amounts of recurrent tumor cells in many cases due 
to the so called graft-versus-tumor effect. However, a major drawback of standard DLI is the 
mixed nature of the cell product, containing many different T cell antigen-specificities. 
Therefore unsorted DLI often cause severe autoimmunity due to graft-versus-host properties. 
A more specific, targeted DLI product, such as expanded WT1-specific T cells, could prevent 
these complications (Bornhauser, Thiede et al. 2011). A typical DLI consists of 1x107 to 
1x108 T cells or total PBMC per kg bodyweight (Luznik and Fuchs 2002, Bachireddy, Hainz 
et al. 2014). In this study up to 1x107 mostly WT1-specific T cells after expansion from 1x108 
starting PBMC were obtained. However, higher starting cell numbers would result in higher T 
cell numbers, which is easily possible by using a leukapheresis product of the healthy stem-
cell donor. For a defined, specific T cell product such high numbers of transferred T cells 
might not be needed, this needs to be evaluated in the future. 
WT1-specific T cells can also be used for adoptive T cell therapy of other cancer entities 
which is a field of ongoing research. A successful first clinical trial using naturally derived, 
avidity selected, WT1126-134-specific CD8+ T cell clones recently demonstrated the feasibility 
and safety of adoptive T cell therapy with WT1-specific T cells derived from the natural, 
autologous repertoire in leukemia (Chapuis, Ragnarsson et al. 2013).  
 
4.2.5 Employing WT1-specific T cells for therapeutic anti-cancer vaccination 
Therapeutic vaccination using WT1 as an antigen is discussed currently as a potential 
treatment of myeloid leukemias (Oka, Tsuboi et al. 2004, Rezvani, Brenchley et al. 2005, 
Keilholz, Letsch et al. 2009, Yasukawa, Fujiwara et al. 2009, Maslak, Dao et al. 2010, Van 
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Tendeloo, Van de Velde et al. 2010, Kitawaki, Kadowaki et al. 2011, Kuball, de Boer et al. 
2011, Rezvani, Yong et al. 2011), but also other cancer entities including breast cancer (Oka, 
Tsuboi et al. 2004, Morita, Oka et al. 2006) and lung cancer (Oka, Tsuboi et al. 2004, Krug, 
Dao et al. 2010). 
The insights into the natural occurring WT1-reactive T cell repertoire have direct implications 
on the design of WT1-based vaccination approaches. In this study, CD8+ T cells specific for 
the WT137-45 epitope were much more abundant than T cells specific for WT1126-134, both after 
CD137 enrichment and expansion (Fig. 3.17) and in ex vivo WT1-MHCI tetramer enrichment 
approaches (Fig. 3.14). This might have implications on the design of therapeutic and 
immunmonitoring strategies, as many published studies solely concentrate on CD8+ T cell 
clones specific for WT1126-134. Multiple vaccination studies that used the WT1126 epitope alone 
or in combination achieved only limited T cell responses in humans (Keilholz, Letsch et al. 
2009, Rezvani, Yong et al. 2011, Uttenthal, Martinez-Davila et al. 2014). In contrast, studies 
including WT1 stimuli, which cover a multitude of WT1 epitopes, such as long peptides 
((Maslak, Dao et al. 2010) in AML, (Krug, Dao et al. 2010) in mesothelioma] and WT1 mRNA 
DC vaccination (Van Tendeloo, Van de Velde et al. 2010), lead to broader WT1-specific 
CD4+ and CD8+ T cell responses. The vaccination studies using long peptides successfully 
induced both CD8+ and CD4+ WT1-specific T cell responses in vivo (Krug, Dao et al. 2010, 
Maslak, Dao et al. 2010), indicating that the success of such vaccination strategies is not 
impaired by the discrepancy in the differentiation status of CD4+ and CD8+ preexisting WT1-
specific T cell populations, which was disclosed in this study. On the contrary, one might 
speculate that pre-existing memory CD4+ WT1-specific TH cells might help to generate a 
CD8+ T cell response from the naïve pool. In consistence with these reported clinical findings, 
both CD4+ and CD8+ WT1-specific T cells could be readily activated ex vivo by stimulation 
with WT1 peptide pool in this study. The results obtained in this study together with the 
mentioned previous studies argue for the usage of WT1 stimuli, which cover the whole WT1 
protein, for vaccination rather than single peptides.  
In order to reveal clinically relevant cell responses of applied vaccinations the techniques 
described in this paper provide compelling tools for immunmonitoring. The ARTE approach is 
a suitable tool to monitor not only frequency but remarkably also functionality of antigen-
specific CD4+ T cell with high resolution. Usage of peptide pools additionally provides the 
opportunity to monitor oligoclonal T cell responses circumventing HLA-restriction. 
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4.3 HPV16-specific T cell immunity in HNSCC patients 
In this study an in-depth characterization of peripheral blood and intratumoral HPV16-
directed T cell immunity in HPV16pos HNSCC patients was conducted. Major results are: (i) 
HPV16-specific CD4+ T cells are present in the blood of all patients; (ii) a subgroup of this 
cohort bears exceedingly high numbers of effector memory HPV16-reactive CD4+ T cells 
compared to other HPV16pos HNSCC patients and HPV16neg HNSCC patients, which (iii) 
might be related to different frequencies of HPV16-reactive naïve T cells; furthermore (iv) 
HPV16-directed T cell immunity in blood of HNSCC patients reflects intratumoral immunity; 
(v) CD25+ cells, most likely Tregs, impair intratumoral HPV16-directed effector T cell 
responses in vivo; nonetheless, (vi) functional HPV16-reactive T cells can be expanded ex 
vivo from blood and tumor tissue of all HPV16pos HNSCC patients after their enrichment. In 
summary, this data support the therapeutic utilization of the existent HPV16-reactive T cells 
in HPV16pos HNSCC patients. 
 
4.3.1 Prevalence and functionality of HPV16-reactive T cells in HPV16pos HNSCC 
patients 
The highly sensitive method based on enrichment of CD154-expressing, activated T cells 
enabled the detection of HPV16-specific memory T cells in blood of all HPV16pos HNSCC 
patients, independent of whether the blood was derived from patients at the time of tumor 
resection or several month after surgery. Intriguingly, five of the nine HPV16pos HNSCC 
patients revealed exceedingly high frequencies of HPV16-reactive CD4+ T cells, which were 
significantly higher compared to frequencies detected in PBMC of healthy donors and 
HPV16neg HNSCC patients. In addition, in blood of two of the five high responders CD3+ CD4- 
HPV16-reactive T cells were found. In the other four of the nine HPV16pos HNSCC patients 
the level of HPV16-reactive CD4+ T cells did not exceed the level determined in healthy 
donors.  
The obtained results clearly show that HPV16-reactive TH cells detected in the blood of the 
high responder HPV16pos HNSCC patients at time of tumor resection were fully functional 
TH1 cells. This is in contrast to data obtained for HPV16pos cervix carcinoma patients, where 
an impaired functionality of circulating HPV16-directed T cells has been suggested (Clerici, 
Merola et al. 1997, de Jong, van Poelgeest et al. 2004, Bais, Beckmann et al. 2005, Sharma, 
Rajappa et al. 2007). However, multiple publications speculate that immunity to HPV16pos 
HNSCC tumors might be profoundly different to immunity against HPV16pos cervix carcinoma, 
simply because HPV16pos HNSCC tumors are mostly located closely or within lymphoid 
tissue of the tonsils. In a recent study on HPV16-reactive T cell immunity in blood of 
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HPV16pos HNSCC patients only in a subgroup of these patients circulating HPV16-reactive T 
cells were detected (Heusinkveld, Goedemans et al. 2012), the detected lack of a peripheral 
HPV16-specific T immunity in some patients might be due to the inability to detect antigen-
specific T cells at low frequencies with the used assay. Therefore, data from Heusinkveld et 
al (Heusinkveld, Goedemans et al. 2012) are in line with data in this study, as they reflect 
remarkable differences in the strength of HPV16-directed T cell immunity in HPV16pos 
HNSCC patients. However, data obtained in the study presented here clearly show, for the 
first time, that a subgroup of HPV16pos HNSCC patients has highly functional HPV16-reactive 
T cells, thereby contrasting the notion that T cell immunity is generally impaired in HPV16pos 
cancer patients. 
Concerning frequencies of HPV16-reactive CD4+ and CD8+ T cells in the peripheral blood, 
samples taken from HPV16pos patients at the time of tumor resection showed similar results 
to samples taken from HPV16pos follow-up patients, as in both groups in approximately half of 
the samples elevated frequencies of CD4+ HPV16-reactive T cells and in approximately a 
quarter of the samples elevated frequencies of CD8+ HPV16-reactive T cells were detected 
compared to HPV16neg patient samples and healthy donors. However, T cells of one high 
responding HPV16pos follow-up patient revealed an exhausted phenotype (TEM-RA, CD45RO- 
CCR7-) and limited functionality, as only a very small proportion of CD4+ HPV16-reactive T 
cells produced TNF-α and IFN-γ upon stimulation. Also the other HPV16pos high responding 
follow-up patient showed somewhat functional impairment, as the CD4+ HPV16-reactive T 
cells produced hardly any IFN-γ and the CD4- HPV16-reactive T cells produced hardly any 
TNF-α, even though the differentiation status of both the CD4+ and CD4- population did not 
primarily indicate an exhausted state of the T cells, but a TEM (CD45RO+ CCR7-) phenotype. 
The samples of these two high-responding follow-up patients had been taken 15 and 31 
months after diagnosis, respectively. The data might indicate that the tumor load was low, i.e. 
infection was not acute anymore in the follow-up patients, but decaying. Notably, the tested 
follow-up patients were in complete remission without relapse. 
Frequencies of HPV16-reactive TH cells in low-responders within the HPV16pos HNSCC 
surgery patients were similar to frequencies in healthy patients. However, all HNSCC 
patients show clear memory formation, indicating that indeed an on-going HPV16 infection 
was sensed by the immune system and induced the formation of memory T cells.  
CD4+ HPV16-reactive T cells of low-responder HPV16pos follow-up patients were of TCM and 
naïve phenotype with rather a higher proportion of naïve T cells compared to HPV16pos low-
responder surgery patients, supporting the idea that in follow-up patients the HPV16 infection 
was decaying. The two low-responder follow-up patients were sampled 36 and 57 months 
after diagnosis and were without relapse until this time point.  
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4.3.2 HPV16-reactive T cells in healthy individuals 
Some healthy individuals also showed quite high frequencies of HPV16-reactive T cells in 
the periphery. In detail, three healthy individuals (of 32 donors tested) had frequencies of 
>1x10-5 within CD4+ T cells, the majority of those HPV16-reactive T cells were of TCM or TEM 
phenotype. This high frequency of memory HPV16-reactive T cells indicates that these 
healthy donors might have had an HPV16 infection. However, for the used healthy 
individuals it was impossible to determine whether those individuals had ever encountered 
an HPV16 infection or were currently HPV16 infected. It is believed that more than 50% of 
people are infected by any type of HPV once during their life time. As most of these 
infections are cleared without any symptoms and are therefore not noticed, exact infection 
rates in the normal population cannot be determined accurately. Additionally, reliable 
detection of HPV infection is hardly possible. The only reliable detection of HPV infection is 
DNA detection in the infected tissue. Additionally, anti-HPV16 antibody titers in the blood can 
be determined as surrogate marker, however, seroconversion of infected individuals does 
not necessarily occur. Even women with HPV16pos or HPV18pos cervical lesions do only 
develop anti-HPV-antibodies in about 60% of cases (Porras, Bennett et al. 2010).  
 
4.3.3 Correlation between HPV16-specific naïve and memory T cell frequencies 
Although all HPV16pos HNSCC patients showed an HPV16-reactive memory response the 
question remains why some donors showed a strikingly stronger effector memory response 
than others? Recent publications provided growing evidence that the T cell response is 
directly proportional to the antigen-specific naïve T cell pool. In detail, the size of the naïve T 
cell pool for one particular epitope is correlated to the size of the resulting memory T cell 
response against this epitope, both in mouse (Moon, Chu et al. 2007, Kotturi, Scott et al. 
2008, Obar, Khanna et al. 2008) and human (Kwok, Tan et al. 2012). Kwok et al. (Kwok, Tan 
et al. 2012) determined frequencies of naïve T cell precursors for different epitopes of 
Bacillus anthracis, to which individuals normally have no contact, and correlated those 
frequencies to frequencies of Bacillus anthracis-specific memory T cells in vaccinated 
subjects. In the study presented here, a positive correlation of naïve and memory HPV16-
reactive T cell frequencies in the HPV16pos HNSCC patients at time of surgery was found. 
Our data cannot be directly compared to the published data, as frequencies of naïve T cells 
were determined in already infected individuals in contrast to individuals before antigen 
contact as in the study of Kwok et al. According to the classical model of T cell development 
a naïve T cell encounters its antigen and differentiates into a memory T cell and is therefore 
lost from the naïve repertoire. Consequently, memory formation would go along with a 
decrease in antigen-specific naïve T cell frequencies. However, a naïve T cell bearing one 
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particular specificity undergoes homeostatic proliferation and therefore builds up a small 
clonal population bearing the exactly same TCR. Not all members of this clonal population 
undergo differentiation at once, but only a subset of naïve T cells gets activated and is 
therefore “lost” from the naïve repertoire. Intriguingly, naïve HPV16-reactive T cells were not 
detectable in HPV16pos follow-up patients, maybe indicating that with prolonged time of 
infection the whole naïve repertoire is recruited to the memory T cell compartment. Activation 
and differentiation of naïve antigen-specific T cells by encounter of the epitope-presenting 
DC in a lymphatic tissue is most likely a stochastic process. Single-cell cloning and TCR 
sequencing of the naïve and memory T cells could give interesting insights into this issue. As 
only five HPV16pos HNSCC patients could be included in this analysis, no conclusive prove 
for an existing correlation between HPV16-specific T cell precursor numbers and memory 
formation in HPV16pos HNSCC patients can be provided. However, the discrepancy in 
HPV16-specific precursor numbers could be one of the factors affecting the strength of 
HPV16-specific immunity in tumor patients. 
An appealing question is whether the frequency of HPV16-reactive T cells in the periphery is 
related to clinical outcome or relapse-free survival of patients? However, the follow-up time of 
the patients included at time of surgery was only a few months and all patients were alive 
and without relapse at the endpoint of this study. Therefore, no correlation can be drawn in 
the course of this study. Knowledge about such a correlation would be of prognostic value  
for patients treated with conventional therapies and also novel immunotherapeutic 
interventions. 
 
4.3.4 In vitro generation of HPV16-reactive T cell populations from blood and tumor 
Propagation of HPV16-reactive T cell lines was performed in this study to: Firstly, enable 
investigation on the functionality of CD8+ HPV16-reactive T cell pool in the blood, which was 
possible only in a restricted way with the ARTE approach; secondly, to extend the analysis to 
T cells in the tumor lesions, and thirdly, to examine, whether blood or tumor tissue are 
suitable sources for functional HPV16-reactive T cell populations for adoptive 
immunotherapy. Strikingly, functional HPV16-reactive T cells could be expanded from the 
tumor tissue and from blood of all HPV16pos HNSCC patients. Expansion of HPV16-reactive 
T cell from blood of oropharyngeal cancer patients was previously reported by Ramos et al. 
(Ramos, Narala et al. 2013), who used a traditionally approach including DC preparation and 
weekly antigen restimulation of PBMC. With this approach they were able to expand HPV16-
reactive T cells from 73% of HPV16pos oropharyngeal cancer patients. Ex vivo no HPV16-
reactive T cells were detected when PBMC of HNSCC patients were incubated with 15-mer 
peptides. Ramos et al. claim that this is due to an anergized state of the HPV16-reactive T 
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cells in cancer patients. However, another reason could be the limited sensitivity of the used 
assay, as an IFN-γ ELISpot was used, which was accounted to be positive when >10 spots 
were detected in 105 PBMC. However, the frequency of HPV16-reactive T cells as 
determined with ARTE was about 2x10-5 within CD4+ T cells in high responders and IFN-γ 
production was detected in approximately 30% of these HPV16-reactive CD4+ T cells; this 
accounts for “only” one IFN-γ producing CD4+ T cell in about 1.5x105 CD4+ T cells, so less 
than one HPV16-reactive IFN-γ producing CD4+ T cells in 1x105 PBMC. The frequency of 
CD8+ HPV16-reactive T cells did not seem to be strikingly higher in most HPV16pos HNSCC 
patients. Consequently, frequencies of HPV16-specific IFN-γ-producing T cells are too low to 
be detected with the IFN-γ ELISpot, as used in the Ramos et al study. Ramos et al. claim 
that HPV16-reactive T cells need to be reactivated in vitro by addition of cytokines (IL-6, IL-7, 
IL-12, and IL-15), which then enabled them to generate T cell cultures containing up to 7% of 
T cells showing HPV16-specific IFN-γ production after five rounds of weekly antigen-specific 
restimulation. This in vitro assay most probably just amplified the number of HPV16-specific 
T cells, rather than re-activating them, and thus allowed their detection after expansion. In 
the study presented here the functionality of HPV16-specific T cells was clearly 
demonstrated ex vivo. 
Expansion of TIL from tumor tissue for clinical use has been initially established at the 
National Institute of Health (NIH, (Dudley, Wunderlich et al. 2003)). A protocol adapted to this 
established technique was also used in this study. In contrast to the protocol based on 
enrichment of CD137+ cells after HPV16 peptide pool stimulation, the classical NIH protocol 
without enrichment only resulted in substantial propagation of HPV16-reactive TIL in one 
patient. We conclude that the protocol for antigen-specific T cell expansion established in this 
study is feasible to selectively expand HPV16-reactive T cells also from tumor material.  
Few studies have, until now, dealt with the selective expansion of tumor-reactive TIL 
populations. pHLA tetramer selection of epitope specific T cells based on mutations found in 
individual melanoma patients demonstrates a novel appealing approach for personalized 
adoptive therapy treatment with a highly tumor-specific T cell product (Heemskerk, Kvistborg 
et al. 2013, Van Rooij, Van Buuren et al. 2013). However, this elaborate approach might be 
too laborious and cost intensive for clinical routine. More general approaches using 
enrichment strategies based on enrichment of activation marker expressing T cells have 
been introduced recently. Such enrichment strategies can, on the one hand, be used to 
enrich in vivo preactivated T cells to enrich the whole population of presumably in vivo tumor-
reactive T cells. Or, on the other hand, also TAA-reactive T cells can be enriched after in 
vitro stimulation using peptides, as demonstrated in this study. 
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Enrichment of tumor-reactive TIL via the activation marker CD137 was recently described in 
a melanoma mouse model (Ye, Song et al. 2014). Ye et al. also exemplarily proved in an in 
vitro model that enrichment of TAA-specific T cells is feasible. In vitro stimulation of 
established MART-1-specific TIL cell lines with MART-1 expressing melanoma cell lines 
resulted in CD137 expression in all MART-1-MHCI tetramer+ TIL. Furthermore, enhanced 
tumor control of CD137pos fraction compared to CD137neg fraction after 7 days of expansion 
in a mouse xenograft model was detected.  
Another marker which proved to be suitable to enrich the overall tumor-reactive CD8+ TIL 
was found to be PD-1 (CD279) (Inozume, Hanada et al. 2010). Rosenberg et al (Gros, 
Robbins et al. 2014), who were the first to report on sorting of TIL subsets of human 
melanoma, found both CD137+ and PD-1+ enriched populations to contain many tumor-
reactive T cells. In detail, they clearly showed that PD-1+ CD137+ TIL contained higher 
percentages of tumor-reactive TIL compared to PD1+ CD137- TIL. In line, sorting of CD137+ 
PD-1+, CD137+ PD-1-, and CD137- PD-1+ TIL done by Ye et al. (Ye, Song et al. 2014) 
revealed that CD137- PD-1+ TIL show diminished in vitro reactivity against target tumor cell 
lines compared to CD137+ PD-1+ and CD137+ PD-1- sorted TIL.  However as CD137 is only 
expressed on a tiny fraction of CD8+ melanoma cells (mean 10.8%) compared to PD-1 
(mean 32.4%), CD137+ cells representing a subpopulation of PD-1+ CD8+ TIL. Rosenberg et 
al. therefore claimed that CD137 as marker misses a large proportion of tumor-reactive T 
cells as sorted PD-1+ CD137- TIL also contained tumor-reactive T cells. Consequently, they 
postulated that PD-1 is a better marker for enrichment of CD8+ tumor-reactive T cells 
compared to CD137. 
Different tumor entities have different expression patterns of CD137 and/or PD-1, which 
might be crucial for the decision which enrichment strategy should be chosen. In TIL of 
dissociated HNSCC tumor tested in this study 4 – 25% of CD4+ (mean 10.0%) and 1 – 7.2% 
of CD8+ (mean 2.7%) TIL expressed CD137. PD-1 expression was observed on 20 – 70% of 
CD4+ TIL (mean 48%) and 35 – 85% of CD8+ TIL (mean 58%), indicating that PD-1 
expression on T cells in HNSCC tumors is higher than in melanoma tissue. For HNSCC 
tumors enrichment of PD-1+ TIL might be redundant, as the majority of TIL express PD-1 
without sorting. In line with data for melanoma, CD137 is only expressed on a minority of TIL 
in HNSCC tumors and therefore enrichment of CD137+ cells selects for a small 
subpopulation of T cells. Data of Rosenberg et al. proved that the CD137+ TIL subpopulation 
represents a population containing high amounts of effective tumor-reactive T cells. Only 
drawback pointed out by Rosenberg et al. is that some tumor-reactive might be lost in the 
CD137- fraction and therefore obtained cell numbers after CD137+ sorting are lower 
compared to PD-1+ cell selection and too low for clinical application. However, the more 
specific the T cell product is the less cells presumably need to be applied. For unsorted TIL, 
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about 10 – 100x109 TIL are given to an adult melanoma patient (Hong, Rosenberg et al. 
2010, Dudley, Gross et al. 2013). Therefore, despite this recently published data in 
melanoma patients, for HNSCC we argue for a usage of the CD137 enrichment and 
expansion protocol established in this study for the generation of HPV16-specific TIL cultures 
rather than a PD-1 enrichment approach. 
Of note, in contrast to previous studies enrichment of activated CD137+ cells in this study 
was done after in vitro antigen stimulation, thus selecting mostly HPV16-specific TIL. A T cell 
product, which is highly specific for HPV16-expressing tumor cells, can be achieved after 
expansion with this enrichment approach. 
 
4.3.5 Cytotoxicity of expanded HPV16-reactive T cells from blood and tumor 
Expanded CD4+ and CD8+ T cells showed cytotoxic potential towards HPV16 E6 and E7 
peptide loaded autologous peripheral blood cells. Additionally, cytotoxicity against 
autologous tumor cells was shown for T cells obtained from both blood and tumor tissue of 
two HPVpos HNSCC patients. However, such autologous tumor cells could only be grown 
efficiently for these two HNSCC donors. For both cytotoxic potential against loaded APC and 
autologous tumor cells seems to be higher for T cells grown from blood compared to T cells 
grown from tumor tissue (Patient 8 and 23). This higher cytotoxic potential might be due to 
differences in differentiation status of expanded T cells, as end-differentiated T cells can 
have diminished effector functions. However, phenotypic analysis after expansion did not 
reveal striking differences in differentiation status of T cell obtained from blood compared to 
T cells expanded from tumor tissue. 
 
4.3.6 Role of Treg in activation and expansion of HPV16-specific T cells  
In healthy donors TAA-specific effector T cells could be efficiently enriched and expanded 
from blood of healthy donors and the presence and enrichment of activated Treg did not result 
in diminished activation and expansion of antigen-specific effector T cells (see section 3.1.2). 
However, for the enrichment of HPV16-reactive T cells via the CD137 enrichment and 
expansion protocol from tumor tissue Treg might indeed be an issue. Within the tumor tissue 
not only HPV16-specific effector T cells but also HPV16-specific Treg might be selectively 
enriched and Treg mediated effector T cell inhibition is most likely a mechanism of major 
importance within HNSCC tumors. For one patient sample depletion of CD25+ cells, which 
include Treg, resulted in substantially enhanced antigen-specific stimulation. Most likely high 
Treg frequencies are responsible for inhibition of activation of HPV16-specific effector T cells. 
Interestingly, also the expansion of CD137 enriched effector TIL was much stronger when 
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CD25+ cells were depleted before stimulation. This is in stark contrast to results observed for 
CD137 enrichment and expansion of T cells from PBMC of healthy donors where CD25 
depletion did not result in changed expansion rates. Therefore, a depletion of CD25+ cells is 
strongly recommend when HPV16-specific T cells are enriched via the CD137 enrichment 
and expansion protocol from HPV16pos HNSCC tumors. 
 
4.3.7 Quantity and quality of T cell immunity in tumor lesions 
To what extent peripheral HPV16-directed immunity is connected to intratumoral immunity 
and prognosis is not well established so far. For cervical carcinoma it was shown that 
patients with a systemic HPV16-specific TH response have higher numbers of CD8+ T cells 
infiltrating the tumor and higher CD8+ to Treg ratios (Piersma, Jordanova et al. 2007). 
Furthermore, higher CD8+ T cell infiltration and higher CD8+ to Treg ratios were correlated to 
the absence of metastases. Likewise, for HNSCC patients a positive correlation of CD8+ to 
Treg ratio with prognosis of HNSCC patients was reported (Watanabe, Katou et al. 2010, 
Nasman, Romanitan et al. 2012), but a clear correlation of systemic HPV16-directed 
immunity to favorable prognosis is missing so far. In this study no statistically significant 
differences in overall T cell infiltration between the HPV16pos HNSCC low and high 
responders were detected. Nevertheless, higher CD8+ to Treg cell ratios, higher levels of 
activated TIL, higher levels of MHC class I expressing tumor cells, and higher IFN- to IL-10 
ratios in tumor supernatants observed for high responder HPV16pos patients hint at a 
favorable cell composition of tumors of high responder patients and an on-going anti-tumor 
response in those patients compared to low responder HPV16pos patients. 
 
4.3.8 Comparison of HPV16-reactive T cell immunity in the blood and tumor 
The results strongly suggest that the HPV16-directed T cell immunity detected in the blood 
reflects HPV16-directed immunity within the tumor tissue. Firstly, favorable T cell 
composition and elevated T cell activity within the tumor was detected in HPV16pos high 
responder HNSCC patients. Secondly, data from ex vivo detection of HPV16-reactive T cells 
from the blood (ARTE) show the same skewing of the ratio of CD4+ to CD8+ T cells of the 
HPV16-directed T cell response as seen within TIL. Thirdly, data on composition of CD4+ and 
CD8+ T cell response against both HPV16 E6 and E7 antigen reveal the presence of the 
same specificities in T cell cultures obtained from blood and tumor tissue. Accordingly, we 
hypothesize that peripheral HPV16-directed T cell immunity reflects intratumoral T cell 
immunity. However, our data also suggest that certain tumor-antigen-specific T cells are 
enriched in the tumor tissue as also suggested recently (Tjin, Krebbers et al. 2014). On the 
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one side, the magnitude of the different HPV16 antigen responses was rather different 
between T cells from PBMC and tumor after expansion. On the other side, only low 
frequencies of HPV16-reactive T cells were detected in the blood of two HPV16pos HNSCC 
patients, but nonetheless HPV16-reactive T cells could be expanded from tumor tissue.  
In line with earlier studies in HNSCC patients (Heusinkveld, Goedemans et al. 2012, Ramos, 
Narala et al. 2013), a bias towards CD4+ T cells directed against HPV16 in both blood and 
tumor tissue was detected. CD4+ TIL can exert an anti-tumor effect (Tran, Turcotte et al. 
2014), but correlations of presence of TIL with better prognosis have mostly be drawn for 
CD8+ TIL, which might be partially due to the fact that many studies did not discriminate 
between CD4+ Teff and Treg. Only one of the five tested donors in this study showed a strong 
HPV16-directed CD8+ T cell response in the blood and in the tumor. Why, for example, the 
other two high responder HPV16pos HNSCC patients did not mount an HPV16-directed CD8+ 
T cell response is not clear.  
Collectively, this data suggest that the tumor-specific T cell repertoire in blood represents 
tumor-specific TILs in quality, but not necessarily in quantity. In the future, examination of 
clonotypes from both, blood and tumor tissue, could reveal more precise insight into the 
relationship of the HPV16-directed T cell repertoires at both sites. 
 
4.3.9 Immunosuppressive conditions in HNSCC tumors  
Activation of effector T cells due to tumor-recognition is a critical step for a successful in vivo 
anti-tumor immunity. Especially HPV16-induced tumors are known to evade host immunity 
by a multitude of mechanisms. One of them is the interference of viral proteins with the 
antigen-presentation machinery in host (tumor) cells, thereby preventing recognition through 
tumor-specific T cells. The E7 protein of HPV high-risk types was shown to down-regulate 
the expression of HLA class I molecules on the surface of tumor cells (Li, Deng et al. 2010). 
In this study elevated expression of MHC class I on tumor cells obtained from HPV16pos high 
responder HNSCC patients was found. This difference in antigen-presentation of the tumor 
cells could either be a reason for the stronger immune response detected in these patients or, 
more likely, a consequence of an on-going T cell mediated anti-tumor response as IFN-γ, 
released by activated T cells, triggers the up-regulation of MHC class I molecules on tumor 
cells (Lopez-Albaitero, Nayak et al. 2006). These three high responder patients also showed 
high CD8+ to Treg ratios, further supporting that in these tumors a higher T cell response is 
on-going. These data hint at a favorable T cell composition in the high responder patients, 
where effector T cells are able to partially overcome Treg suppression. High CD8+ to Treg ratios 
have been positively correlated to a good prognosis in HNSCC (Watanabe, Katou et al. 2010, 
Nasman, Romanitan et al. 2012). However, our small patient cohort does not allow any 
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conclusive statements concerning a favorable outcome of these high responder patients, 
especially as at closing of this study all patients were in complete remission and no relapse 
had occurred. 
We and others detected prominent immunosuppressive conditions within the tumor. In 
general tumors, and HPV16pos tumors in particular, are able to create a prominent 
immunosuppressive microenvironment within the tumor tissue. Strong IL-10 production could 
be detected in supernatants of dissociated HPV16pos HNSCC tumors, which hints at an 
unfavorable, immunosuppressive cytokine profile probably affecting the effector functions of 
the resident TIL. Higher IFN- to IL-10 ratios in tumor supernatants of HPV16pos high 
responder patients compared to HPV16pos low responder patients further argues for a 
stronger intratumoral immune response in the high responder  patients. The magnitude of 
immunosuppression might vary in different patients and lead to a different strength in T cell 
impairment. Furthermore, evidence was provided that CD25+ cells, which include CD4+ 
CD25+ FoxP3+ regulatory T cells, are responsible for a strong suppression of HPV16-reactive 
T cell response, because removal of CD25+ cells enhances IFN- release and expansion of 
specific T cells in vitro. These data are in line with other publications reporting a strong 
immunosuppressive environment in HPV16-positive HNSCC tumors. The 
immunosuppressive mechanisms most likely hinder the strong HPV16-specific immunity 
detected in some HPV16pos HNSCC patients to fight the infected tumor cells. 
Collectively, a functional HPV16-directed T cell immunity was detected ex vivo in both blood 
and tumor of HPV16pos HNSCC patients. Functionality of tumor resident HPV16-directed T 
cells might be impaired due to strong immunosuppressive mechanisms. However, 
functionality can be restored by weakening immunosuppression or removal of the T cells 
from the suppressive tumor microenvironment.  
 
4.3.10 Implications on immunotherapeutic approaches 
In vivo anti-tumor reactivity of the ex vivo and in vitro detected HPV16-directed TIL seems to 
be limited in the patients, as the tumor was able to grow. Strikingly, functionally HPV16-
reactive T cells can be expanded from the tumor tissue in vitro, probably due to removal of 
the T cells from their suppressive tumor environment, as suggested earlier (Ramos, Narala 
et al. 2013, Tjin, Krebbers et al. 2014). These immunosuppressive conditions need to be 
taken into consideration for immune therapy and argue for implementation of combinational 
therapy. One compelling option would be the combination of immunotherapeutic 
interventions like vaccination or adoptive transfer of HPV16-specific T cells subsequent to 
conventional interventions like chemo- or radiotherapy, to partially destroy the compact tumor 
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microcosm. C. Melief’s group already provided first evidence for an enhanced CD8+ T cell 
activity in a mouse cervical cancer model when treated with a combined chemo-
immunotherapy including vaccination and cisplatin treatment (Van der Sluis T.C. 2014). 
Furthermore, it was shown that HPV16pos tumor patients respond better to chemotherapy and 
combined chemo-radiation therapy (Fakhry, Westra et al. 2008), probably as a partial 
disruption of the tumor microenvironment by the conventional therapies helps the existent 
HPV16-directed immunity of the patients to become active in tumor cell defense and provide 
prolonged protection against relapse. 
For pre-stages of cervical cancer exciting results have been achieved using a combination of 
therapeutic vaccination using a HPV16 E6E7L2 fusion protein and the immunmodulator 
imiquimod, with this treatment 63% of the women showed complete regression. These 
responder patients also showed an increased local T cell infiltration, whereas non-
responders had higher infiltration of Treg cells in the lesion (Daayana, Elkord et al. 2010). 
For one patient sample it could be shown that depletion of CD25+ cells lead to an increased 
TIL in vitro. Therefore, strategies to reduce immunosuppression via CD25+ cells are 
especially promising for therapy in HPV16pos HNSCC. Different strategies have been 
implemented in the past to address the issue of Treg-mediated immunosuppression in cancer 
patients. Firstly, Treg can be targeted in vivo by an antibody, which blocks IL-2 binding to the 
IL-2 receptor. Such an anti-CD25 antibody (PC61) was shown to reduce infiltration of Treg 
cells into tumor lesions in mice and thus provides a compelling approach (Onizuka, Tawara 
et al. 1999). First clinical trials in humans were done using the Food and Drug Administration 
(FDA)-approved anti-CD25 antibody daclizumab in brain (Sampson, Schmittling et al. 2012) 
and breast cancer (Rech, Mick et al. 2012). These pilot-studies demonstrated that human 
Treg can be safely and selectively depleted in vivo with daclizumab and indicated a higher 
immune response rate to vaccination in daclizumab-treated patients. Secondly, 
cyclophosphamide, used frequently for chemotherapy, was shown to selectively deplete Treg 
cells in the periphery of cancer patients when applied in low-doses (Ghiringhelli, Menard et al. 
2007, Walter, Weinschenk et al. 2012, Heylmann, Bauer et al. 2013). Thirdly, genetically 
engineered TGF-β-resistant CTL, carrying a malfunctional TGF-β receptor, have been shown 
to resist the inhibitory effects of tumor-derived TGF-β in vitro and in vivo (Foster, Dotti et al. 
2008). 
A skewing of the HPV16-directed immunity rather towards CD4+ T cells than CD8+ CTLs in 
some HPV16pos HNSCC patients was detected in this and previous studies (Ramos, Narala 
et al. 2013) and should be considered when immunotherapeutic interventions are designed. 
Consequentially, vaccination approaches might be favorable, which focus on the induction of 
a CD8+ T cell response, e.g. through co-administration of DNA encoded antigen or a 
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xenogenic MHC molecule, which presumably enhances efficient cross-presentation (Kang, 
Chung et al. 2010). Intriguingly, immunotherapy using CD4+ T cells in epithelial cancer (Tran, 
Turcotte et al. 2014) has clearly proven the anti-tumor function of CD4+ T cells. However, the 
exact mechanism of action of those anti-tumor CD4+ T cells remains elusive. Several 
mechanisms have been described. Firstly, co-activation of CD8+ T cells (Matthew 2012 
CancerRes); secondly, recruitment of innate immune cells, such as macrophages (Corthay, 
Skovseth et al. 2005) and NK cells (Perez-Diez, Joncker et al. 2007); thirdly, direct 
cytotoxicity of CD4+ T cells (Paludan, Bickham et al. 2002). The latter is hampered by the fact 
that MHC class II expression is restricted to professional APC, however, other cells are 
capable of upregulating MHC class II upon pathogen challenge. MHC class II upregulation 
was reported for epithelial cells when they are activated by infection (Debbabi, Ghosh et al. 
2005) or IFN-γ-mediated signals (Cunningham, Zhang et al. 1997).  
The obtained results on expansion of blood- and tumor-derived HPV16-reactive T cells in this 
study strongly argue for the implementation of a CD137 enrichment approach for the 
generation of a HPV16-targeted T cell product for adoptive T cell transfer to HPV16pos 
patients. However, CD25+ cell depletion seems to be mandatory to ensure efficient 
stimulation and expansion of such isolated HPV16-reactive T cells. Which tissue source 
should be used of generation of HPV16-specific T cells for adoptive therapy of HPV16pos 
HNSCC patients, blood or tumor? Considering the here presented results both sources are 
suitable for the generation of HPV16-reactive T cells. However, HPV16-reactive T cells from 
the blood might have a better anti-tumor function, as they showed higher cytotoxic capacity 
compared to tumor-derived HPV16-reactive T cells in most patients. Furthermore, 
enrichment of Treg might be of minor importance when peripheral T cells are enriched 
compared to tumor-resident T cells. Additionally, generating these HPV16-reactive T cells 
from blood provides a compelling opportunity as the approach can lead to a cell product 
faster, as higher starting T cell numbers can be obtained from blood compared to tumor. 
In summary, the study shows that a HPV16-directed, functional peripheral and intratumoral T 
cell immunity exists in HPV16pos patients, which argues for their clinical usage. Based on the 
obtained results a combinational therapy is favored, as strong immunosuppressive 
mechanisms in the HNSCC tumor need to be overcome to facilitate functional anti-tumor T 
cell responses. 
 
Discussion 
104 
 
4.4 Juxtaposition of WT1-specific T cells and HPV16-specific T cells 
The main aim of this study was to characterize WT1- and HPV16-specific T cells regarding 
their use in immunotherapeutic approaches. Additionally, it also allows a direct comparison of 
WT1- and HPV16-specific T cells, which are expected to bear distinct features, as these two 
tumor-associated antigens are of different origin, WT1 being a self-antigen and HPV16 E6 
and E7 being viral antigens. Surprisingly, in most healthy donors CD4+ T cells specific for 
both antigens were found in similar frequencies. For HPV16 some donors (3 of 32 healthy 
individuals) had extraordinary high frequencies of CD4+ HPV16-specific T cells (>1x10-5 
within CD4+ T cells), most probably resulting from an (non-persistent) infection with HPV16. 
Interestingly, concerning the differentiation status of the T cells, in healthy donors the 
frequency of individuals bearing CD4+ memory T cells was higher for WT1 (65% of healthy 
donors) compared to HPV16 (50% of healthy donors). For HPV16 this frequency probably 
represents the frequency of healthy individuals, which have been infected with the virus 
recently. For the self-antigen WT1 we suggest other mechanisms to be responsible for 
memory formation, such as cross-reactivity to environmental antigens. 
Both antigens have proven to be immunogenic in cancer patients and therefore provide 
favorable targets for immunotherapeutic approaches. In this study a novel, straight-forward 
protocol, based on antigen-specific stimulation and enrichment of CD137+ cells, for the 
efficient propagation of WT1- and HPV16-specific T cells was established, which has great 
potential for clinical implementation. For both antigens functional and non-exhausted specific 
T cells could be expanded from blood of healthy individuals. HPV16-specific T cells were 
additionally expanded from blood and tumor tissue of HPV16pos HNSCC patients. We 
suggest to use this established expansion protocol for the generation of WT1-specific T cells 
from healthy stem-cell donors for infusion into leukemia patients after hematopoietic stem 
cell transplantation to prevent or treat relapse. HPV16-specific T cells can be expanded 
using our protocol for adoptive HPV16-specific T cell transfer in HPV16pos HNSCC patients 
after easing the suppressive milieu of the tumors or after tumor resection. For the design of 
therapeutic vaccination approaches our study also bears valuable insights, as a detailed ex 
vivo analysis of WT1- and HPV16-specific T cells is provided. The broad presence of WT1-
specific T cells and their high functional avidity clearly argue for the use of peptide pool- or 
DNA-based WT1 vaccination as supplemental therapy in leukemia. Therapeutic HPV16 
vaccination in HPV16pos HNSCC also present a compelling therapy option when combined 
with other interventions. Results of currently ongoing clinical trials will give more insights. 
Furthermore, the here presented highly sensitive detection methods can be implemented for 
a sensitive monitoring of patients during vaccination and other immunotherapeutic 
interventions. 
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